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Summary 
An aberrant regulation of the hypothalamic-pituitary-adrenal (HPA) axis is closely 
associated with the pathophysiology of affective disorders such as major depression 
(MD). Accordingly, patients suffering from MD frequently show profound 
neuroendocrine alterations with hyper- or hypo-cortisolism as a result of a dysregulated 
stress hormone system. Focussing on this key endophenotype of MD, the ‘stress 
reactivity’ (SR) mouse model was recently established, consisting of three independent 
mouse lines, the high (HR), intermediate (IR) and low (LR) stress reactivity line, 
selectively bred for differences in their corticosterone (CORT) secretion in response to a 
psychological stressor. Previous studies revealed distinct differences between HR, IR 
and LR animals regarding sleep architecture, activity rhythms, emotional behaviour, 
cognition as well as neuroendocrine functions, resembling several endophenotypes 
observed in depressed patients. 
In the series of studies presented in this work, we aimed to investigate whether the 
differences between HR, IR and LR mice were restricted to the peripheral phenomenon 
of adrenal CORT secretion, or whether these endophenotypes were brought about by an 
aberrant regulation of upstream control centres of the HPA axis. To this end, we 
performed experiments investigating all functional levels of HPA axis control, i.e. the 
adrenals, the pituitary and brain centres known to be involved in the neuroendocrine 
stress response. Moreover, we assessed the expression of corticosteroid-binding 
globulin (CBG), which contributes to the transport and delivery of CORT to its target 
tissues. Finally, we studied HPA axis regulatory mechanisms by means of the combined 
dexamethasone/corticotropin-releasing hormone (Dex/CRH) test. 
At the level of the adrenal, we found that pharmacological inhibition of the biosynthesis 
and secretion of CORT using metyrapone had a significant impact on the stress-coping 
behaviour of HR, IR and LR animals as determined in the forced swim test (FST). As 
another peripheral factor influencing the secretion of CORT, we assessed the adrenal 
sensitivity of the animals to adrenocorticotropic hormone (ACTH) in vivo. After a Dex-
mediated inhibition of endogenous ACTH release from the anterior pituitary, LR 
animals showed a markedly reduced CORT surge compared to HR mice in response to 
a stimulation of the adrenals with two doses of exogenous ACTH, indicating an 
enhanced adrenal sensitivity in HR mice and a blunted responsiveness to ACTH in LR 
mice. In addition, we found significant differences in plasma CBG levels between the 
three mouse lines (HR>IR>LR), concomitant with differences in free plasma CORT 
both, basal and in response to 15 min restraint stress (HR>IR>LR). Since only free 
CORT is biologically active, these results indicate that CBG might play a role in the 
endophenotypes of the SR mouse lines. 
At the pituitary level, we detected significantly altered ACTH protein levels 
(HR>IR≥LR) and proopiomelanocortin mRNA expression (HR>IR>LR), suggesting a 
differential activation of the anterior pituitary between the three lines, which is in line 
with the observed differences in stress reactivity. 
In the brain, we assessed the neuronal activation induced by an acute stressor in regions 
known to be involved in HPA axis function such as the prefrontal cortex, the basolateral 
amygdala, the hippocampus and the paraventricular nucleus of the hypothalamus (PVN) 
using c-fos in-situ hybridisation. Acute stress exposure markedly increased neuronal 
activation in all investigated brain areas. However, significant differences in the 
neuronal excitation between the three lines were only detected in the PVN 
(HR>IR>LR), indicating an altered activation of the animals’ HPA system orchestrated 
by this nucleus. 
Finally, we assessed HPA axis regulatory mechanisms by means of the Dex/CRH test. 
Our results revealed considerable similarities to clinical studies, with HR mice showing 
signs of Dex non-suppression in addition to an overshooting CORT surge after CRH 
stimulation, mirroring the HPA axis hyper-active state of patients suffering from the 
psychotic or melancholic subtype of MD. In contrast, LR animals presented a strong 
Dex-induced CORT suppression and a blunted response to the CRH stimulation, 
resembling the situation observed in atypically depressed patients. Strikingly, chronic 
fluoxetine (Flx) treatment enhanced the negative feedback regulation of the HPA axis in 
all three lines of the SR mouse model. In particular, the Dex-mediated CORT 
suppression in HR mice was restored by Flx. Furthermore, Flx affected the stress-
coping behaviour of the animals in the FST. Flx induced a reduction in active coping, 
indicating an attenuation of the hyper-aroused state, particularly in HR mice. 
Taken together, the series of studies presented here demonstrated that the SR mouse 
model shows functional alterations on all levels of the HPA axis - peripheral, central 
and regarding the regulation – similar to the endophenotypes of MD patients, thus 
revealing a high level of face and construct validity of the model. Hence, the SR mouse 
model can serve as a valuable tool in the discovery and validation of new drug targets 
and improve already existing treatments of MD, particularly those targeting the HPA 
system. 
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1 Introduction 
Its not stress that kills us, it is our reaction to it 
-Hans Selye (1907-1982) 
1.1 Major depression 
Stress-related disorders such as major depression (MD) are among the most prevalent and 
costly mental illnesses (Fava et al., 2000; Nestler et al., 2002) with about 120 million 
people worldwide being affected, accounting for an estimated lifetime prevalence of 
around 17 % to develop the disease (Fava et al., 2000). According to the World Health 
Organisation (WHO), depression causes 6 % of the burden of all diseases in Europe in 
terms of disability adjusted life years (DALYs) (Sobocki et al., 2006). Moreover, MD is 
projected to be the second most important cause of disability worldwide by the year 2020 
(Davidson et al., 1999). 
MD occurs in persons of all genders, ages, and backgrounds, although women are 
affected twice as much as men (Nestler et al., 2002; Levinson, 2006). The 
symptomatology is widespread and very heterogenic and includes psychological 
symptoms such as depressed mood, loss of interest or pleasure, feelings of worthlessness 
and guilt, low self-esteem, as well as psychosomatic alterations such as disturbed sleep, 
changes in appetite and weight, fatigue, and cognitive deficits (Lewinsohn et al., 1998; 
Nestler et al., 2002; Hasler et al., 2004). Tragically, the personal suffering coming along 
with this symptomatology eventually peaks in about 850.000 suicides a year 
(http://www.who.int, accessed June 12th, 2012). 
Apart from the tremendous personal afflictions of affected individuals and their relatives, 
MD also presents a considerable socioeconomic burden. The total annual cost of 
depression in Europe alone was estimated at 118 billion Euros in 2004. This makes 
depression the most costly brain disorder in Europe, accounting for 33 % of the total 
treatment costs of psychiatric diseases (Sobocki et al., 2006). Several reasons help to 
explain why the economic burden of depression is so large. MD is among the most 
commonly occurring chronic diseases in both, the labour force and the general 
population. Moreover, MD is associated with substantial loss in productivity, much of 
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which results from the fact that MD has an earlier age of onset (typically late 20s) than 
other common diseases affecting individuals before or during their prime working years 
(Wang et al., 2003). 
Risk factors to develop MD are as heterogenic as the symptomatology. Epidemiologic 
studies showed that roughly 40-50 % of the risk for depression is genetic (Nestler et al., 
2002; Levinson, 2006), making MD a highly heritable disease. Moreover, non-genetic, 
‘environmental’ factors such as the experience of a traumatic event, e.g. childhood abuse 
(Goldberg, 1994; Levitan et al., 1998; Gibb et al., 2003) or loss of a beloved person 
(Kendler et al., 2003), drug abuse (Deykin et al., 1987; Deykin et al., 1992) as well as 
viral infections (Bode et al., 1993) can increase the vulnerability to develop MD (Nestler 
et al., 2002). 
Thus, it becomes apparent that depressive disorders such as MD are multidimensional and 
heterogenic diseases, involving genetic (Levinson, 2006), epigenetic (Mill et al., 2007), 
environmental (Kendler et al., 1992) and psychosocial (Hirschfeld et al., 1982) 
components, which are difficult to track down to one common mechanism of onset. 
Therefore, a major goal of psychiatric research is to understand the comprehensive 
network of factors which are involved in the aetiology of MD. 
 
1.2 Subtypes of major depression 
According to the ‘diagnostic and statistical manual of affective disorders’ (DSM-IV), MD 
is categorised in several subtypes with partly overlapping but characteristic (sometimes 
even contrasting) symptomatic features allowing diagnostic differentiation. The two 
probably most important subtypes of MD are the melancholic (also termed ‘endogenous’ 
or ‘typical’) and the ‘atypical’ subtype of depression. The melancholic subtype is 
commonly associated with increased anxiety, loss of responsiveness to environmental 
stimuli, insomnia as well as decreased appetite and weight. Furthermore, patients show 
diurnal variations in their depressive state which is worst in the morning. Interestingly, 
patients suffering from atypical depression virtually present the opposite symptomatology 
comprising lethargy and fatigue, hyperphagia and weight gain, hypersomnia, increased 
reactivity to the environment, social aggression as well as a diurnal variation in their 
emotional states that is at its best in the morning (Gold et al., 2002; Nestler et al., 2002; 
Hasler et al., 2004; Antonijevic, 2006). 
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In addition, it has been reported that apart from psychosomatic dissimilarities, patients 
suffering from these two subtypes of MD show distinct differences regarding the 
organisation of their stress systems. Individuals with the psychotic and melancholic 
subtype of depression present high corticotropin-releasing hormone (CRH) as well as 
norepinephrine (NE) states, which are associated with high plasma cortisol (CORT) 
concentrations (hypercortisolism), while in atypically depressed patients, hypocortisolism 
was shown to be associated with low CRH and NE levels (Gold et al., 1996; Gold et al., 
2002). Thus, in recent years evidence has emerged, that pathological alterations in the 
stress systems, i.e. the sympathetic nervous system and, in particular, the hypothalamic-
pituitary-adrenal axis (HPA) axis, are prominently involved in the development of MD. 
Hence, a major sector of psychiatric research focuses on the understanding of HPA axis 
function both, under physiological as well as pathophysiological conditions (Plotsky et 
al., 1998; Holsboer, 2000; Charmandari et al., 2005; de Kloet et al., 2005; Pariante et al., 
2008; Holsboer et al., 2010).  
 
1.3 The physiology of the hypothalamic-pituitary-adrenal axis 
The HPA axis is a major neuroendocrine system in mammalian organisms and is involved 
in the regulation of a plethora of physiological processes implicating developmental, 
cardiovascular, immunological and metabolic aspects and in particular, the stress 
response (Tsigos et al., 2002; Charmandari et al., 2005; Melmed et al., 2011). The key 
elements of the HPA axis are the paraventricular nucleus of the hypothalamus (PVN), the 
pituitary gland and the cortices of the adrenal glands (Tsigos et al., 2002). The activity of 
the HPA axis underlies a diurnal as well as ultradian rhythmicity (Lightman et al., 2008; 
Sarabdjitsingh et al., 2012) which is under control of a pacemaker located in the 
suprachiasmatic nucleus (SCN) of the hypothalamus (Engeland et al., 2012). This 
rhythmic activity of the HPA axis evokes a circadian release of CORT (cortisol in 
humans, corticosterone in murine rodents), that peaks at the beginning of the activity 
cycle, thus enabling the organism to cope with everyday physiological demands, and 
reaches trough levels at the start of the resting period (Melmed et al., 2011). Furthermore, 
limbic brain structures, which are involved in the processing of environmental stimuli, 
project directly and/or via neuronal intermediaries to the PVN, thus interconnecting the 
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‘emotional’ brain centres and the neuroendocrine stress system (Herman et al., 1997; 
Herman et al., 2003). 
In response to stress, the PVN receives stimulatory inputs from a multitude of brain areas, 
eventually culminating in the synergistical secretion of CRH and arginine-vasopressin 
(AVP) from parvocellular neurons of the PVN into the hypophyseal portal system of the 
median eminence (see Figure 1). Upon receptor binding at the anterior lobe of the 
pituitary, adrenocorticotropic hormone (ACTH) is released and transported via the 
systemic blood circulation to the adrenal glands where it binds to its receptor, the 
melanocortin-2-receptor (MC2R), which induces de novo steroidogenesis and release of 
glucocorticoids (GCs) from the zona fasciculata of the adrenal cortex (Simpson et al., 
1988; Abdel-Malek, 2001; Tsigos et al., 2002; Charmandari et al., 2005). 
Adequate control of GC levels is accomplished by inducing a negative feedback 
mechanism that restricts the continuous release of HPA secretagogues. In the healthy 
organism, GCs bind to glucocorticoid (GR) and mineralocorticoid (MR) receptors in the 
pituitary, the hypothalamus (mainly in the PVN), and the hippocampus. By forming 
hetero- or homo-dimers, the cytoplasmic corticosteroid receptors act as a transcription 
factor and translocate to the nucleus to inhibit the expression of AVP, CRH, and ACTH 
via binding to GC response elements at the genomic DNA (Heitzer et al., 2007; Prager et 
al., 2009). In addition, non-genomic feedback mechanisms have been reported, involving 
fast (within minutes) GC-mediated signalling via membrane associated corticosteroid 
receptors (Tasker et al., 2006; Joels et al., 2008; Groeneweg et al., 2011, 2012). 
Moreover, a significant impact of the endocannabinoid system in mediating these fast 
feedback mechanisms has been shown (Steiner et al., 2008b; Tasker et al., 2011). 
Thus, it becomes clear, that the HPA axis is a fine-tuned orchestra involving a plethora of 
signalling molecules and receptors as well as many different regulatory circuits, assuring 
physiological homeostasis as well as an adequate stress response. Moreover, it is not 
surprising that an enduring disruption of this homeostatic balance, e.g. by repeated 
exposure to disproportional physical and/or psychological demands (stressors), can lead 
to pathophysiological conditions which can eventually culminate in the development of 
affective disorders such as MD. 
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Figure 1: Schematic diagram illustrating the different levels of hypothalamic-
pituitary-adrenal (HPA) axis control. In response to circadian stimuli or stress, the 
paraventricular nucleus of the hypothalamus (PVN) synergistically releases 
corticotropin-releasing hormone (CRH) and arginine-vasopressin (AVP) into the 
portal system of the median eminence. Upon adrenal stimulation by 
adrenocorticotropic hormone (ACTH) released from the anterior pituitary, 
glucocorticoids such as corticosterone (CORT) are secreted from the adrenal cortex 
into the systemic circulation. Subsequently, negative feedback mechanisms at the 
pituitary and the PVN restrict the release of ACTH and CRH/AVP, respectively. SCN, 
suprachiasmatic nucleus; CNS, central nervous system. Figure adopted from 
(Lightman et al., 2010).  
 
1.4 The pathophysiology of the hypothalamic-pituitary-adrenal axis 
In 1957, Board and colleagues were the first to report altered plasma CORT levels in 
depressed patients (Board et al., 1957). Despite the very complex nature of MD, such 
neuroendocrine symptoms are observed in about 60% of depressed patients, namely 
hyper- or hypocortisolemia which is associated with a dysregulated HPA axis function 
(Ising et al., 2005). Interestingly, pathological changes in HPA axis regulation could be 
found on all levels of the stress system, i.e. in the brain, the pituitary and the adrenals. 
In the brain, post mortem studies on severely depressed suicide victims revealed high 
levels of CRH, concomitant with increased levels of CRH-expressing neurons and a 
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decreased amount of CRH receptors in brain regions such as the prefrontal cortex 
(Nemeroff et al., 1988; Austin et al., 2003; Merali et al., 2004; Merali et al., 2006). 
Furthermore, the number of AVP-containing PVN neurons was increased in the brain of 
depressed subjects (Merali et al., 2006; Meynen et al., 2006), suggesting an 
overstimulation of the pituitary by these neuropeptides. Accordingly, CRH levels were 
increased in the cerebrospinal fluid of MD patients (Nemeroff et al., 1984; Banki et al., 
1987; Arato et al., 1989). Moreover, a decreased function of the MR and the GR has been 
reported in depressed patients, which was associated with a decrease in the GC-mediated 
feedback inhibition of the PVN due to GC resistance (de Kloet et al., 1998; Pariante et 
al., 2001). 
At the pituitary level, increased expression of ACTH and its precursor, 
proopiomelanocortin (POMC), have been reported (Charlton et al., 1988). Consistently, 
increased numbers of ACTH-secretory episodes from corticotropes and subsequent 
exaggerated adrenal CORT secretion have been observed in depressed patients (Sher, 
2004). 
On the adrenal level, the increased stimulation by ACTH resulted in hyperplasia as well 
as hypertrophy of adrenal cells which was associated with an increased release of GCs 
from the adrenal cortex (Amsterdam et al., 1987; Szigethy et al., 1994; Plotsky et al., 
1998). The crucial role of GCs in the aetiology of MD is further supported by clinical 
observations of subjects suffering from pathophysiological adrenal GC secretion. Patients 
with Cushing’s syndrome, who secrete high amounts of GC due to benign tumours in the 
pituitary or adrenocortical hyperplasia, show symptoms similar to melancholically 
depressed subjects. The treatment of Cushing’s disease normalised GC levels and 
psychiatric symptoms were improved (Sonino et al., 1993). In contrast, patients with a 
inherited or acquired pituitary hypofunction as seen in Addison’s disease, resulting in 
adrenal insufficiency, display symptoms similar to those seen in atypically depressed 
patients (Melmed et al., 2011). 
Furthermore, MD patients commonly show profound alterations in the regulation of the 
HPA axis. In the combined dexamethasone/corticotropin-releasing hormone (Dex/CRH) 
test, patients suffering from MD show a decreased HPA axis suppression following an 
exogenously administered dose of the synthetic GR agonist Dex (Dex non-suppressors). 
A subsequent stimulation of the pituitary by CRH application, in turn, results in an 
overshooting CORT secretion, thus revealing a reduced function of the negative GC 
feedback, i.e. a decreased suppression of ACTH secretion. In contrast, it has been shown 
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that in patients suffering from post traumatic stress disorder (PTSD) or atypical 
depression (Kasckow et al., 2001; Rydmark et al., 2006), the GC response after CRH 
challenge was significantly attenuated compared to healthy controls, due to an increased 
negative feedback signal on the HPA axis. Therefore, the Dex/CRH test has been 
suggested to be a suitable surrogate marker for depression. Moreover, it has been shown 
that the outcome of the Dex/CRH test is a good indicator for the efficacy of 
antidepressant treatment (Ising et al., 2005) as well as a measure for the risk of relapse at 
the time of discharge (Zobel et al., 2001). 
 
1.5 Treatment of major depression 
Classical treatment approaches of MD focus on the monoaminergic system, since a 
depletion of monoamines has been reported as an important factor in the development of 
the disease (Delgado, 2000; Elhwuegi, 2004; Belmaker et al., 2008). 
Since the 1950s when monoamine oxidase inhibitors (MAOIs) and tricyclic 
antidepressants (TCAs) were first discovered by serendipity (Pletscher, 1991), the 
development of psychopharmaca has steadily improved, especially gaining a better side-
effect and safety profile of the drugs. Nowadays, the most common and first-line 
treatment of MD is a combination of psychotherapy and pharmacotherapy with selective 
serotonin (5-HT) reuptake inhibitors (SSRIs) such as fluoxetine (Flx) or combined 5-HT 
noradrenaline reuptake inhibitors (SNRIs) such as venlafaxine. All these classes of drugs 
have a common mechanism of action. They increase the availability of monoamines in 
the synaptic cleft by inhibiting the intracellular degradation of monoamines (MAOIs) or 
by blocking the reuptake of the monoaminergic neurotransmitters from the synaptic cleft 
back into the presynapse (TCAs, SSRIs, SNRIs), respectively (Nemeroff, 1998). 
However, as already mentioned the side-effects of pharmacotherapy are manifold and can 
comprise body weight changes, sexual dysfunction, nausea, constipation, insomnia or 
cardiovascular toxicity (Vanina et al., 2002; Youdim et al., 2006; Kennedy et al., 2009) 
which, in turn, cause a high incidence of non-compliance in patients. In addition, 
approximately 50 % of patients do not respond to classical SSRI treatment. In those cases, 
therapy is switched to alternative substances (Rubinow, 2006; Maoz, 2007), which 
increases the risk of toxicity by drug-drug interactions through the inhibition of drug-
Introduction 
12 
 
metabolising liver enzymes of the cytochrome P 450 family (Gillman, 2007). Hence, it is 
apparent that there is a need for better and more refined treatment strategies for MD. 
However, the improvement of antidepressant drugs turned out to be highly challenging. 
There is still poor knowledge about how antidepressants exert their therapeutic effects 
since the biochemical function of these drugs are initiated shortly after their intake 
(minutes to hours), but an amelioration of psychic and physical symptoms in MD patients 
is delayed by approximately two to four weeks (Nestler et al., 2002; Schloss et al., 2004). 
This suggests, that not the accumulation of bioactive monoamines in the brain per se but 
rather functional and structural changes in neuronal networks, i.e. neuronal plasticity, are 
causative for the antidepressant effects (Schloss et al., 2004).  
Indeed, it has been shown that the SSRI Flx increased human hippocampal neurogenesis 
by activating the GR (Anacker et al., 2011). Consistently, Surget and colleagues showed 
that Flx treatment initiated hippocampal neurogenesis in chronically stressed mice and 
thereby restored HPA axis function and negative feedback regulation (Surget et al., 2008; 
Surget et al., 2011). Furthermore, it has been shown that 5-HT transporter knockout (KO) 
mice presented an impaired HPA axis activity and negative feedback mechanism, 
providing evidence for the prominent role of 5-HT in the regulation of the HPA axis 
(Jiang et al., 2009). In humans, a genetic variation resulting in a short 5-HT transporter 
gene promoter region was associated with an aberrant regulation of the HPA axis (Gotlib 
et al., 2008), suggesting the involvement of genetic risk factors in the aetiology of MD 
(Caspi et al., 2006). Considering the high heritability of MD (Fava et al., 2000; Nestler et 
al., 2002), it becomes apparent that psychiatric disorders are multidimensional diseases, 
developing from a combination of multiple factors such as a vulnerable genetic 
predisposition and environmental stimuli, leading to HPA axis dysregulation and 
alterations in the monoaminergic system. These factors interact in a highly complex 
manner to affect the risk of developing MD.  
Hence, it becomes evident that, due to the complexity of the underlying biological 
mechanisms of the disorder, the research in humans is drastically limited and that the use 
of valid animal models is essential in psychiatric research. 
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1.6 Animal models in scientific research 
Animal models have become an essential and powerful scientific tool in order to shed 
light on the complex molecular-genetic underpinnings as well as the behavioural 
endophenotypes of affective disorders such as MD. Mice and rats are frequently used 
model organisms in biomedical research as they can easily be kept in large numbers, are 
easy to handle and breed, have short generation times and cause relative low maintenance 
costs. 
Additionally, the mouse genome is completely sequenced and mice can be genetically 
modified, which makes the mouse an interesting organism for e.g. gene association 
studies since approximately 99 % of the mouse genes have human counterparts (Tecott, 
2003). Consistent with their genomic homologies, humans and mice share numerous 
features of brain organisation and behavioural responses to environmental stimuli as well 
as pharmacological agents despite their apparently different physiognomy (Tecott, 2003). 
Therefore, the mouse has become the favoured model organism for biomedical research 
in general and specifically in the field of psychiatric diseases. 
A good animal model is characterised by its validity at different levels (Willner, 1984, 
1995), i.e. the symptom profile (face validity) and the causality of the pathological 
condition (construct validity). Additionally, the amelioration or attenuation of symptoms 
by treatments (predicitive validity) should be similar between the model and clinical 
conditions. Moreover, events that potentially induce the pathology (aetiological validity) 
should match (Anisman et al., 2005; Schmidt, 2011). Although it is apparent that 
depressive symptoms such as suicidal tendencies and recurrent thoughts of death cannot 
be modelled in mice, it is possible to study specific behavioural domains in relation to 
psychiatric endophenotypes such as anxiety, anhedonia, sleep disturbances, diminished 
cognitive function or hormonal dysregulations (Gould et al., 2006). Accordingly, 
different approaches have been taken to induce these endophenotypes in mice thereby 
forming valid animal models, although none of these animal models is without 
shortcomings (Anisman et al., 2005). Frequently, rodents are subjected to aversive, 
environmental stimuli such as chronic mild or chronic stress paradigms, or are exposed to 
early life stress (maternal or peer separation), which resembles cases of early neglect. 
However, these paradigms do not take into account the individual’s genetic 
predisposition. Other models use genetically engineered mice with conventional 
(complete) or conditional (regionally and temporally controlled) gene KOs in order to 
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investigate the impact of a single gene on the behavioural and physiological 
endophenotype, thus disregarding the multi-genetic background of psychiatric diseases 
and the possibility of compensatory mechanisms resulting from the KO. Furthermore, 
many conventional KOs are lethal in early stages of development thereby prohibiting the 
manipulation of specific target genes (Cryan et al., 2002; Cryan et al., 2004; Cryan et al., 
2005). Therefore, another very promising approach is the use of selective, bidirectional 
inbreeding paradigms. In this approach, animals are selected for extremes of a specific 
behavioural phenotype such as anxiety (Krömer et al., 2005; Landgraf et al., 2007), 
aggressiveness (Veenema et al., 2003), or avoidance behaviour (Steimer et al., 2003). 
More recent approaches used a neuroendocrine phenotype such as the corticosterone 
secretion in response to stress as a selection criterion (Touma et al., 2008). Consequently, 
the animals which show the most extreme phenotypes in either direction are mated, and 
hence, the shift from the average endophenotype is increased throughout the generations. 
This approach is of advantage since multiple genetic factors which are associated with the 
respective phenotype are taken into account and thus, the genetic heritability in the 
aetiology of psychiatric diseases is considered (Gershon et al., 1976; Bienvenu et al., 
2011). 
 
1.7 The ‘stress reactivity’ mouse model 
Using a bidirectional selective inbreeding approach, a new mouse model for affective 
disorders was established in 2005, in order to model one key endophenotype of MD, a 
dysregulated HPA axis. This model consists of three mouse lines showing distinct 
differences in their adrenal CORT secretion in response to stressors, the high (HR), 
intermediate (IR) and low (LR) stress reactivity line (Touma et al., 2008). Starting from a 
parental generation of outbred CD-1 mice, the animals were selected according to the 
outcome of a so-called ‘stress reactivity test’ (SRT), consisting of a 15-min restraint 
period and two blood samplings, one immediately before and one right after the restraint 
stressor (Touma et al., 2008). The animals’ CORT increase in response to the SRT served 
as the selection criterion.This test was repeated with every generation. Males and females 
of both extremes, i.e. with high or low CORT increase, were mated, creating the HR and 
LR line, respectively. Additionally, a third line was established showing intermediate 
stress reactivity, resembling the population mean phenotype. Already in the first 
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generation, animals of the three breeding lines which were subjected to the SRT displayed 
significant differences in CORT increase which was even more pronounced in the 
following generations (see Figure 2). 
 
 
Figure 2: Corticosterone (CORT) increase in the stress reactivity test (SRT) of (A) male and (B) female 
mice of the CD-1 founder population (parental generation, PG) and the descendent generations (Gen I-
XII) of high (HR), intermediate (IR) and low (LR) reactivity breeding line. Already in Gen I, significant 
differences in the stress-induced CORT increase between the three mouse lines could be observed (KWH-
test, all p≤0.001***). This divergence was further increased in the subsequent generations (Figure 
adopted from Touma et al., 2008; Touma, 2011). 
 
 
Introduction 
16 
 
The stress reactivity (SR) mouse model has been established as a mouse model for 
affective disorders such as MD. In addition to the robust differences in plasma CORT 
concentrations in response to stressors between the three lines (Touma et al., 2008; 
Touma et al., 2009), elevated CORT levels were also found in the hippocampus 
(Heinzmann et al., 2010) of HR mice which was associated with cognitive deficits, 
impaired learning abilities and reduced brain derived neurotrophic factor (BDNF) 
expression in these animals (Knapman et al., 2010a). Interestingly, increased stress 
reactivity was also associated with reduced hippocampal activity and neuronal integrity in 
HR mice (Knapman et al., 2012). Furthermore, HR mice presented a flattened diurnal 
rhythm of CORT secretion with elevated trough levels compared to IR and LR animals 
(Touma et al., 2009). It was also shown that motor activity as well as sleep rhythmicity 
was different between the three lines, with HR mice presenting an elevated number of 
activity bouts and an increased sleep fragmentation in addition to increased rapid eye 
movement sleep and decreased slow wave activity compared to IR and LR animals, 
resembling symptoms of altered sleep architecture observed in melancholically depressed 
patients (Touma et al., 2009).  
Assessing the behavioural phenotype of HR, IR and LR mice, it was shown that animals 
of the HR line presented a hyper-active coping style in the forced swim test (FST), 
reflected by an increased struggling and decreased floating behaviour while LR mice 
displayed a more passive phenotype with decreased struggling and increased floating, 
which was interpreted as behavioural despair (Touma et al., 2008; Knapman et al., 
2010a). Therefore, HR animals present a neuronendocrine and behavioural phenotype 
which resembles the melancholic or psychotic subtype of MD, while LR mice show 
features of atypical depession. In addition, animals of the LR line share other similarities 
to patients suffering from atypical depression, such as increased body weight and elevated 
social aggression (Touma et al., 2008). Hence, HR and LR animals of the stress reactivity 
mouse model provide good face and construct validity as a model for 
melancholic/psychotic and atypical depression, respectively. 
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1.8 Aims and scope of the thesis 
The purpose of the studies presented in this thesis was to characterise the molecular-
genetic underpinnings of HPA axis dysregulation in HR, IR and LR mice, mirrored by the 
differences in stress-induced adrenal CORT secretion. As outlined above, it has been 
reported, that MD patients show HPA regulatory malfunctions, affecting all levels of this 
stress hormone system. Hence, we were interested whether the robust neuroendocrine 
phenotypes of the animals of the SR mouse model are a peripheral phenomenon brought 
about by the distal branches of the HPA axis such as the pituitary and/or the adrenal. 
Additionally, we wanted to elucidate whether control centres in the brain, which are 
known to be involved in HPA axis function and negative feedback regulation such as the 
hippocampus, the PVN or the prefrontal cortex, are differentially activated in HR, IR and 
LR animals, thus suggesting a central origin of HPA dysfunction in the SR mouse lines. 
Since the physiological regulation of the HPA axis is critically dependent on negative 
feedback mechanisms, and dysregulations of this system in patients suffering from MD 
are assessed by the Dex/CRH test, we were also interested in adapting the clinical settings 
of the Dex/CRH test to our experiments and subjecting animals of the SR mouse model to 
this neuroendocrine test. Furthermore, we aimed to pharmacologically characterise the SR 
mouse model in order to assess its predictive validity and thus, highlighting the model as 
a good model for affective disorders. 
To this end, we designed a series of experiments to investigate the activity and regulatory 
functions at the different levels of the HPA axis, i.e. in the brain, the pituitary and the 
adrenals. 
At the adrenal level, we pharmacologically inhibited CORT synthesis and secretion using 
metyrapone in order to evaluate whether the differences in stress reactivity between the 
three lines are associated with the divergent coping strategies in behavioural tests. 
Furthermore, we determined the adrenal weight and assessed the adrenal sensitivity of 
HR, IR and LR animals towards ACTH. Gene expression analysis in the adrenals was 
performed to identify the expression pattern of candidate genes critically involved in 
CORT secretion and steroidogenesis. 
At the pituitary level, we assessed ACTH protein abundance and release, both, basal and 
in response to stress. Furthermore, the gene expression pattern of candidate genes 
involved in the functional activity of the pituitary was studied. 
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In the blood, we investigated the role of corticosteroid-binding globulin (CBG), including 
its expression and release from the liver, since this protein is critically involved in the 
binding as well as the transport of CORT and regulate the amount of free, biologically 
active GCs. 
Once peripheral aspects of HPA axis dysfunction in the SR mouse lines had been 
assessed, we addressed the question whether the different behavioural and 
neuroendocrine phenotypes of the SR mice have molecular correlates in the central 
nervous system. In the same experimental approach, we aimed to investigate whether 
these phenotypes are affected by antidepressant treatment. 
In two experiments, we chronically treated mice of the three SR lines with the SSRI Flx, 
which is widely used as a first-line treatment in patients suffering from MD. 
In the first experiment, we studied the effect of chronic Flx treatment on the emotional 
behaviour of the animals. Additionally, we assessed the stress-induced HPA axis 
reactivity in response to the FST as well as HPA axis regulation in the Dex/CRH test in 
response to Flx treatment. Moreover, gene expression studies of candidate genes relevant 
for HPA axis function in the hippocampus and the pituitary of the animals were 
determined. Furthermore, GR and FK506 binding protein (FKBP51) abundance in the 
hippocampus was assessed. 
In the second experiment, we investigated whether Flx is able to exert beneficial effects 
on the cognitive performance of HR, IR and LR animals and is able to reverse the spatial 
learning deficits observed in HR mice in the Y-maze task. Subsequently, we wanted to 
elucidate whether the central perception and interpretation of stressful stimuli is different 
between HR, IR and LR animals. To this end, we assessed the stress-induced neuronal 
activitation in different limbic brain regions by means of C-fos in-situ hybridisation, i.e. 
monitoring the neuronal excitation in brain areas relevant for HPA axis activation and 
feedback regulation.  
The overall aim of this thesis was to gain detailed insights into the molecular-genetic 
underpinnings of one key endophenotype of MD, a dysregulation of the HPA axis. In a 
translational experimental approach, we used the SR mouse lines to characterise the 
interplay of all functional levels of the multidimensional cascade of the HPA axis, thereby 
contributing to the understanding of the involvement of a dysfunctional stress hormone 
system in the aetiology of affective disorders such as MD. 
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2 Animals, material and methods 
2.1 Animals 
In all studies, young adult male mice derived from generation XVI to XX of the SR 
mouse model were used. After weaning, the mice were housed in groups of four animals 
in transparent polycarbonate cages (standard Makrolon cages type III, Bayer 
MaterialScience, Leverkusen, Germany; 38 x 22 x 15 cm) with wood chips as bedding 
and wood shavings as nesting material. At the age of about eight weeks, plasma CORT 
concentrations were assessed in all animals by means of the SRT (Touma et al., 2008). At 
least ten days before performing the experiments of this study, animals were single 
housed by transferring them into smaller cages (standard Macrolon cages type II, Bayer 
MaterialScience; 23 x 16 x 14 cm). The mice were aged three to five months during all 
experiments. Housing and experimental rooms were kept under standardised laboratory 
conditions (12⁄12 h light⁄dark cycle, lights on 8:00 h; temperature: 22±1 °C; relative 
humidity: 55±10 %). Commercial mouse diet (Altromin No. 1324; Altromin GmbH, 
Lage, Germany) and tap water were available ad libitum. The presented work complies 
with the current regulations covering animal experimentation in Germany and the EU 
(European Communities Council Directive 86 ⁄ 609 ⁄ EEC). All experiments were 
announced to the appropriate local authority and were approved by the Animal Welfare 
Officer of the Max Planck Institute of Psychiatry (Az. 55.2-1-54-2531-64-07). 
2.2 Neuroendocrine tests 
2.2.1 The ‘stress reactivity test’ 
In order to test the reactivity of the HPA axis, the SRT was performed. This test is 
routinely carried out in all animals of the SR mouse model at the age of about eight weeks 
and consists of a 15-min restraint period, corresponding to an acute, moderate 
psychological stressor and two blood samplings drawn from the animals’ ventral tail 
vessel by means of a small incision immediately before and right after the restraint 
period, with the first blood sampling not exceeding 2 min after touching the cage, i.e. to 
rule out acute effects of handling on the first, baseline blood sample. The animals were 
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restrained in a 50 ml Falcon tube (Sarstedt, Nürnbrecht, Germany) with a ventilation hole 
at the conical tip of the tube and a hole for the tail in the lid (see Figure 3). In order to 
shield the mice from external cues and additional stress other than the confinement, the 
tubes were covered with non-transparent aluminium boxes during the restraint period. 
Blood samples were collected in EDTA-coated tubes (Microvette, Sarstedt, Nürnbrecht, 
Germany), centrifuged at 4000 x g for 10 min and plasma CORT concentrations were 
determined by means of a radioimmunoassay (see 2.4.3.1). By substracting the plasma 
CORT concentrations of the first blood sample from the restraint stress-induced plasma 
CORT values of the second sample, the CORT increase in response to the stressor was 
calculated for each animal, which served as neuroendocrine marker for the selective 
breeding approach of the SR mouse model (Touma 2008). 
 
 
Figure 3: Mouse being restraint during the ‘stress reactivity’ test (SRT). 
2.2.2 The combined dexamethasone/corticotropin-releasing hormone test  
In order to assess HPA axis activity and regulation in animals of the SR mouse model, we 
performed a combined Dex/CRH test. Therefore, we adapted the Dex/CRH test, which is 
widely used in clinical settings (Bardeleben et al., 1989; Heuser et al., 1994; Hatzinger et 
al., 1996; Ising et al., 2007) to mice. In humans, as well as in rats, blood samples are 
repeatedly drawn via a venous catheter to allow the determination of plasma ACTH and 
CORT concentrations over a particular period of time after CRH stimulation. Such an 
approach is not feasible in mice due to their small body size. Repeated blood sampling by 
means of incisions in the ventral tail vessel in mice of the SR mouse model are critical, 
since every sampling event would further activate the HPA axis, thus excluding unbiased 
neuroendocrine analysis. To avoid this, we performed the Dex/CRH test with slight 
modifications, i.e. only one blood sample was collected after Dex suppression and CRH 
challenge, respectively. A reference blood sample was collected by an incision in the 
ventral tail vessel at 15:00, three days prior to the test. On the experimental day, HR, IR 
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and LR mice were injected intraperitoneally (i.p.) with a low dose of Dex (0.05 µg/g BW; 
ratiopharm GmbH, Ulm, Germany) at 9:00, i.e. during the trough of the circadian CORT 
release, in order to suppress HPA axis activity. It should be noted that we chose a low 
dose of Dex to avoid (i) an overstimulation of the Dex-mediated negative feedback and 
(ii) a Dex surge in the brain, since this synthetic GC is restricted from entering the brain 
under physiological conditions (Schinkel, 1997). At 15:00, a second blood was drawn 
from the ventral tail vessel by means of a tail nick in order to analyse the CORT-
suppressive effect of Dex in the plasma of the animals, followed by an immediate CRH 
injection (0.15 µg/g BW i.p.) to stimulate HPA axis activity. Thirty minutes later the mice 
were sacrificed and trunk blood was collected in EDTA-coated tubes (KABE 
Labortechnik GmbH, Nürnbrecht-Elsenroth) equipped with 10 µl of the protease inhibitor 
Trasylol (Bayer Vital GmbH, Leverkusen, Germany). All other blood samples were 
collected in EDTA-coated tubes (Sarstedt, Nürnbrecht, Germany), centrifuged for 10 min 
(4000 x g at 4 °C) and plasma CORT concentrations were determined (see 2.4.3.1). 
2.2.3 The adrenal sensitivity test 
To investigate whether the distinctly different neuroendocrine phenotypes, i.e. adrenal 
CORT secretion in response to stressors, of HR, IR and LR mice are brought about by 
differences in the sensitivity of the adrenals of the animals, an adrenal sensitivity test was 
performed. In this test, animals of all three lines received a high dose of Dex (4 µg/g BW) 
at 9:00 with the aim of suppressing the release of ACTH via GR-mediated negative 
feedback mechanism at the level of the pituitary, thus minimising masking effects of 
endogenous ACTH on adrenal CORT release. Six hours after the Dex injection (15:00), 
when maximal suppression of endogenous ACTH and CORT was reached (Keller-Wood 
1984, Steimer 2007), a blood sample was collected by means of a tail nick in order to 
verify the ACTH- and CORT-suppressive effect of Dex. Subsequently, animals were 
injected with either vehicle (Ringer solution, Berlin-Chemie AG, Berlin, Germany) or one 
of two doses of ACTH (0.1 ng/g or 1 ng/g BW, Synacthen®, Defiante Farmacêutica, 
S.A., Funchal, Portugal) diluted in vehicle to stimulate CORT secretion from the adrenal 
cortex. Thirty minutes after the injection, animals were deeply anaesthetised (Isoflurane, 
Forene, Abbott GmbH, Wiesbaden, Germany), sacrificed by decapitation and trunk blood 
was collected in EDTA-coated tubes (KABE Labortechnik GmbH, Nürnbrecht-Elsenroth) 
equipped with 10 µl of the protease inhibitor Trasylol (Bayer Vital GmbH, Leverkusen, 
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Germany). The blood samples were centrifuged for 10 min (4000 x g at 4 °C) and plasma 
was transferred into fresh tubes and frozen at -20 °C. Plasma ACTH concentrations were 
determined from the blood sample taken 6 h after the Dex injection (see 2.4.3.2) to 
confirm the Dex-mediated ACTH suppression. Furthermore, plasma CORT 
concentrations were analysed in all collected blood samples (see 2.4.3.1). 
2.3 Behavioural tests 
2.3.1 Open field test 
The Open Field (OF) test is based on evoking a conflict between the animal’s exploratory 
drive and its evolutionary innate fear of novel and open areas. The OF apparatus consists 
of a black, open topped PVC cylinder (60 cm in diameter, 40 cm in height) mounted on a 
grey PVC floor plate (see Figure 4). The circular test area was divided into a more 
aversive, inner zone (30 cm in diameter) and a more protective, ring-shaped outer zone 
near the walls of the OF. The apparati were placed into test chambers surrounded on three 
sides by black PVC walls, the fourth side could be closed by a black curtain to prevent the 
experimental animals from visual or auditory cues. In all experiments, the test apparati 
were dimly and evenly illuminated with 15 lux, thereby reducing the averseness of the 
test situation since we were not interested in the assessment of anxiety-related 
behavioural parameters, but rather in the exploratory drive and locomotor activity of the 
mice. During the 10-min test period, the animals’ total distance of travelling, the time 
within each zone, as well as the ratio between the path length in the inner and outer zone 
were automatically assessed utilising the ANY-Maze Video Tracking Software (version 
4.72, Stoelting Co., Wood Dale, IL, USA). After testing an animal, the OF was 
thoroughly cleaned with soapy water and 70% ethanol. 
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Figure 4: Experimental setup of the Open Field (OF) test. 
2.3.2 Forced swim test 
The Forced Swim Test (FST) is widely used in pharmacological research using mice and 
rats to screen pharmaceutical compounds for their antidepressant activity. In the FST, 
animals are subjected to a psychological (inescapable), as well as physiological 
(swimming), stressful situation in order to monitor their depression-like behaviour and 
individual stress-coping style, respectively. This paradigm is especially demanding for 
mice since they rarely swim in their natural environment. Being placed in a glass beaker 
(12 cm in diameter, 23.5 cm in height) filled two thirds with 23 °C warm water (see 
Figure 5) and unable to touch the bottom with their hind paws or tail, the mice actively try 
to escape from the situation by attempting to climb out of the tank (struggling), followed 
by periods of active swimming. Eventually, the animals adopt immobile postures, so 
called floating (defined as complete immobility of the animals extremities excluding 
small movements to keep balance in the water), with the amount of immobility 
representing depression-like behaviour or behavioural despair. In our studies, the duration 
of struggling, swimming and floating behaviour during a 6-min FST period was scored by 
a trained observer blind to line and treatment using EVENTLOG software (EVENTLOG 
Event Recorder, version 1.0, EMCO software). 
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Figure 5: Experimental setup of the Forced Swim Test (FST). 
2.3.3 Y-Maze test 
To assess the spatial, hippocampus-dependent learning and memory of the experimental 
animals, the Y-Maze test was used. The Y-Maze apparatus used in our tests consisted of 
three similarly shaped arms made of grey PVC, each 11 cm wide and 30 cm long, 
surrounded by 15 cm high walls and interconnected through a triangular central zone (see 
Figure 6). To facilitate the mice’ orientation in the maze, the wall of each arm was tagged 
with a distinctive symbol in the shape of a bar, a triangle or a plus, respectively. During 
the 10-min acquisition phase, one arm was blocked by a grey PVC inlay, leaving two 
arms for the mice to explore. To avoid a preference for one arm during the acquisition 
phase, the animals were first placed into the central zone facing the partition wall. After 
returning the animals for 1 h to their home cages (inter-trial interval), they were placed 
back into the test apparatus (retrieval phase), this time with the opportunity to explore all 
three arms of the maze. The retrieval phase lasted for 5 min. The apparati were placed in 
test chambers surrounded by black PVC walls and a black curtain to avoid additional 
distal orientation cues apart from the proximal cues positioned on the Y-Maze walls. 
After each animal and each trial the Y-Maze was thoroughly cleaned with soapy water 
and 70 % ethanol to prevent mutual interference of the test animals. 
The retrieval phase of each animal was analysed regarding the time spent in each of the 
three arms using ANY-Maze Video Tracking Software (version 4.72, Stoelting Co., 
Wood Dale, IL, USA). If the experimental animals were able to discriminate between the 
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familiar arms, i.e. the two arms open during the acquisition phase, and the novel arm, i.e. 
the newly opened arm during the retrieval phase, this was reflected by an extended 
amount of time spent in this new arm. In order to counterbalance differences in 
locomotion and therefore in total time spent in the respective arms, the mean percent time 
spent in the familiar arms was compared to the percent time spent in the novel arm.  
Additionally, a ‘discrimination ratio’ (% time spent in the novel arm/familiar arms) was 
calculated reflecting the accuracy of the animals’ memory performance. The higher the 
ratio, the more accurately the animals were assumed to remember the ‘old’, previously 
explored arms. 
 
 
Figure 6: Experimental setup of the Y-maze test. 
2.4 Molecular biology techniques 
2.4.1 Western blot 
In order to analyse hippocampal, pituitary and liver homogenates as well as plasma 
samples from the experimental animals regarding potential differences in protein 
expression, semi-quantitative protein analysis was performed using Western blotting. 
Whole cell protein was extracted from the tissue (hippocampus and pituitary) using an 
automatic tissue homogeniser (VDI 12, VWR International GmbH, Darmstadt, Germany) 
in 150 µl homogenisation buffer (H-buffer). After homogenisation, 50 µl of extraction 
buffer (E-buffer) was added to the solution and the samples were sonified for 
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approximately 20 s (Branson Sonifier 250, Schwäbisch Gmünd, Germany). A detailed 
overview of all used buffers is outlined in the appendix (Table 1). The samples were 
subsequently incubated on ice for 15 min, centrifuged for 30 min (11350 x g at 4 °C) and 
the supernatant, holding the cell protein, was transferred into fresh tubes. The pellet was 
discarded. An aliquot of 4 µl was pipetted and further diluted 1:10 with distilled water for 
protein concentration analysis (see below).  
Liver samples were processed as described above with slight modifications. Protein was 
extracted from liver samples using radioimmunoprecipitation assay (RIPA) buffer. After 
homogenisation and sonification, the samples were incubated for 30 min to accomplish 
cell lysis. After centrifuging 1 ml of the homogenate for 30 min (11350 x g at 4 °C), the 
supernatant was transferred into a new tube. An aliquot of 4 µl was pipetted and further 
diluted 1:100 with distilled water for protein concentration analysis. 
Plasma samples were directly diluted 1:10 with distilled water in order to determine the 
plasma protein concentration. 
The protein concentration of all tissue and plasma samples was detected using a BCA 
protein assay according to the manufacturer’s protocol (Thermo Scientific, Rockford, 
USA). The samples were analysed in triple estimation by photometric measure (Dynatech 
MR 7000, Denkendorf, Germany) at a wavelength of 550 nm and the protein 
concentration was set to 0.5 µg/µl to 2 µg/µl with a final volume of 100 µl to 200 µl per 
sample, always containing protein loading buffer (PLB, see Table 1 in the appendix) in a 
1/5 ratio of the final volume. 
Ten microlitres (5 µg to 20 µg) of protein solution was loaded and separated by sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE, 10 % or 12 %, 
depending on the size of the protein of interest) for 90 min at 120 V and transferred (60 
min at 400 mA) onto a nitrocellulose membrane (Whatman GmbH, Dassel, Germany). To 
block unspecific binding sites, the membranes were incubated for 1-2 h in 5 % (w/v) fat 
free milk solution (Carl Roth GmbH, Karlsruhe, Germany) and incubated overnight at 4 
°C in the respective first antibody in 2.5 % Tris-buffered saline and Tween 20 
(TBST)/milk solution. After the membranes were rinsed with TBST on the next day, the 
incubation time with the respective horseradish peroxidase-conjugated secondary 
antibody was 1 h at room temperature, followed by washing with TBST. A detailed 
overview of the used primary and secondary antibodies is outlined in Table 1. 
Glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) and Transferrin (TF) were used 
as standard proteins for hippocampal, pituitary and liver samples or plasma samples, 
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respectively. After being incubated in enhanced chemiluminescence (ECL) solution (see 
appendix, Table 2), the membranes were either (i) exposed to a ECL sensitive film (GE 
Healthcare, Amersham Hyperfilm™ ECL, Little Chalfont, UK), scanned and the signal 
intensity of the protein band (optical density) was assessed by Image J software (version 
1.44p, National Institute of Health, USA, http://imagej.nih.gov/ij/) or (ii) the protein 
bands were detected by the chemoluminescence-sensitive camera of the ChemiDoc MP 
imaging system (Bio-Rad Laboratories GmbH, Munich, Germany) and analysed by 
Image Lab software (version 4.0.1 build 4, Bio-Rad Laboratories GmbH, Munich, 
Germany). 
 
Table 1: List of antibodies with their respective specifications and dilutions used for Western blot analysis. kDa, 
kilodalton. 
Target protein Abbreviation 
Protein size 
(kDa) 
Primary antibody Secondary antibody 
specification dilution specification dilution 
Glucocorticoid 
Receptor 
GR 95 
GR (M-20) rabbit 
polyclonal 
antibody (Santa 
Cruz, sc 1004) 
1:500 
goat anti-rabbit 
horseradish 
peroxidase 
conjugated 
antibody (Sigma, 
A9169) 
1:30000 
FK506 binding 
protein 51 
FKBP51 51 
FKBP51 (F-14) 
goat polyclonal 
antibody (Santa 
Cruz, sc 11518) 
1:500 
donkey anti-goat 
horseradish 
peroxidase 
conjugated 
antibody (Santa 
Cruz, sc2056) 
1:10000 
Adrenocortico-
tropic hormone 
ACTH 29 
ACTH rabbit 
polyclonal 
antibody 
(Abcam, ab 
74976) 
1:3000 
goat anti-rabbit 
horseradish 
peroxidase 
conjugated 
antibody (Sigma, 
A9169) 
1:30000 
Glyceraldehyde-3-
phosphate-
dehydrogenase 
GAPDH 37 
GAPDH (A-3) 
mouse 
monoclonal 
antibody (Santa 
Cruz, sc 
137179) 
1:2000 
goat anti-mouse 
horseradish 
peroxidase 
conjugated 
antibody (Sigma, 
A9917) 
1:15000 
Corticosteroid 
binding globulin 
CBG 55 
hCBG rabbit 
antibody 
(Affiland, 
CB017H) 
1:2000 
goat anti-rabbit 
horseradish 
peroxidase 
conjugated 
antibody (Sigma, 
A9169) 
1:30000 
Transferrin TF 79 
Transferrin (M-
70) rabbit 
polyclonal 
antibody (Santa 
Cruz, sc 30159) 
1:1000 
goat anti-rabbit 
horseradish 
peroxidase 
conjugated 
antibody (Jackson, 
111-035-003) 
1:10000 
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2.4.2 Quantitative real-time PCR 
2.4.2.1 RNA extraction and reverse transcription 
RNA extraction from hippocampal, pituitary and adrenal tissue was performed using 
guanidinium thiocyanate-phenol-chloroform extraction (=TRIzol method). To this end, 
the tissue was homogenised in TRI reagent (1 ml TRI reagent per 50 mg tissue, Sigma-
Aldrich, Steinheim, Germany) with a plastic pestle. After adding 200 µl chloroform (Carl 
Roth GmbH, Karlsruhe, Germany) per ml TRI reagent, the solution was incubated for 5 
min at room temperature and subsequently centrifuged for 15 min (11350 x g at 4 °C). 
The supernatant was transferred into a fresh tube, 500 µl isopropanol (Carl Roth GmbH, 
Karlsruhe, Germany) per ml TRI reagent was added and the samples were incubated over 
night at -20 °C for RNA precipitation. The next day, samples were centrifuged for 10 min 
(11350 x g at 4 °C), the supernatant was discarded and the pellet was washed three times 
with 70 % ethanol, air dried and redissolved in approximately 50 µl of H2O. Total RNA 
concentration was analysed using the NanoDrop photometer (Implen GmbH, Munich, 
Germany) and was set to 50 ng/µl. In order to control for RNA quality, the absorbance 
ratio of the RNA at a wavelength of 260 nm and 280 nm (A260/A280) was calculated. 
Values higher than 1.8 were accepted, indicating good RNA quality. A total amount of 
500 ng of RNA per sample was reverse transcribed into complementary DNA (=cDNA) 
by means of a high-capacity cDNA reverse transcription kit (Applied Biosystems, 
Darmstadt, Germany) following the manufacturer’s protocol (thermal cycler settings: 10 
min at 25 °C, 120 min at 37 °C, 5 min at 85 °C, ∞ at 4 °C) using a Peqlab thermal cycler 
(Peqlab Biotechnologie GmbH, Erlangen, Germany). The cDNA concentration was 
analysed by the NanoDrop photometer (Implen GmbH, Munich, Germany) and set to 150 
ng/µl. 
2.4.2.2 Quantitative real-time PCR analysis 
The quantitative real-time PCR (qPCR) is based on the simultaneous amplification and 
quantification of PCR products allowing quantitative conclusions regarding expression 
patterns of a gene of interest. cDNA gene transcripts were analysed using the Qiagen 
QuantiFast SYBR Green PCR kit (Qiagen GmbH, Hilden, Germany) following the 
manufacturer’s protocol. Samples were prepared as follows: 5 µl QuantiFast SYBR 
Green, 1 µl forward primer (10 pM), 1 µl reverse complementary primer (10 pM), 2 µl 
cDNA and 1 µl nuclease-free water. Additionally, one control sample was prepared, 
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containing water instead of cDNA (negative control). Experiments were performed in 
duplicates using the Roche Lightcycler® 2.0 instrument (Roche Diagnostics, Mannheim, 
Germany) under following conditions: initial preincubation phase (95 °C 10 min), 
followed by 40 cycles of repetitive denaturation (95 °C 10 s) and combined annealing and 
extension (60 °C 30 s). After each cycle fluorescence was assessed. A melting curve was 
created at the end of each run in order to denature all PCR products (50-95 °C with 0.1 
°C/s temperature increase) and control for their quality. Primer specificity was assured 
when an equal melting temperature of the amplicon was detected. TATA-binding protein 
(TBP) and Hypoxanthine-Guanine Phosphoribosyltransferase (HPRT) were used as 
housekeeping genes. A detailed list of all applied oligonucleotide primers is outlined in 
Table 2. Crossing points (CP) were calculated with the LightCycler® Software 4.05 
(Roche Diagnostics GmbH, Mannheim, Germany) using the absolute quantification fit 
points method. Threshold and noise band were set to the same level in all compared runs. 
Relative gene expression was calculated using the 2-∆∆CT algorithm (Livak et al., 2001). 
The efficiency of each run was used as calculated from an internal standard curve 
prepared from a dilution series (1/1, 1/5 and 1/10) containing an aliquot of cDNA from 
each sample. CPs were normalised to the mean of the two housekeeping genes TBP and 
HPRT and all values were calculated to the relative expression mean of IR animals. 
 
Table 2: List of oligonucleotides (primers) used for qPCR analysis. For full gene names see 2.5.2.1.3. All primers 
were purchased from Sigma Aldrich. Tm, melting temperature; bp, base pairs 
Target 
gene 
Orientation 
(5' - 3') 
Sequence 
Tm 
[°C] 
Product length 
[bp] 
Nr3c1 
forward CAA GGG TCT GGA GAG GAC AA 64.2 
220 
reverse TAC AGC TTC CAC ACG TCA GC 64.1 
Nr3c2 
forward GTG TGT GGA GAT GAG GC  57.2 
155 
reverse GGA CAG TTC TTT CTC CGA AT  59.6 
Fkbp4 
forward CAA CGC CAC ACT TGT ATT TGA 63.5 
143 
reverse CTT CCA CCA TAG CAC CAT CAT 63.7 
Fkbp5 
forward AGA ATC AAA CGG AAA GGC GAG 66.3 
103 
reverse CTC GGC AAT CAA ATG TCC TTC 65.6 
Abcb1a 
forward GAA GAT CAA CTC GCA AAA GCA T 64.3 
161 
reverse GGC ACA GAA TAT ACC AAC CAC A 63.4 
Abcb1b 
forward GAA CAT TAC TTC CCC TCT TGA T 59.9 
130 
reverse CTG TTG CTG ATG ATC AGA GTA C 59.0 
Crhr1 
forward GGT CCT GCT GAT CAA CTT TA 59.2 
152 
reverse ACA TGT AGG TGA TGC CCA 59.9 
Cfl1 
forward ATG ATC TAT GCC AGC TCC AAG 63.0 
127 
reverse CGC TGC CAC CTA GTT TCT CT  63.3 
Gilz forward GTG GCC CTA GAC AAC AAG ATT 61.9 122 
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reverse GAG TTC TTC TCA AGC AGC TCA 61.5 
Pomc 
forward GAA GAT GCC GAG ATT CTG CT 63.4 
222 
reverse TTT TCA GTC AGG GGC TGT TC 64.1 
Star 
forward GCT GGA AGC TCC TAT AGA CAT 59.0 
191 
reverse GAC AGC TCC TGG TCA CTA TAG 58.0 
Mc2r 
forward CCA AGG AGA GGA GCA TTA TTG 62.5 
141 
reverse GTT TGC CGT TGA CTT ACA GAA 61.7 
Tbp 
forward CCC CCT TGT ACC CTT CAC C 65.4 
285 
reverse TGG ATT GTT CTT CAC TCT TGG 65.3 
Hprt 
forward GTT GGA TAC AGG CCA GAC TTT GT 65.1 
225 
reverse CCA CAG GAC TAG AAC ACC TGC TA 64.3 
Th 
forward CTG TGG AGT TTG GGC TGT GTA 65.0 
160 
reverse GTT TGA TCT TGG TAG GGC TGC 64.7 
Pnmt 
forward GCT GCA TGG CAC AAG TCT TTG 68.0 
198 
reverse CAC TCC AGT CAA AGG CTC CTG 66.2 
2.4.3 Radioimmunoassays 
2.4.3.1 Corticosterone radioimmunoassay 
Plasma CORT was measured using a commercially available CORT radioimmunoassay 
(RIA) kit (DRG Instruments GmbH, Marburg, Germany) following the manufacturer’s 
protocol with slight modifications. In order to increase the applicable sample size of the 
RIA, half of the recommended volume of all reagents was used. Ten microlitres of plasma 
of each sample were applied to the assay and all samples were analysed in duplicate. 
Furthermore, the same “pool” samples were run in every assay as an internal standard to 
control for intra- and interassay variations. The CORT-RIA is based on the competitive 
binding of radiolabelled 125Iodine (I)-CORT and non-radioactive CORT in the plasma 
samples for a limited number of accessible binding sites of a specific antibody. The 
higher the content of unlabelled antigen in the plasma samples, the less 125I-CORT can be 
bound by the applied antibody. Hence, the amount of the 125I-CORT is negatively 
proportional to the amount of unlabelled plasma CORT in the samples. To isolate the 
antibody-CORT-complex in the solution, a second antibody is applied and centrifuged, 
the unbound CORT is decanted and the radioactivity in the pellet is measured by a 
gamma counter (Wallac Wizard 1470 automatic gamma counter, Perkin Elmer life 
science, Rodgau, Germany). CORT concentrations were calculated by means of a 
standard curve. Double estimations were accepted if the coefficient of variation was 
below 10 %. The detection limit of the CORT-RIA was 1 ng/ml. 
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2.4.3.2 Adrenocorticotropic hormone radioimmunoassay 
Plasma ACTH was measured using a commercially available ACTH-RIA kit (DRG 
Instruments GmbH, Marburg, Germany) following the manufacturer’s protocol. 50 µl of 
plasma of each sample was analysed in duplicate if not otherwise indicated. Double 
estimations were accepted if the coefficient of variation was below 15 %. The ACTH-
RIA is based on the same principle as the CORT-RIA (see 2.4.3.1) using the double 
antibody-antigen technique. The detection limit of the ACTH-RIA was 7 pg/ml. 
2.4.4 In-situ hybridisation 
The in-situ hybridisation (ISH) technique allows the detection of local expression patterns 
of a gene of interest in target tissues and therefore provides information of its distribution 
or involvement in particular brain functions and processes. In order to assess mRNA 
expression levels of C-fos as a marker for neuronal activity in HR, IR and LR mice, ISH 
was performed in different brain areas (see Figure 7) known to be critically involved in 
HPA axis regulation (prefrontal cortex, paraventricular nucleus of the hypothalamus, 
basolateral amygdala, dorsal and ventral hippocampus). An exon-spanning ribonucleotide 
probe for C-fos was designed using Primer3 software 
(http://primer3.sourceforge.net/releases.php), spanning from exon 1 to exon 4 of the 
murine C-fos gene, with a total length of 480 base pairs (forward primer 5’-3’: 
ATGGGCTCTCCTGTCAACAC; reverse primer 5’-3’: GGCTGCCAAAATAAACT 
CCA). Frozen brains were mounted in a cryostat (Cryo-Star HM 560 M, MICROM 
GmbH, Waldorf, Germany) and cut in 18 µm slices in the coronal section with a knife 
and sample temperature of -15 °C. Brain slices were adhered to superfrost plus slides 
(VWR, Darmstadt, Germany), shortly dried and stored at -80 °C until further analysis. 
ISH using a 35S-UTP-labelled riboprobe for C-fos was performed as described earlier 
(Schmidt et al., 2007; Scharf et al., 2011). Briefly, brain sections were fixed in 4 % 
paraformaldehyde, washed and acetylated in 0.25 % acetic anhydride. Subsequently, 
slides were dehydrated in ascending concentrations of ethanol, degreased with chloroform 
and air dried. After adding 100 µl of hybridisation buffer per slide, containing 0.65 to 
1.7x106 counts per minute of 35S-UTP-labelled riboprobe, the slides were coverslipped 
and incubated overnight at 55 °C. The next day, coverslips were removed, the slides were 
washed and incubated in RNase A solution. Finally, the sections were desalted and 
dehydrated and exposed to radiation-sensitive films (Kodak Biomax MR films, Eastman 
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Kodak Co., Rochester, NY, USA) for 5 days except for the ventral hippocampus, which 
was exposed for 12 days due to a lower signal intensity. The films were scanned and the 
C-fos signal intensity (optical density) was assessed by Image J software (version 1.44p, 
National Institute of Health, USA, http://imagej.nih.gov/ij/). For each animal, bilateral 
structures of one slice were calculated, substracting the background from the value. The 
background signal was measured in structures not expressing C-fos. 
 
 
Figure 7: Schematic overview of the anatomical location of the brain regions investigated for C-fos expression by 
in–situ hybridisation. Upper left: prefrontal cortex (PFC). Upper right: basolateral amygdala (BLA) and 
paraventricular nucleus of the hypothalamus (PVN). Lower left: dorsal hippocampus including the cornu 
ammonis 1-3 subfields (CA1, CA2, CA3) and the dentate gyrus (DG). Lower right: ventral hippocampus. Figures 
adopted from (Franklin et al., 2001). 
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2.5 Experimental design 
2.5.1 Peripheral regulation of the hypothalamic-pituitary-adrenal axis 
2.5.1.1 Experiment 1: Inhibition of corticosterone secretion by the 11β-hydroxylase 
inhibitor metyrapone 
2.5.1.1.1 Introduction 
Adrenal cortex steroid biosynthesis is stimulated by ACTH released from the anterior 
pituitary and performed by multiple enzymatic steps, converting cholesterol into different 
steroid hormones, among them CORT (Jefcoate et al., 1992; Miller et al., 2011). It has 
been repeatedly reported that CORT, either endogenously secreted in response to stress or 
exogenously administered, has the ability to shape behavioural phenotypes, e.g. in 
memory tasks (de Quervain et al., 1998; Akirav et al., 2004), stress-coping paradigms 
(Baez et al., 1994) or anxiety-related tests (Calvo et al., 1998). In the same studies, it was 
shown that metyrapone was able to reverse the CORT-induced behavioural effects in the 
experimental animals, suggesting antidepressant properties of this pharmaceutical 
compound. Metyrapone was originally synthesised by Allen and Rencze in 1958 (Jenkins 
et al., 1958). It inhibits the enzymatic activity of cytochrome P450 11β-hydroxylase, the 
final enzymatic step of CORT production (Yanagibashi et al., 1988), leading to a dose-
dependent decrease in CORT secretion from the adrenal cortex (Jenkins et al., 1958). 
However, the induction and depletion of CORT synthesis or secretion, respectively, is not 
an intrinsic mechanism but is functionally interwoven with the biosynthetic pathway of 
catecholamines in the adrenal medulla (Axelrod et al., 1984). It has been reported that 
glucocorticoids can modulate the enzymatic production of the catecholamines adrenaline 
and noradrenaline (Axelrod et al., 1984) and vice versa (Bornstein et al., 1999), which are 
originally released from the adrenal medulla in response to sympathetic nervous system 
activity via the splanchnic nerve (Engeland, 1998). The rate-limiting step of 
catecholamine biosynthesis in the adrenal medulla is the conversion of tyrosine into Dopa 
by tyrosine hydroxylase (TH), whereas the enzyme phenylethanolamine-N-
methyltransferase (PNMT) synthesises adrenaline from noradrenaline. Collectively, 
glucocorticoids and catecholamines have complementary actions throughout the body, 
including energy metabolism and maintenance of blood pressure (Ulrich-Lai et al., 2009), 
respectively, thus playing a pivotal role in the physiological stress response. 
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2.5.1.1.2 Objective of the experiment 
In this experiment, we were interested in investigating the behavioural and physiological 
effects of CORT in animals of the SR mouse model. It has been shown that in these 
animals, which are selectively bred for extremes in stress reactivity, the HR line has a 
significantly increased secretion of CORT from the adrenal cortex compared to LR 
animals in response to stress, concomitantly showing differences in stress-coping 
strategies, e.g. in the FST. HR mice display a hyperactive coping, i.e. more struggling, 
while LR animals show more passive behaviour, i.e. reduced mobility in this test (Touma 
et al., 2008). Based on this observation, we investigated (i) whether pharmacological 
inhibition of CORT synthesis and secretion by metyrapone affects the behavioural 
phenotype of the animals of the SR mouse model and (ii) whether the three mouse lines 
of the SR mouse model show differences in the gene expression patterns of TH and 
PNMT in the adrenals according to their distinctly different CORT release in response to 
stress. Furthermore, we assessed adrenal mRNA expression of the ACTH receptor 
(melanocortin 2 receptor, Mc2r) as well as the steroid acute regulatory protein (Star), 
which are both critically involved in the release of CORT from the adrenals and in the 
induction of steroidogenesis in the adrenal cortex, respectively (Lefkowitz et al., 1971; 
Xia et al., 1996; Stocco, 2001; Miller, 2007). 
2.5.1.1.3 Experimental setup 
Adult males of the HR, IR and LR line derived from Gen XVI of the SR mouse model 
were acutely injected intraperitoneally (i.p.) with a dose of 50 µg/g BW metyrapone 
dissolved in vehicle (Ringer solution containing 5 % ethanol). Control animals received 
just the vehicle solution. At this dose metyrapone produces a greater than 50 % reduction 
in plasma CORT within the first hour after injection, which gradually returns to baseline 
within 20-24 h (Jenkins et al., 1958; Roberts et al., 1984; Piazza et al., 1994). Moreover, 
we performed dose-finding studies, which confirmed the effectiveness of this particular 
dose on stress-induced CORT levels in a separate batch of HR, IR and LR mice. One hour 
after the injection, two behavioural tests were performed consisting of a 10-min OF test, 
directly followed by a 6-min FST in order to assess locomotor activity and stress-coping 
behaviour, respectively. Additionally, plasma CORT concentrations were determined. To 
this end, a blood sample of the yet untreated animals (reference) was obtained three days 
before the start of the experiment. To assess the stress-induced rise in plasma CORT, a 
second blood sample was collected immediately after the FST (trunk blood sample). 
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Animals were sacrificed by decapitation, trunk blood was collected and both adrenals 
were dissected, cleared from fat tissue and quickly frozen on dry ice until further analysis. 
RNA was isolated from the adrenals and gene expression analysis was performed using 
qPCR (see 2.4.2). The blood samples were centrifuged for 10 min (4000 x g at 4 °C) and 
plasma was transferred into fresh tubes and frozen at -20 °C until CORT concentration 
was analysed (see 2.4.3.1). An overview of the experimental schedule is depicted in 
Figure 8. 
 
 
Figure 8: Schematic overview of the experimental schedule with time and intervals of the collected blood 
samples, metyrapone injection and behavioural tests. OF, open field test; FST, forced swim test; i.p., 
intraperitoneal; t, time; d, day. 
 
2.5.1.2 Experiment 2: Adrenal sensitivity towards adrenocorticotropic hormone 
2.5.1.2.1 Introduction 
It has been shown in a number of studies that adrenal sensitivity, i.e. GC release from the 
adrenal cortex upon binding of ACTH, is largely dependent on ligand binding of the 
MC2R. The MC2R is a G-protein coupled receptor with seven transmembrane domains 
(Abdel-Malek, 2001), which is located mainly in the zona fasciculata and zona 
glomerulosa of the adrenal cortex, the site of glucocorticoid and aldosterone synthesis, 
respectively (Mountjoy et al., 1992; Xia et al., 1996). Upon binding of ACTH to this 
receptor, a signalling cascade is activated, stimulating the production of cyclic adenosine 
monophosphate (cAMP) by adenylyl cyclase, which, in turn, activates catalytic subunits 
of the protein kinase A (PKA). The PKA then triggers the phosphorylation of proteins 
and enzymes involved in the conversion of cholesterol to corticosteroids, i.e. activating de 
novo steroidogenesis (Lefkowitz et al., 1971; Abdel-Malek, 2001; Kirschner, 2002). 
However, changes in MC2R sensitivity towards its ligand and/or alterations in the 
subsequent signalling cascade can lead to pathological conditions such as adrenal 
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insufficiency, e.g. familial glucocorticoid deficiency (FGD) or Addison’s disease. It has 
been reported that in FGD mutations in the MC2R gene result in an impaired cAMP 
response due to decreased ligand binding affinity of the receptor (Elias et al., 1999; Elias 
et al., 2000). Furthermore, it was shown that the MC2R accessory protein (MRAP) is 
required for processing, trafficking and proper insertion of functional MC2R in the 
plasma membrane of adrenal cells and that disruption of this protein can lead to an 
insufficient response of the adrenal to ACTH (Metherell et al., 2005). On the other hand, 
Swords and colleagues showed that two missense mutations in the MC2R gene lead to 
adrenal hypersensitivity towards ACTH resulting in increased plasma CORT 
concentrations (Swords et al., 2004). Additionally, it has been reported that repeated 
adrenal stimulation with ACTH induces an enhanced expression of the MC2R, which 
results in an increased ACTH binding and cAMP response in adrenal cells (Penhoat et al., 
1989; Mountjoy et al., 1994; Abdel-Malek, 2001). Furthermore, it was shown that stress 
exposure leads to adrenal hypertrophy associated with elevated concentrations of plasma 
CORT (Gamallo et al., 1986; Moraska et al., 2000; Ulrich-Lai et al., 2006). Both, adrenal 
insufficiency, as well as adrenal hyperactivity, are pathological states involving the 
MC2R and are associated with a dysregulation of the HPA axis under basal conditions or 
in response to stressors, a condition which is mirrored in the animals of the SR mouse 
model. 
2.5.1.2.2 Objective of the experiment 
The purpose of this experiment was to address the question whether the distinct 
differences in stress-induced plasma CORT concentrations observed in HR, IR and LR 
mice arise from differences in adrenal sensitivity. Previous studies by Touma and 
colleagues showed that an ACTH challenge of these animals with a supraphysiological 
dose (1 µg/g BW) of exogenously administered ACTH caused a similar increase in 
plasma CORT concentrations in all three lines, suggesting that the capacity of the 
adrenals to produce and secrete CORT was not different between the lines (Touma et al., 
2008). Hence, we hypothesised that the significant differences in CORT secretion in 
response to stressors could potentially be based on differences in adrenal sensitivity to 
ACTH. 
To test this hypothesis, we performed an adrenal sensitivity test in vivo with HR, IR and 
LR mice (see 2.2.3). Two different doses of ACTH were chosen with the lower dose 
resembling the physiological ACTH response to a relatively strong stressor, e.g. FST 
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(Müller et al., 2003), and the higher dose corresponding to a supraphysiological level of 
ACTH, to induce ACTH-mediated CORT release from the adrenals. Furthermore, we 
assessed the adrenal weight of HR, IR and LR animals since it has been shown that 
repeated stress exposure can lead to adrenal hypertrophy (Gamallo et al., 1986; Moraska 
et al., 2000; Ulrich-Lai et al., 2006). 
2.5.1.2.3 Experimental schedule 
An overview of the experimental schedule is depicted in Figure 9. A detailed description 
of the adrenal sensitivity test is given in section 2.2.3. Briefly, at 9:00 on the experimental 
day, HR, IR and LR males derived from Gen XX of the SR mouse model were acutely 
injected intraperitoneally (i.p.) with a high dose (4 µg/g BW) of dexamethasone in order 
to suppress endogenous ACTH and CORT secretion. Six hours later, blood was collected 
from the ventral tail vessel for the verification of the ACTH- and CORT-suppressive 
effect of Dex, immediately followed by an ACTH (or vehicle) injection to stimulate 
adrenal CORT secretion. Thirty minutes later, i.e. at 15:30, the animals were sacrificed 
and trunk blood was collected to determine plasma CORT concentrations. In a final step, 
the adrenals were dissected, cleared from fat tissue and immediately weighed. 
 
 
Figure 9: Schematic overview of the experimental schedule with time and intervals of the collected blood samples 
and dexamethasone or adrenocorticotropic hormone (ACTH) injections. i.p., intraperitoneal; t, time. 
 
2.5.1.3 Experiment 3: Expression and release of corticosteroid-binding globulin in 
response to stress 
2.5.1.3.1 Introduction 
Once released into the blood stream, steroid hormones such as oestrogens, progesterone 
and testosterone, but also CORT, bind to albumin (Slaunwhite et al., 1959), which is the 
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most abundant plasma protein synthesised in the liver, comprising as much as 50 per cent 
of the productive effort (Rothschild et al., 1972a,b). Albumin binds CORT with high 
capacity but low affinity. In contrast, transcortin, also called corticosteroid binding 
globulin (CBG), binds CORT with high affinity but low capacity (Sandberg et al., 1964; 
Breuner et al., 2002; Moisan, 2010). Like albumin, CBG is synthesised in the liver and 
secreted from hepatocytes (Weiser et al., 1979; Kuhn et al., 1986; Henley et al., 2011) 
into the plasma, binding 80-90 % of circulating CORT while 10-15 % of total CORT is 
bound to albumin, leaving a fraction of about 5 % free CORT to be biologically active 
(Lewis et al., 2005; Henley et al., 2011; Cizza et al., 2012) according to the free hormone 
hypothesis by Mendel (Mendel, 1989). This equilibrium between CBG-bound CORT, 
albumin-bound CORT and a minor fraction of free CORT in the plasma is challenged as 
soon as an organism is exposed to stressful stimuli and CORT secretion from the adrenal 
cortex is elevated. In a study by Qian and colleagues it was shown in rats that a 15-min 
swim stress evoked a fast and profound rise in plasma CBG with a concomitant rise in 
plasma total CORT. Interestingly, in compartments such as the brain, plasma and 
subcutaneous tissue, the rise in free CORT was delayed for 20-30 min as measured by 
microdialysis. Hence, it was concluded that the increase in circulating CBG levels after 
stress restrains the rise in free CORT concentrations for approximately 20 min in face of 
mounting total hormone levels in the circulation, suggesting that CBG may serve as a 
buffer allowing the organism to respond to stress in an adequate way (Qian et al., 2011). 
Moreover, it was reported that CBG deficient mice display an increased activity of the 
HPA axis associated with a 10-fold increase in free CORT levels. Furthermore, the half-
life of CORT was significantly reduced in CBG deficient mice and drug metabolising 
enzymes in the liver were elevated (Petersen et al., 2006). In a recent study, CBG 
deficient mice were studied with the aim of unravelling the effect of CORT-binding to 
CBG on HPA axis function and behaviours linked to anxiety and depression traits. These 
mice showed a dysregulated HPA axis function with reduced total CORT levels, basally 
and in response to stress, while free CORT was normal at rest but presented a reduced 
surge after restraint stress (Richard et al., 2010). In addition to this, CBG deficient mice 
showed a depression-like behavioural phenotype with increased immobility in the FST as 
well as enhanced learned helplessness after prolonged uncontrollable stress. However, 
there were no alterations in paradigms measuring anxiety-related behavioural (Richard et 
al., 2010). 
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In summary, these findings highlight the critical role of corticosteroid binding proteins in 
providing an adequate neuroendocrine and behavioural response to stress, and underline 
the eminent role of CBG in the bioavailability, local delivery and cellular signal 
transduction of CORT, thereby exceeding its role as a mere steroid transporter (Petersen 
et al., 2006; Moisan, 2010; Richard et al., 2010; Henley et al., 2011). 
2.5.1.3.2 Objective of the experiment 
Considering the essential role of CBG in the physiological stress response, we 
investigated whether HR, IR and LR mice, with their distinctly different neuroendocrine 
phenotypes regarding their stress-induced secretion of CORT, would differ in the 
expression and release of CBG in the liver and in plasma, both, basally and in response to 
restraint stress. Additionally, we addressed the question (i) whether the increased CORT 
release in response to stressors was reflected by elevated levels of ACTH in the pituitary 
of the animals and (ii) whether stress-induced plasma ACTH concentrations parallel the 
rise in plasma CORT levels, implicating a decrease in the amount of vesicularly stored 
pituitary ACTH.  
2.5.1.3.3 Experimental setup 
HR, IR and LR animals derived from Gen XX of the SR mouse model were subjected to a 
SRT (see 2.2.1) on the experimental day at 9:00. Blood was sampled immediately before 
(t=0) and straight after (t=15) the 15-min restraint period. Subsequently, animals were 
transferred back to their homecages. Thirty minutes after the beginning of the restraint 
period, when animals were assumed to have reached maximal concentrations of CBG in 
the plasma (according to the experiment of Qian et al., 2011), animals were sacrificed and 
trunk blood was collected (t=30). The brain, pituitary and liver were dissected, 
immediately frozen on dry ice and stored at -80 °C until further analysis. Animals of the 
control group were not subjected to the SRT but killed under unstressed conditions. Trunk 
blood was collected and organs were dissected, stored and processed as described above. 
All blood samples were centrifuged for 10 min (4000 x g at 4 °C) and plasma CORT 
concentrations were determined (see 2.4.3.1). Plasma ACTH concentrations were 
determined in the unstressed control group, as well as in the samples collected straight 
after (t=15) and 15 min after the cessation of the stressor (t=30) (see 2.4.3.2). Due to the 
lower amount of plasma available, ACTH was determined in single estimation in the 
sample collected straight after the end of the stressor (t=15). CBG in the liver and in the 
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plasma, as well as ACTH in the pituitary, was quantified by Western blot (see 2.4.1). An 
overview of the experimental schedule is depicted in Figure 10. 
 
 
Figure 10: Schematic overview of the experimental schedule with time and intervals of the collected blood 
samples. Stressed animals were subjected to 15 min of restraint stress and returned back to their homecages for 
15 min before they were sacrificed. The unstressed control group was killed under basal conditions. t, time. 
2.5.2 Central regulation of the hypothalamic-pituitary-adrenocortical axis 
In the experiments presented in this work so far, we mainly focused on the peripheral 
aspects of HPA axis function in HR, IR and LR animals, such as regulatory mechanisms 
at the pituitary level, GC secretion from the adrenals and corticosteroid-binding globulin 
in the plasma. However, since alterations or maladaptions of the HPA system, both 
peripherally and centrally, contribute to the pathogenesis of affective disorders such as 
MD (Holsboer, 2000; Juruena et al., 2004; Charmandari et al., 2005; Pariante et al., 
2008) and psychiatric diseases such as MD originate from the brain, we further 
investigated central aspects of HPA axis dysfunction in the animals of the SR mouse 
model in order to establish a more comprehensive picture. Simultaneously, we addressed 
the question whether treatment with the SSRI Flx, which is widely used in clinical 
settings as a first-line treatment in patients suffering from MD, would affect the 
neuroendocrine and behavioural phenotype of HR, IR and LR mice. Although its 
mechanism of action is still poorly understood, it has been shown in preclinical and 
clinical studies that Flx influences GC receptor expression (Budziszewska et al., 2000; 
Heydendael et al., 2010; Elakovic et al., 2011), emotional behaviour (Dulawa et al., 
2004; Norcross et al., 2008) and cognition (Grote et al., 2005). Furthermore, the impact 
of Flx treatment on the regulation of the HPA axis has been shown (Szymanska et al., 
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2009; Surget et al., 2011). This is of interest since normalisation of HPA axis function 
was found to be a potent predictor for the successful treatment of MD (Ising et al., 2005; 
Ising et al., 2007) and can significantly reduce the risk of relapse (Zobel et al., 2001), 
emphasising the importance of a balanced HPA system. 
Therefore, in two translational experimental approaches, we investigated the impact of 
chronic Flx treatment on the neuroendocrine and behavioural phenotype of HR, IR and 
LR mice. In the first experiment, we focused on the effects of chronic Flx treatment on 
the emotional behaviour as well as HPA axis regulation. In the second experiment, we 
were interested whether animals of the SR mouse model were affected by chronic Flx 
treatment regarding their cognitive performance as well as HPA axis reactivity and 
neuronal activation in response to stress. 
2.5.2.1 Experiment 1: Effects of chronic fluoxetine treatment on emotional behaviour and 
hypothalamic-pituitary-adrenal axis regulation in HR, IR and LR mice 
HR, IR and LR mice derived from Gen XVII of the SR mouse model were chronically 
administered 10 µg/g BW Flx or vehicle by means of a daily intraperitoneal (i.p.) 
injection over a time period of 34 days. The injection was given once daily at 16:00. Flx 
was dissolved in Ringer solution. Control animals (Veh) only received Ringer solution. A 
detailed outline of the experimental schedule is depicted in Figure 11. After 25 days of 
treatment, a reference blood sample was collected at 9:00 from all animals to assess basal 
CORT conditions. In order to exclude interfering effects of the blood sampling procedure 
with the behavioural testing, the animals were allowed to recover for 3 days before the 
start of the behavioural test battery. However, the daily injection was also maintained on 
these days. 
2.5.2.1.1 Assessment of emotional behaviour and hypothalamic-pituitary-adrenal axis 
activity in response to stress 
On day 28, a behavioural test battery was performed to assess the animals’ locomotor 
activity and exploratory drive in a 10-min OF test (see 2.3.1). Subsequently, depression-
like behavioural parameters were analysed by means of a 6-min FST (see 2.3.2). Right 
after the FST, a blood sample was collected in order to assess stress-induced plasma 
CORT concentrations. 
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2.5.2.1.2 Assessment of hypothalamic-pituitary-adrenal axis regulation by means of a 
combined dexamethasone/corticotropin-releasing hormone test 
On day 32, a reference blood sample was taken at 15:00, resembling basal/untreated 
conditions. After allowing the animals to recover for 3 days, a combined Dex/CRH test 
was performed (see 2.2.2). Subsequently, the animals were sacrificed and the 
hippocampus and the pituitary were dissected and immediately frozen on dry ice. One 
hippocampal hemisphere was used for protein expression analysis using Western blot (see 
2.4.1). From the other hippocampal hemisphere, as well as from the pituitary, RNA was 
isolated and gene expression analysis was performed (see 2.4.2). All blood samples were 
centrifuged for 10 min (4000 x g at 4 °C) and CORT concentrations were determined 
from the plasma (see 2.4.3.1). 
2.5.2.1.3 Gene expression analysis 
After the Dex/CRH test, animals were sacrificed and the hippocampus and the pituitary 
were dissected for qPCR-based gene expression analysis. In the hippocampus, the 
following candidate genes were investigated known to be involved in HPA axis function 
as well as negative feedback regulation: the glucocorticoid receptor (nuclear receptor 
subfamily 3, group C, member 1, Nr3c1), the mineralocorticoid receptor (nuclear receptor 
subfamily 3, group C, member 2, Nr3c2), the glucocorticoid receptor co-chaperones 
FK506 binding protein 4 (Fkbp4) and FK506 binding protein 5 (Fkbp5), the multidrug 
resistance transporters ATP-binding cassette, sub-family B, member 1A (Abcb1a) and 1B 
(Abcb1b), the corticotropin-releasing hormone receptor 1 (Crhr1), the actin modulating 
protein cofilin-1 (Cfl1) and the glucocorticoid induced leucine zipper (Gilz). 
Additionally, the following candidate genes were analysed in the pituitary of the animals: 
Nr3c1, proopiomelanocortin (Pomc), Fkbp5, Abcb1a, Abcb1b, Crhr1 and Gilz (for 
abbreviations see above). 
2.5.2.1.4 Protein expression in the hippocampus 
In addition to the hippocampal gene expression analysis, GR and FKBP51 protein 
abundance was assessed in Veh- and Flx-treated HR, IR and LR animals in the 
hippocampal hemisphere which was not used for qPCR analysis. 
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Figure 11: Schematic overview of the experimental schedule showing the day of behavioural testing (day 28) and 
the Dex/CRH test (day 35). The detailed experimental schedules on the respective days are given in the timelines 
on top or below. OF, open field test; FST, forced swim test; Dex, dexamethasone; CRH, corticotropin-releasing 
hormone; i.p., intraperitoneal; t, time; d, day; BW, body weight. 
 
2.5.2.2 Experiment 2: Effects of chronic fluoxetine treatment on spatial reference 
memory, hypothalamic-pituitary-adrenal axis function and neuronal activation in HR, IR 
and LR mice 
In the second Flx experiment, HR, IR and LR mice derived from Gen XIX of the SR 
mouse model were used. Similarly to the first experiment, animals were chronically 
administered 10 µg/g BW of Flx by means of a daily intraperitoneal (i.p.) injection over a 
time period of 34 days. The injection was given once daily at 16:00. Flx was dissolved in 
Ringer solution. Control animals (Veh) only received Ringer solution. In this experiment, 
two control groups consisting of animals of the HR, IR and LR line, were used (control I 
and control II, see Figure 12). Similar to the experimental animals, mice of control I 
received a daily injection of Flx or Veh over a period of 34 days and were subjected to the 
Y-maze test. This group served to control for effects of the daily injection procedure on 
(i) CORT levels and (ii) C-fos expression, while control II consisted of entirely untreated, 
naïve HR, IR and LR mice reflecting basal plasma CORT levels and brain C-fos 
expression. 
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2.5.2.2.1 Assessment of spatial reference memory by means of the Y-maze test 
After 28 days of chronic Flx treatment, mice of the experimental and control I group were 
subjected to the Y-maze test to assess their hippocampus-dependent, spatial reference 
memory (see 2.3.3). The Y-maze test has been validated previously as a hippocampus-
dependent spatial task (Conrad et al., 1996; Conrad et al., 1997) and previous 
experiments in HR, IR and LR mice showed that animals of the HR line display cognitive 
deficits regarding their hippocampus-dependent memory performance (Knapman et al., 
2010a; Knapman et al., 2012). Thus, we were interested whether the cognitive deficits in 
HR mice could be rescued by Flx treatment. 
2.5.2.2.2 Assessment of stress-induced hypothalamic-pituitary-adrenal axis function and 
neuronal activation in the central nervous system 
After allowing the animals to recover for seven days to avoid confounding influences of 
the Y-maze test on plasma CORT concentrations and brain C-fos expression, they were 
subjected to a SRT starting at 9:00. A blood sample was collected immediately before and 
after the 15-min restraint period in order to assess unstressed and stress-induced CORT 
levels, respectively. Subsequently to the SRT, animals were transferred back to their 
homecages for 45 min. Sixty minutes after the onset of the stressor, the mice were 
sacrificed, trunk blood was collected and the brain was dissected. The brain was 
immediately shock-frozen in dry-ice cooled methylbutane (Carl Roth GmbH, Karlsruhe, 
Germany), wrapped in aluminium foil, and stored at -80 °C until analysis of C-fos 
expression by means of in-situ hybridisation (see 2.4.4). All blood samples were 
centrifuged for 10 min (4000 x g at 4 °C) and CORT concentrations were determined 
from the plasma (see 2.4.3.1). An overview of the experimental schedule is depicted in 
Figure 12. 
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Figure 12: Schematic overview of the experimental schedule of the experimental group, control I and control II, 
respectively. The day of Y-maze testing (day 28) and the SRT (day 35) are given. The detailed experimental 
schedule of the SRT is outlined in the timeline on top. i.p., intraperitoneal; t, time; d, day; BW, body weight. 
2.6 Statistical analysis 
Since normal distribution and variance homogeneity of the data could not always be 
assumed, statistical analysis was performed using exclusively non-parametric statistics. 
Two independent samples were compared using the Mann-Whitney U-tests (MWU-test), 
while group comparisons of more than two independent samples were analysed using the 
Kruskal-Wallis H-Test (KWH-test). In case of a significant difference revealed by the 
KWH-test, post-hoc pairwise comparisons were applied using the MWU-test. 
Consequently, significance levels were corrected according to the sequential Bonferroni 
technique for multiple testing. 
In order to evaluate differences between two dependent samples the Wilcoxon test (W-
test) was applied. More than two dependent samples were analysed using the Friedman 
test (F-test). Post-hoc pairwise comparisons applying the W-test were calculated if the F-
test yielded significant results. Consequently, significance levels were corrected 
according to the sequential Bonferroni technique for multiple testing. 
Animals, material and methods 
46 
 
All tests were applied two-tailed and were calculated using the software package SPSS, 
version 16.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was accepted from 
p<0.05, while p<0.1 was considered as a trend. 
2.7 Graphic illustration  
Graphs were created using SigmaPlot software package version 9.01 (Systat Software 
Inc., San Jose, USA). Data are given as box plots showing medians (lines in the boxes) 
and 25 % to 75 % percentiles (boxes). The 10 % percentile and 90 % percentile are 
indicated by the whiskers.
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3 Results 
3.1 Peripheral regulation of the hypothalamic-pituitary-adrenal axis 
3.1.1 Experiment 1: Inhibition of corticosterone secretion by the 11β-hydroxylase 
inhibitor metyrapone 
In this experiment, animals derived from Gen XVI of the SR mouse model were used. 
The animals of the HR, IR and LR line were subdivided into two groups receiving vehicle 
solution (Veh; HR/IR/LR, N=8/9/9) or metyrapone (Met; HR/IR/LR, N=8/8/8), 
respectively. 
3.1.1.1 Plasma corticosterone concentrations 
In the reference blood sample (-3d) collected three days prior to the testing day, animals 
of the Veh and Met group did not differ regarding their plasma CORT concentrations in 
all three lines. Only in the Veh group the between-line comparison revealed significant 
differences between HR, IR and LR mice (KWH-test: N=8/9/9, H=10.2, df=2, p<0.01) 
with HR and IR mice showing higher basal CORT concentrations than LR mice (post-hoc 
MWU-test: HR vs IR, U=27.5, p>0.1; HR vs LR, U=10.5, p<0.05; IR vs LR, U=8, 
p<0.05). However, all groups showed low CORT concentrations with a mean range of 3 
ng/ml to 10 ng/ml (mean ± SEM, Veh, HR: 6.9 ± 2.1, IR: 9.5 ± 3.3, LR: 2.2 ± 0.4; Met, 
HR: 3.2 ± 0.4, IR: 4.9 ± 1.8, LR: 2.3 ± 0.3), which is in line with initial CORT levels 
detected prior to the restraint period in the SRT (Touma et al., 2008; Heinzmann et al., 
2010; Knapman et al., 2010a). 
There was a significant increase in plasma CORT concentrations in the Veh group (W-
test: HR/IR/LR, N=8/9/9, Z=-2.5/-2.6/-2.6, all p<0.05), as well as in the Met group (W-
test: HR/IR/LR, N=8/8/8, all Z=-2.5, all p<0.05) of all three lines compared to the 
reference sample in response to the OF and FST. However, the swim stress-induced 
increase in CORT was significantly lower in Met-treated animals compared to Veh 
animals (MWU-test: Veh vs Met; HR: N=8/8, U=0, p≤0.001; IR: N=9/8, U=0, p≤0.001; 
LR: N=9/8, U=0, p≤0.001, see Figure 13), indicating a drastically decreased secretion of 
CORT from the adrenals following Met treatment. Comparing the magnitude of the 
CORT increase in the Veh group, HR, IR and LR mice differed significantly (KWH-test: 
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N=8/9/9, H=12.5, df=2, p<0.01), with HR mice showing a clearly higher CORT increase 
compared to the IR line, while LR animals showed the lowest increase in CORT (post-
hoc MWU-test: HR vs IR, U=8, p<0.05; HR vs LR, U=5, p<0.01; IR vs LR, U=20, 
p<0.1). Interestingly, similar significant differences between the lines could be observed 
in Met-treated animals (HR>IR>LR; KWH-test: N=8/8/8, H=14.2, df=2, p≤0.001; post-
hoc MWU-test: HR vs IR, U=15, p<0.05; HR vs LR, U=0, p<0.01; IR vs LR, U=10, 
p<0.05). However, the absolute CORT levels were much lower in all Met-treated animals. 
In summary, animals of all three lines showed a significant increase in plasma CORT 
concentrations in response to the OF and FST, which was dramatically attenuated by Met 
treatment. However, the line specific differences in plasma CORT increase in response to 
stress (HR>IR>LR) were conserved also after Met treatment. 
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Figure 13: Plasma corticosterone increase in response to the forced swim test in high (HR), intermediate (IR) 
and low (LR) reactivity mice of Gen XVI. For statistical differences between the three lines see text. Statistical 
differences between the Veh and Met group are given on top of the panel (MWU-test: p≤0.001***). 
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3.1.1.2 Assessment of emotional behaviour 
3.1.1.2.1 Locomotor activity and exploratory drive in the open field test 
One hour after the Met or Veh injection, the animals were subjected to a 10-min OF test 
in order to assess their locomotor activity and exploratory drive. Due to technical 
problems of the ANY maze tracking software, one LR animal of the Veh group had to be 
excluded from analysis, thereby reducing the number of LR animals in this group from 
nine to eight. 
Independent of treatment, the animals of all three lines neither showed significant 
differences in their total distance travelled, time spent in the inner or outer zone of the OF 
apparatus, nor in the ratio between inner and outer zone path length (see Table 3). Thus, 
Met treatment did not induce changes in the locomotion or exploratory drive in the tested 
animals. 
 
Table 3: Behavioural readout of high (HR), intermediate (IR) and low (LR) reactivity mice of Gen XVI 
determined in the open field (OF) test. Independent of treatment, the animals of all three lines did not show 
significant differences in their locomotor activity or exploratory drive. 
Parameter 
measured 
NHR/IR/LR treatment 
HR IR LR 
between-line 
comparison 
mean SEM mean SEM mean SEM H p  
total 
distance 
travelled 
[m] 
8/9/8 Veh 39.70 4.27 42.11 4.98 42.48 3.68 0.1 0.906 n.s. 
8/8/8 Met 43.13 6.20 44.80 5.49 45.71 2.86 0.1 0.924 n.s. 
time inner 
zone [s] 
8/9/8 Veh 75.14 16.77 59.06 15.76 73.38 11.18 1.9 0.383 n.s. 
8/8/8 Met 74.59 13.17 44.46 5.95 64.95 8.96 2.4 0.296 n.s. 
time outer 
zone [s] 
8/9/8 Veh 524.86 16.77 540.94 15.76 526.61 11.18 1.9 0.383 n.s. 
8/8/8 Met 525.40 13.17 555.54 5.95 535.05 8.96 2.4 0.296 n.s. 
ratio 
inner/ 
outer path 
length 
8/9/8 Veh 0.19 0.02 0.20 0.05 0.20 0.02 0.7 0.691 n.s. 
8/8/8 Met 0.20 0.02 0.14 0.02 0.15 0.02 3.5 0.168 n.s. 
 
3.1.1.2.2 Assessment of stress-coping behaviour in the forced swim test 
In the FST performed immediately after the OF test, a line comparison between HR, IR 
and LR animals of the Met-treated group revealed significant differences in the stress-
coping behaviour of these animals regarding their floating time (KWH-test: N=8/8/8, 
H=16.6, df=2, p<0.001). Met-treated HR mice showed a significantly reduced floating 
time compared to IR animals, while LR mice displayed the highest immobility (post-hoc 
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MWU-test: HR vs IR, U=0, p<0.01; HR vs LR, U=2, p<0.01; IR vs LR, U=10, p<0.05). 
In the Veh-treated group, similar significant differences between the three lines could be 
observed (KWH-test: N=8/9/9, H=6.6, df=2, p<0.05), although they were less 
pronounced in this group (post-hoc MWU-test: HR vs IR, U=7, p<0.05; HR vs LR, 
U=20.5, p>0.1; IR vs LR, U=35, p>0.1, see Figure 14 A). Interestingly, the within-line 
comparison showed that Met induced a significant increase in active stress-coping 
behaviour, i.e. struggling, in the HR and IR line compared to the Veh-treated group of the 
respective line (MWU-test: Veh vs Met; HR: N=8/8, U=13, p≤0.05; IR: N=9/8, U=13.5, 
p≤0.05). However, Met treatment did not affect the stress-coping behaviour of LR 
animals (MWU-test: Veh vs Met; LR: N=9/8, U=33, p>0.1, see Fig. Figure 14 B). 
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Figure 14: Stress-coping behaviour of high (HR), intermediate (IR) and low (LR) reactivity mice of Gen XVI 
during the 6-min forced swim test (FST) period. (A) time spent floating (B) time spent struggling. For statistical 
differences between the three lines (KWH-test) see text. Statistical differences between the Veh and Met group 
are given on top of the panel (MWU-test: p>0.1 n.s., p≤0.05*). 
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In summary, this data shows that Met efficiently inhibited adrenal CORT secretion in 
response to stressors in HR, IR and LR animals. Additionally, the pharmacological 
inhibition of CORT secretion induced behavioural changes regarding the stress-coping 
style in the FST of HR and IR animals in the absence of changes in general locomotion or 
exploratory drive as shown in the OF. 
3.1.1.3 Gene expression analysis 
To investigate whether the distinct differences in CORT increase between the three lines 
in response to stress have persistent effects on adrenal gene expression patterns, total 
RNA was isolated from the adrenals of the Veh animals and relative gene expression 
analysis was performed using quantitative real-time PCR. One LR animal had to be 
excluded due to low RNA quality. Hence, the final number of samples was eight for HR, 
nine for IR and eight for LR animals. 
There were no significant differences between HR, IR and LR mice regarding the relative 
gene expression of tyrosine hydroxylase (Th, see Figure 15 A), phenylethanolamine-N-
methyltransferase (Pnmt, see Figure 15 B) and the melanocortin 2 receptor (Mc2r, see 
Figure 15 C) (KWH-test: N=8/9/8, H=1.1-2.2, df=2, all p>0.1). However, significant 
differences were detected between HR, IR and LR animals in the relative gene expression 
of steroid acute regulatory protein (StAR, see Figure 15 D) (KWH-test: N=8/9/8, H=9, 
df=2, p<0.05). Interestingly, StAR mRNA was increased in HR and LR animals compared 
to IRs (post-hoc MWU-test: HR vs IR, U=6, p<0.05; IR vs LR, U=13, p<0.1), whereas 
there was no significant difference between HR and LR animals (post-hoc MWU-test: HR 
vs LR, U=31.5, p>0.1). 
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Figure 15: Gene expression in the adrenals of high (HR), intermediate (IR) and low (LR) reactivity mice of Gen 
XVI (Veh group) relative to two housekeeping genes (Hprt and Tbp), normalised to the IR group. (A) tyrosine 
hydroxylase (Th) mRNA expression. (B) phenylethanolamine-N-methyltransferase (Pnmt) mRNA expression. (C) 
melanocortin 2 receptor (Mc2r) mRNA expression. (D) steroid acute regulatory protein (StAR) mRNA 
expression. Statistical differences between the three lines are given on top of each panel (KWH-test), pairwise 
group comparisons (post-hoc MWU-test) are indicated below (p≤0.05*, p<0.1 T, p>0.1 n.s.). 
3.1.2 Experiment 2: Adrenal sensitivity towards adrenocorticotropic hormone 
3.1.2.1 Neuroendocrine response 
Whether the distinct differences in stress-induced plasma CORT concentrations of HR, IR 
and LR mice were brought about by differences in adrenal sensitivity towards ACTH, 
was investigated by means of an adrenal sensitivity test. To this end, mice were injected 
with a high dose of Dex, suppressing endogenous ACTH release from the pituitary. 
Subsequently, defined doses of ACTH were applied and the CORT release from the 
adrenals in response to this stimulation with exogenous ACTH was determined. 
For the assessment of the ACTH-suppressive effect of Dex in the plasma of the animals, 
one HR animal had to be excluded due to the low amount of blood obtained, reducing the 
number to 15 HR, 16 IR and 16 LR animals.  
In the blood sample collected six hours after the Dex injection, ACTH concentrations 
were determined with a median range between 29 pg/ml and 33 pg/ml in the HR, IR and 
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LR group. There were no significant differences in plasma ACTH concentration between 
the three lines (KWH-test: N=15/16/16, H=0.6, df=2, p>0.1), suggesting a similar 
suppression of ACTH by Dex in HR, IR and LR animals (see Figure 16). It should be 
noted, that similarly to CORT, ACTH follows a circadian rhythm with trough levels in 
the morning and peak levels in the afternoon. Therefore, the determined plasma ACTH 
levels (at 15:00) were clearly below the expected levels for this time of day, supporting 
the effectiveness of Dex in clearly suppressing ACTH release from the pituitary. 
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Figure 16: Plasma adrenocorticotropic hormone (ACTH) concentration after dexamethasone (Dex) suppression 
in high (HR), intermediate (IR) and low (LR) reactivity mice of Gen XX. Statistical differences between the three 
lines are given on top of the panel (MWU-test: p>0.1 n.s.). 
 
Similar to ACTH, plasma CORT concentrations of HR, IR and LR mice were markedly 
decreased after the Dex treatment (mean ± SEM, HR: 2.1 ± 0.1, IR: 2.2 ± 0.2 LR: 2.3 ± 
0.3) with no significant difference between the lines (KWH-test: N=22/22/22, H=1.8, 
df=2, p>0.1). Furthermore, after saline injection, the CORT concentrations remained very 
low (mean ± SEM, HR: 1.9 ± 0.3, IR: 1.3 ± 0.3 LR: 1.5 ± 0.3), close to the detection limit 
of the radioimmunoassay, showing no significant differences between HR, IR and LR 
animals (KWH-test: N=6/6/6, H=3.4, df=2, p>0.1). This indicates (i) that the injection 
procedure per se did not induce a release of CORT from the adrenals and (ii) that the low 
concentrations of endogenous ACTH detected in the plasma after Dex injection (see 
above) did not stimulate the release of meaningful amounts of CORT from the adrenal 
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cortex (see Figure 17 A). However, after stimulation with the lower dose of ACTH (0.1 
ng/g BW), HR and IR animals showed a significant increase in plasma CORT 
concentrations (mean ± SEM, HR: 7.5 ± 1.8, IR: 17.0 ± 6.4 LR: 2.9 ± 0.5), whereas LR 
animals remained unaffected (KWH-test: N=10/10/10, H=8.5, df=2, p<0.05; post-hoc 
MWU-test: HR vs IR, U=36.5, p>0.1; HR vs LR, U=28.5, p>0.1; IR vs LR, U=10.5, 
p<0.01). This rise in ACTH-induced CORT secretion was also observed in the group of 
HR and IR animals receiving the high dose (1 ng/g BW) of ACTH (mean ± SEM, HR: 
127.9 ± 37.4, IR: 76.1 ± 20.0 LR: 4.5 ± 1.2) compared to animals of the LR line (KWH-
test: N=6/6/6, H=12.1, df=2, p<0.01; post-hoc MWU-test: HR vs IR, U=10, p>0.1; HR vs 
LR, U=0, p<0.01; IR vs LR, U=0, p<0.05), although the effect was much more 
pronounced. Hence, LR animals did not respond with a marked increase in their plasma 
CORT concentrations to either dose of ACTH (see Figure 19 B). 
In summary, this experiment revealed that high doses of Dex efficiently suppressed 
plasma CORT and ACTH concentrations in all three lines. Furthermore, we could show 
that the adrenal responsiveness towards defined, exogenously administered doses of 
ACTH is markedly decreased in LR mice compared to animals of the HR and IR line, 
suggesting a decreased adrenal sensitivity in LR animals. 
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Figure 17: Plasma corticosterone (CORT) concentrations in high (HR), intermediate (IR) and low (LR) 
reactivity mice of Gen XX. (A) left: plasma CORT concentrations 6h after dexamethasone injection, right: 
plasma CORT concentrations 6 h after dexamethasone injection followed by a saline injection. (B) plasma 
CORT concentrations after stimulation with 0.1ng/g BW ACTH (left) and 1ng/g BW ACTH (right). Statistical 
differences between the three lines are given on top of the panel (KWH-test), pairwise group comparisons (post-
hoc MWU-test) are indicated below (p≤0.01**, p≤0.05*, p>0.1 n.s.). 
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3.1.2.2 Determination of the adrenal weight 
The adrenal weight was assessed using six animals from each line of the SR mouse model 
and was calculated as a ratio of the body weight of the respective animal. 
As it has been shown before (Touma et al., 2008), there was a significant difference in the 
relative adrenal weight between HR, IR and LR animals (KWH-test: N=6/6/6, H=9.8, 
df=2, p<0.01, see Figure 18 A) with HR animals showing an increased relative adrenal 
weight compared to LR animals (post-hoc MWU-test: HR vs IR, U=6, p>0.1; HR vs LR, 
U=0, p<0.05; IR vs LR, U=8, p>0.1). When weighed separately, a trend towards a heavier 
left adrenal was observed in HR and LR animals (MWU-test: left vs right; HR: N=6/6, 
U=7, p<0.1; LR: N=6/6, U=7, p<0.1, see Figure 18 B). 
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Figure 18: Relative adrenal weight (with respect to body weight) of high (HR), intermediate (IR) and low (LR) 
reactivity mice of Gen XX. (A) both adrenals pooled. (B) adrenals weighed separately. Statistical differences 
between the three lines are given on top of the panel (KWH-test), pairwise group comparisons (MWU-tests) are 
indicated below (p≤0.01**, p≤0.05*, p≤0.1 T, p>0.1 n.s.). 
3.1.3 Experiment 3: Expression and release of corticosteroid-binding globulin in 
response to stress 
In this experiment, animals derived from Gen XX of the SR mouse model were used. The 
unstressed control group consisted of eight animals per line (HR/IR/LR, N=8/8/8), while 
ten animals of each line were subjected to the SRT (HR/IR/LR, N=10/10/10). 
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3.1.3.1 Plasma corticosterone concentrations 
As expected, in the blood sample collected immediately before the 15-min restraint 
period (t=0), plasma CORT concentrations were low in HR, IR and LR animals (mean ± 
SEM [ng/ml], HR: 8.7 ± 2.9, IR: 16.5 ± 11.2, LR: 4.6 ± 0.8) with no significant 
differences between the lines (KWH-test: N=10/10/10, H=3.0, df=2, p>0.1, see Figure 
19). Similarly, plasma CORT concentrations were low in all three lines of the control 
group, (mean ± SEM [ng/ml], HR: 21.6 ± 6.9, IR: 11.0 ± 3.8, LR: 4.7 ± 0.7) although a 
line comparison showed that HR animals had significantly increased plasma CORT 
concentrations compared to mice of the LR line (KWH-test: N=8/8/8, H=6.8, df=2, 
p<0.05; post-hoc MWU-test: HR vs IR, U=19, p>0.1; HR vs LR, U=9, p<0.05; IR vs LR, 
U=17, p>0.1). However, a within-line comparison revealed no significant differences in 
plasma CORT concentrations between control animals and samples of the stressed group 
(t=0) immediately before the restraint (MWU-test: unstressed vs t=0; HR: N=8/10, U=20, 
p<0.1; IR: N=8/10, U=32.5, p>0.1; LR: N=8/10, U=39.5, p>0.1), indicating basal plasma 
CORT levels in these two groups. 
Right after the 15-min restraint period (t=15), plasma CORT concentrations were 
markedly increased in all three lines and were even further elevated 30 min (t=30) after 
the onset of the restraint stressor (F-test: HR/IR/LR, N=10/10/10, all Chi2=20, all df=2, 
all p<0.001; post-hoc W-test: t=0 vs t=15, all Z=-2.8, all p≤0.01; t=0 vs t=30, all Z=-2.8, 
all p<0.01; t=15 vs t=30, all Z=-2.8, all p<0.05). Furthermore, there was a significant 
difference in the magnitude of the CORT increase between the three lines, both at t=15 
and t=30 (HR>IR>LR; KWH-test: N=10/10/10, H=24.0-24.3, df=2, all p≤0.001), with 
HR animals displaying higher plasma CORT concentrations than IR mice, while LR 
animals had the lowest increase (post-hoc MWU-test: HR vs IR, U=4-5, all p≤0.001; HR 
vs LR, all U=0, p<0.01; IR vs LR, U=1-3, p<0.05). 
In summary, controls and unstressed animals showed low plasma CORT concentrations at 
t=0, while there was a significant rise in plasma CORT levels after the restraint (t=15), 
which was further elevated 30 min (t=30) after the onset of the stressor (see Figure 19). 
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Figure 19: Plasma corticosterone (CORT) concentrations in high (HR), intermediate (IR) and low (LR) 
reactivity mice of Gen XX. Control animals were killed under basal conditions. Plasma CORT concentrations of 
HR, IR and LR animals which were subjected to a 15-min restraint period were determined right before (t=0) 
and immediately after (t=15) the stress as well as 30 min (t=30) after the onset of the stressor. Statistical 
differences between the three lines are given on top of the panel (F-test), pairwise group comparisons (W-tests) 
are indicated below (p≤0.01**, p≤0.05*, p≤0.1 T, p>0.1 n.s.). 
 
3.1.3.2 Corticosteroid-binding globulin expression 
In order to quantify corticosteroid binding globulin (CBG) protein abundance and 
dynamics in response to stress in the liver and in the plasma of the experimental animals, 
Western blot analysis was performed.  
3.1.3.2.1 Liver corticosteroid-binding globulin 
CBG abundance in the liver of HR, IR and LR animals was analysed, in eight animals per 
line and treatment (HR/IR/LR, Nunstressed=Nstressed=8/8/8). 
The between-line comparison revealed no significant differences between HR, IR and LR 
mice of both, the unstressed and stressed group (KWH-tests: HR/IR/LR, 
Nunstressed=Nstressed=8/8/8, H=0.1-2.7, df=2, all p>0.1). Furthermore, there was no 
significant effect of stress within IR and LR animals (MWU-test: unstressed vs stressed; 
IR: N=8/8, U=20, p>0.1; LR: N=8/8, U=19, p>0.1). In contrast, stressed HR animals 
showed a significantly increased CBG expression in the liver after stress (MWU-test: 
unstressed vs stressed; HR: N=8/8, U=11, p<0.05, see Figure 20). 
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Figure 20: (A) Representative Western blot pictures of corticosteroid binding globulin (CBG) and 
glyceraldehyde-3-phosphate-dehydrogenase (GAPDH). (B) CBG expression in the liver of high (HR), 
intermediate (IR) and low (LR) reactivity mice of Gen XX relative to GAPDH, normalised to the IR control 
group. Statistical differences between the three lines (KWH-test) are given in the text, within-line comparisons 
(MWU-test) are indicated on top of the panel (p≤0.05*, p>0.1 n.s.). 
 
3.1.3.2.2 Plasma corticosteroid-binding globulin 
Due to technical problems, one IR animal of the unstressed control group had to be 
excluded, reducing the number of samples to seven in this group (HR/IR/LR, N=8/7/8). 
The number of samples in the stressed group was ten per line (HR/IR/LR, N=10/10/10). 
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Figure 21 shows the relative plasma CBG protein amount of control and stressed (t=30) 
HR, IR and LR animals normalised to the IR control group. In contrast to CBG protein 
abundance in the liver, there was a significant difference between HR, IR and LR animals 
regarding the CBG protein amount in the plasma in both, the control group and the 
stressed animals (KWH-tests: HR/IR/LRcontrol, N=8/7/8, HR/IR/LRstressed, N=10/10/10, 
H=13.6-18.9, df=2, all p≤0.001). HR mice showed a clearly increased plasma CBG 
content compared to IR animals, while animals of the LR line had the lowest amount of 
CBG (post-hoc MWU-tests: control, HR vs IR, U=5, p<0.05; HR vs LR, U=3, p<0.01; IR 
vs LR, U=9, p<0.05; stressed, HR vs IR, U=11, p<0.01; HR vs LR, U=0, p<0.01; IR vs 
LR, U=18, p<0.05). However, a within-line comparison did not reveal significant 
differences between control and stressed animals of the respective line (MWU-test: 
control vs stressed; HR: N=8/10, U=23, p>0.1; IR: N=7/10, U=32, p>0.1; LR: N=8/10, 
U=40, p>0.1). 
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Figure 21: (A) Representative Western blot pictures of corticosteroid binding globulin (CBG) and transferrin. 
(B) CBG expression in the plasma of high (HR), intermediate (IR) and low (LR) reactivity mice of Gen XX 
relative to transferrin, normalised to the IR control group. Statistical differences between the three lines (KWH-
test) are given in the text, within-line comparisons (MWU-test) are indicated on top of the panel (p>0.1 n.s.). 
 
In summary, this data revealed significant differences in plasma concentrations of CBG 
between HR, IR and LR animals (HR>IR>LR), which were not affected by stress 30 min 
after the onset of the stressor. Furthermore, a within-line comparison showed that an 
acute stress exposure did not induce a significant change in liver CBG abundance in 
animals of the IR and LR line, while there was a slight increase in liver CBG after stress 
(t=30) in HR animals. 
3.1.3.3 Plasma adrenocorticotropic hormone concentrations 
Due to technical problems during the ACTH RIA, the plasma sample of one LR animal 
collected immediately after the stressor (t=15), as well as one HR plasma sample 
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collected 30 min after the onset of the stressor (t=30) were lost. Thus, the final sample 
size was HR/IR/LRcontrol N=8/8/8, HR/IR/LRt=15 N=10/10/9 and HR/IR/LRt=30 N=9/10/10. 
The plasma ACTH concentrations in the animals of the control group did not show 
significant differences between the three lines (KWH-test: HR/IR/LR, N=8/8/8, H=2.9, 
df=2, p>0.1; see Figure 22). In HR animals, however, a higher individual variation in 
ACTH concentrations with markedly increased mean levels compared to the other two 
lines (mean ± SEM [pg/ml], HR: 327.3 ± 103.8, IR: 135.3 ± 34.4, LR: 222.0 ± 47.1) was 
observed. However, median plasma ACTH levels in the animals of all three lines were 
similarly low, ranging between 106 pg/ml and 233 pg/ml. After 15 min of restraint stress, 
only the IR line showed a significant surge of ACTH concentrations (MWU-test: control 
vs t=15, U=4, p≤0.001), whereas there was no statistical detectable stress-induced rise in 
animals of the HR and LR line (MWU-test: control vs t=15, U=23-31, all p>0.1). 
However, a between-line comparison showed that immediately after the restraint period 
(t=15), LR animals had lower plasma ACTH levels compared to HR and IR mice (KWH-
test: HR/IR/LR, N=10/10/9, H=12.1, df=2, p<0.01; post-hoc MWU-test: HR vs IR, U=29, 
p>0.1; HR vs LR, U=13, p<0.05; IR vs LR, U=8, p<0.01). It was not until 30 min after 
the onset of the stressor that significantly increased plasma ACTH levels could be 
detected in the animals of all three lines (MWU-test: control vs t=30; HR: N=8/9, U=8, 
p<0.01; IR: N=8/10, U=0, p<0.001; LR: N=8/10, U=1, p≤0.001). Interestingly, there was 
no difference in the magnitude of the ACTH rise between HR, IR and LR animals at this 
time point (KWH-test: HR/IR/LR, N=9/10/10, H=1.2, df=2, p>0.1). 
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Figure 22: Plasma adrenocorticotropic hormone (ACTH) concentrations in high (HR), intermediate (IR) and low 
(LR) reactivity mice of Gen XX. Control animals were killed under basal conditions. Plasma CORT 
concentrations of HR, IR and LR animals which were subjected to a 15-min restraint period were determined 
immediately after (t=15) the stress as well as 30 min (t=30) after the onset of the stressor. Statistical differences 
between independent samples (MWU-test: control vs t=15, control vs t=30) and dependent samples (W-test: t=15 
vs t=30) are given on top of the panel (p≤0.001***, p≤0.01**, p≤0.05*, p>0.1 n.s.). 
 
3.1.3.4 Adrenocorticotropic hormone expression in the pituitary 
In order to determine the amount of pituitary ACTH protein, Western blot analysis was 
performed. Due to technical problems during the protein extraction, one IR sample of the 
stressed group was lost, reducing the number of samples in this group to nine (HR/IR/LR, 
N=10/9/10). The number of samples in the unstressed control group was eight per line 
(HR/IR/LR, N=8/8/8). 
Figure 23 shows the relative ACTH protein amount of control and stressed (t=30) HR, IR 
and LR animals standardised to GAPDH and the IR control group. HR animals showed a 
significantly higher ACTH protein amount in the pituitary compared to IR and LR 
animals in both the control (KWH-test: HR/IR/LR, N=8/8/8, H=8.6, df=2, p<0.05; post-
hoc MWU-test: HR vs IR, U=7, p≤0.05; HR vs LR, U=9, p<0.05; IR vs LR, U=31, 
p>0.1) and the stressed group (KWH-test: HR/IR/LR, N=10/9/10, H=10.6, df=2, p<0.01; 
post-hoc MWU-test: HR vs IR, U=13, p<0.05; HR vs LR, U=11, p<0.01; IR vs LR, 
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U=44, p>0.1). Interestingly, a within-line comparison revealed no significant differences 
in pituitary ACTH protein abundance between control and restraint-stressed animals of 
the HR, IR and LR line (MWU-test: control vs stressed; HR: N=8/10, U=40, p>0.1; IR: 
N=8/9, U=29, p>0.1; LR: N=8/10, U=33, p>0.1). 
Thus, despite the prominent release of CORT from the adrenals in response to stress in all 
three lines, the restraint stress had only a minor impact regarding the depletion of the 
available ACTH pool in the pituitary. Furthermore, animals of the IR and LR line showed 
a similar ACTH abundance in the pituitary despite significant differences in their stress-
induced adrenal CORT release. In addition, the stress-induced increase in plasma ACTH 
levels did not parallel the rise in plasma CORT concentrations in response to stress, 
particularly in HR and LR animals. This suggests that further mechanisms in addition to 
ACTH expression, abundance and release are involved in the distinctly different stress 
response of HR, IR and LR animals. 
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Figure 23: (A) Representative Western blot pictures of adrenocorticotropic hormone (ACTH) and 
glyceraldehyde-3-phosphate-dehydrogenase (GAPDH). (B) ACTH expression in the pituitary of high (HR), 
intermediate (IR) and low (LR) reactivity mice of Gen XX relative to GAPDH, normalised to the IR control 
group. Statistical differences between the three lines (KWH-test) are given in the text, within-line comparisons 
(MWU-test) are indicated on top of the panel (p>0.1 n.s.). 
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3.2 Central regulation of hypothalamic-pituitary-adrenal axis activity 
3.2.1 Experiment 1: Effects of chronic fluoxetine treatment on emotional 
behaviour and hypothalamic-pituitary-adrenal axis regulation in HR, IR and 
LR mice 
3.2.1.1 Assessment of emotional behaviour 
3.2.1.1.1 Locomotor activity and exploratory drive in the open field test 
After 28 days of chronic Flx treatment, the animals were subjected to a 10-min OF test in 
order to assess their locomotor activity and exploratory drive. Due to technical problems 
of the ANY-maze software, one Flx-treated LR animal had to be excluded from the 
analysis, thereby reducing the number of LR animals in this group from nine to eight. 
Independent of treatment, the animals of all three lines neither showed significant 
differences in the total distance travelled, time spent in the inner or outer zone of the OF 
apparatus, nor in the ratio between inner and outer zone path length (see Table 4). Thus, 
Flx treatment did not induce changes in locomotion or exploratory drive of the tested 
animals. 
 
Table 4: Behavioural readout of high (HR), intermediate (IR) and low (LR) reactivity mice of Gen XVII 
determined in the open field (OF) test. Independent of treatment, the animals of all three lines did not show 
significant differences in their locomotor activity or exploratory drive. 
Parameter 
measured 
NHR/IR/LR treatment 
HR IR LR 
between-line 
comparison 
mean SEM mean SEM mean SEM H p  
total 
distance 
travelled 
[m] 
8/8/8 Veh 48.41 6.18 37.96 4.98 34.75 2.89 4.3 0.113 n.s. 
8/9/8 Flx 39.84 2.95 37.66 2.37 33.48 1.34 3.1 0.206 n.s. 
time inner 
zone [s] 
8/8/8 Veh 47.28 9.96 39.38 9.26 34.54 9.2 1.8 0.403 n.s. 
8/9/8 Flx 32.79 5.23 40.03 6.77 32.58 6.88 0.5 0.776 n.s. 
time outer 
zone [s] 
8/8/8 Veh 552.73 9.96 560.63 9.26 565.46 9.2 1.8 0.403 n.s. 
8/9/8 Flx 567.21 5.23 559.96 6.77 567.43 6.88 0.5 0.776 n.s. 
ratio inner 
outer path 
length 
8/8/8 Veh 0.18 0.03 0.16 0.02 0.16 0.04 0.7 0.682 n.s. 
8/9/8 Flx 0.14 0.02 0.17 0.02 0.13 0.03 2.1 0.342 n.s. 
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3.2.1.1.2 Assessment of stress-coping behaviour in the forced swim test 
Immediately after the OF test, a 6-min FST was performed. A line comparison between 
HR, IR and LR animals of the Veh-treated group revealed significant differences in 
stress-coping behaviour regarding their struggling time (KWH-test: N=8/8/8, H=8.8, 
df=2, p<0.05, see Figure 24 B). Veh-treated HR mice showed a significantly increased 
time spent struggling compared to IR and LR animals (post-hoc MWU-test: HR vs IR, 
U=10, p<0.05; HR vs LR, U=6, p<0.05). There was no difference between Veh-treated IR 
and LR animals (post-hoc MWU-test: HR vs IR, U=27.5, p>0.1). Furthermore, a trend in 
the same direction was observed in Flx-treated HR, IR and LR animals (KWH-test: 
N=8/9/9, H=4.6, df=2, p<0.1). In line with this, HR, IR and LR animals of both treatment 
groups displayed a significantly different passive stress-coping behaviour, i.e. floating 
(KWH-test: Veh, N=8/8/8, H=11.6, df=2, p<0.01; Flx, N=8/9/9, H=9.3, df=2, p<0.01, see 
Figure 24 A), with HR mice of both treatment groups showing less immobility compared 
to IR and LR animals (post-hoc MWU-test: Veh, HR vs IR, U=8, p<0.05; HR vs LR, 
U=4, p<0.01; Flx, HR vs IR, U=8, p<0.05; HR vs LR, U=10, p<0.05). Strikingly, a 
within-line comparison revealed that Flx-treated HR and IR animals had a significantly 
increased floating time compared to the Veh-treated animals of the respective line 
(MWU-test: HR and IR, Veh vs Flx, all U=11, all p<0.05).  
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Figure 24 Stress-coping behaviour of high (HR), intermediate (IR) and low (LR) reactivity mice of Gen XVII 
during the 6-min forced swim test (FST) period. A: time spent floating. B: time spent struggling. For statistical 
differences between the three lines (KWH-test) see text. Statistical differences between the Veh and Flx group 
are given on top of the panel (MWU-test: p≤0.05*, p≤0.1 T, p>0.1 n.s.). 
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In addition, the latency until the onset of the first floating episode was reduced in Flx-
treated animals of all lines compared to Veh-treated animals (MWU-test: Veh vs Flx; HR, 
U=8, p<0.05; IR, U=7, p<0.01; LR, U=18, p<0.1, see Figure 25), while HR mice of both 
treatment groups had a significantly higher latency until their first floating episode 
compared to the other two lines (KWH-test: Veh, N=8/8/8, H=15, df=2, p<0.001; Flx, 
N=8/9/9, H=8.3, df=2, p<0.05; post-hoc MWU-test: Veh, HR vs IR, U=3, p<0.01; HR vs 
LR, U=0, p<0.01; Flx, HR vs IR, U=8, p<0.05; HR vs LR, U=12, p<0.05).  
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Figure 25: Latency to the first floating episode of high (HR), intermediate (IR) and low (LR) reactivity mice of 
Gen XVII during the 6-min forced swim test (FST) period. For statistical differences between the three lines 
(KWH-test) see text. Statistical differences between the Veh and Flx group are given on top of the panel (MWU-
test: p≤0.01**, p≤0.05*, p≤0.1 T). 
 
In summary, these results show that HR, IR and LR mice use a distinctly different 
strategy to cope with the physiologically as well as psychologically demanding situation 
of the FST, with LR mice resembling a phenotype of behavioural despair, while HR mice 
display clearly more agitated behaviour. Furthermore, the results suggest that Flx 
treatment increases the passive stress-coping behaviour of HR and IR animals in the FST 
compared to their Veh-treated littermates, while LR mice are less affected by the Flx 
treatment. 
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3.2.1.2 Hypothalamic-pituitary-adrenal axis reactivity in response to swim stress 
In the reference blood sample collected three days prior to the behavioural testing, CORT 
concentrations were low in HR, IR and LR animals, ranging between mean values of 5 
ng/ml and 26 ng/ml (mean ± SEM, Veh, HR: 25.8 ± 8.6, IR: 11.5 ± 5.4, LR: 5.1 ± 1.2; 
Flx, HR: 14.3 ± 4.0, IR: 13.0 ± 2.9, LR: 5.1 ± 1.6), with no significant differences 
between Veh and Flx-treated animals (see Figure 26). However, HR animals of the Veh 
group showed slightly elevated plasma CORT concentrations compared to LR animals 
(KWH-test: Veh, N=8/8/8, H=6.1, df=2, p<0.05; post-hoc MWU-test: HR vs IR, U=16, 
p>0.1; HR vs LR, U=9.5, p<0.1; IR vs LR, U=24, p>0.1). In the Flx-treated group, HR 
and IR animals displayed higher plasma CORT concentrations in the reference sample 
compared to the LR group (KWH-test: Flx, N=8/9/9, H=8.1, df=2, p≤0.05; post-hoc 
MWU-test: HR vs IR, U=35, p>0.1, HR vs LR, U=9.5, p<0.05; IR vs LR, U=14, p<0.05). 
Regarding the plasma CORT concentrations determined right after the behavioural test 
battery (OF + FST), a between-line comparison showed significant differences in the 
swim stress-induced plasma CORT concentrations between HR, IR and LR animals of 
both the Veh and Flx group (KWH-test: Veh, N=8/8/8, H=19.2, df=2, p<0.001; Flx, 
N=8/9/9, H=21.0, df=2, p<0.001), with HR mice showing clearly higher plasma CORT 
concentrations compared to the IR line, while LR animals had the lowest increase (post-
hoc MWU-test: Veh, HR vs IR, U=3, p<0.01; HR vs LR, U=0, p<0.01; IR vs LR, U=1, 
p<0.01; Flx, HR vs IR, U=2, p<0.01; HR vs LR, U=0, p≤0.001; IR vs LR, U=2, p<0.01). 
However, there was no significant effect of Flx-treatment within the three lines (MWU-
test: Veh vs Flx; HR, U=18, p>0.1; IR, U=20, p>0.1; LR, U=30, p>0.1), i.e. chronic Flx 
treatment did not affect the acute, swim stress-induced CORT secretion from the adrenals. 
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Figure 26: Plasma corticosterone (CORT) concentrations in high (HR), intermediate (IR) and low (LR) 
reactivity mice of Gen XVII three days before (reference) and immediately after the behavioural testing (after 
FST). Statistical differences between the three lines (KWH-test) are given in the text, pairwise group 
comparisons (MWU-tests) are indicated on top of the panel (p>0.1 n.s.). 
 
3.2.1.3 Hypothalamic-pituitary-adrenal axis activity in the combined 
dexamethasone/corticotropin-releasing hormone test 
Not only to assess HPA axis reactivity in response to an acute stressor (e.g. FST, see 
above) but to further investigate regulatory mechanisms involved in HPA axis activity, 
we performed a combined Dex/CRH test with the same animals of the HR, IR and LR 
line. Due to technical problems, one IR animal of the Flx-treated group had to be 
excluded, reducing the number of experimental animals to eight in this group (Veh, 
HR/IR/LR, N=8/8/8; Flx, HR/IR/LR, N=8/8/9). 
On day 32, three days prior to the Dex/CRH test, a reference blood sample was collected 
at 15:00 and plasma CORT concentrations were determined. There were no significant 
differences between HR, IR and LR mice of both, the Veh and Flx-treated group (KWH-
test: Veh, HR/IR/LR, N=8/8/8, H=0.4, df=2, p>0.1; Flx, HR/IR/LR N=8/8/9, H=3.4, 
df=2, p>0.1). Additionally, a within-line comparison revealed no significant differences 
between the Veh- and Flx-treated animals (see Figure 27). It should be noted that in 
general, the plasma CORT levels in these samples (afternoon) were higher compared to 
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morning samples due to the circadian rhythm of CORT secretion (Touma et al., 2004; 
Touma et al., 2008; Touma et al., 2009). 
On day 35, all animals received an i.p. injection with a low dose of Dex. Six hours after 
the injection, blood was sampled and plasma CORT levels were assessed. Independently 
of treatment, Dex induced a suppression of plasma CORT concentrations in all animals 
(Wilcoxon-test: Veh, HR/IR/LR, N=8/8/8, Z=-2.1/-2.1/-2.5, all p<0.05; Flx, HR/IR/LR, 
N=8/8/9, Z=-2.5/-2.6/-2.6, all p<0.05). In Veh-treated animals, the between-line 
comparison revealed a significantly enhanced Dex-mediated CORT suppression in LR 
mice compared to HR and IR animals (KWH-test: N=8/8/8, H=10.7, df=2, p<0.01; post-
hoc MWU-test: HR vs IR, U=25, p>0.1; HR vs LR, U=2, p<0.01; IR vs LR, U=10, 
p<0.05), while Dex induced a prominent CORT suppression in all Flx-treated animals, 
which was not different between the lines (KWH-test: N=8/8/9, H=2, df=2, p>0.1). 
Interestingly, however, the CORT-suppressive effect of Dex was significantly higher in 
HR and IR animals of the Flx-treated group (MWU-test: Veh vs Flx; HR: N=8/8, U=1, 
p≤0.001; IR: N=8/8, U=9.5, p<0.05, see Figure 27), indicating that Flx treatment 
enhanced the Dex-mediated negative feedback signal on the HPA axis. In animals of the 
LR line both, Veh and Flx-treated mice showed a highly effective CORT suppression by 
Dex, which was not significantly different between the two treatment groups. 
In response to the injection of CRH, significant differences in plasma CORT 
concentrations between HR, IR and LR mice of the Veh and Flx group were observed. 
Independent of treatment, HR mice showed the most pronounced rise in CORT, while LR 
animals had a clearly attenuated CORT release in response to CRH (HR>IR>LR; Veh, 
KWH-test: N=8/8/8, H=19.2, df=2, p≤0.001; post-hoc MWU-test: HR vs IR, U=3, 
p<0.01; HR vs LR, U=0, p<0.01; IR vs LR, U=1, p<0.01; Flx, KWH-test: N=8/8/9, 
H=20.4, df=2, p≤0.001; post-hoc MWU-test: HR vs IR, U=3, p<0.01; HR vs LR, U=0, 
p<0.01; IR vs LR, U=0, p<0.01). There was no significant effect of Flx treatment in 
animals of the HR and IR line. In LR mice, however, the Flx treatment produced a 
markedly decreased CORT secretion in response to the CRH stimulation compared to 
Veh-treated LR animals (MWU-test: Veh vs Flx, U=4, p<0.01). 
Taken together, Flx induced a more pronounced suppression of CORT after Dex 
treatment as seen in animals of the HR and IR line, which is indicative of a higher Dex-
induced negative feedback signal in these animals. In LR animals, albeit their already 
prominent Dex-induced CORT suppression (as observed in the Veh-treated group), Flx 
further enhanced the Dex-mediated negative feedback, resulting in a significantly 
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decreased CORT surge after CRH stimulation. Thus, the results revealed that chronic Flx 
treatment amplified the negative feedback signal on the HPA axis in all three lines of the 
SR mouse model, most considerable LR mice. 
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Figure 27: Plasma corticosterone (CORT) concentrations of high (HR), intermediate (IR) and low (LR) 
reactivity mice of Gen XVII in the Dex/CRH test. Blood samples were collected three days before the test 
(reference), six hours after Dex application (after Dex) and 30 min after CRH stimulation (after CRH). 
Statistical differences between the three lines (KWH-test) are given in the text, pairwise group comparisons 
(MWU-tests) are indicated on top of the panel (p≤0.001***, p≤0.01**, p≤0.05*, p>0.1 n.s.). 
 
3.2.1.4 Gene expression analysis 
3.2.1.4.1 Gene expression in the hippocampus 
Directly after the Dex/CRH test, animals were sacrificed and their hippocampi were 
dissected. From one hippocampal hemisphere RNA was isolated and gene expression 
analysis was performed. 
In the hippocampus of Flx-treated animals, a significant difference between the lines was 
found in the gene expression profile of Fkbp4, Abcb1b and Crhr1. In Veh-treated 
animals, only Abcb1b was differentially expressed between HR, IR and LR animals. 
Results 
73 
 
Solely in LR animals, a within-line comparison (Veh vs Flx-treated animals) revealed 
significant differences regarding Fkbp5, Abcb1a and Gilz. The results of the qPCR 
analysis are summarised in Table 5. 
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HR IR LR 
between line 
comparison 
post-hoc MWU-test 
(KWH-test) HR vs IR HR vs LR IR vs LR 
candidate treatment mean SEM mean SEM mean SEM H p U p U p U p 
Nr3c1 
Veh 0.98 0.08 1.00 0.07 1.01 0.12 0.1 0.945 
     
  
Flx 1.14 0.11 0.90 0.09 1.01 0.06 2.0 0.362             
Nr3c2 
Veh 1.08 0.12 1.00 0.16 0.92 0.09 1.0 0.581             
Flx 1.17 0.30 0.87 0.10 1.19 0.16 2.0 0.352             
Fkbp4 
Veh 1.04 0.15 1.00 0.16 0.88 0.14 0.5 0.756             
Flx 0.97 0.15 0.64 0.06 1.20 0.16 8.3 0.016* 15 0.086 27 0.386 10 0.021* 
Fkbp5 
Veh 0.86 0.11 1.00 0.06 0.76 0.04 5.8 0.054T             
Flx 0.95 0.07 0.98 0.08 0.95** 0.05 0.0 0.979             
Abcb1a 
Veh 1.04 0.09 1.00 0.11 0.80 0.05 5.6 0.059T 
     
  
Flx 1.07 0.09 0.90 0.10 1.09* 0.10 1.4 0.478             
Abcb1b 
Veh 1.91 0.13 1.00 0.27 0.42 0.06 12.4 0.002** 11 0.054 0 0.003** 18 0.141 
Flx 1.94 0.17 1.00 0.29 0.70 0.27 7.7 0.020* 14 0.068 8 0.021* 39 0.895 
Crhr1 
Veh 1.18 0.16 1.00 0.10 1.17 0.14 0.9 0.636 
     
  
Flx 1.28 0.14 0.90 0.07 1.29 0.13 6.2 0.043* 16 0.108 36 1.000 14 0.057 
Cfl1 
Veh 1.03 0.08 1.00 0.07 1.00 0.10 0.2 0.888 
     
  
Flx 1.25 0.11 1.00 0.13 1.16 0.08 2.1 0.341             
Gilz 
Veh 1.12 0.08 1.00 0.07 0.95 0.08 3.7 0.153 
     
  
Flx 1.22 0.10 1.10 0.10 1.27** 0.08 1.0 0.596             
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3.2.1.4.2 Gene expression in the pituitary 
Similarly to the hippocampus, RNA was isolated from the pituitary and gene expression 
analysis was performed. 
In the pituitary of Flx-treated animals, a significant difference between the lines was 
found in the gene expression profile Pomc and Abcb1b. In Veh-treated animals, solely 
Abcb1a was differentially expressed between HR, IR and LR animals. 
A within-line comparison (Veh vs Flx-treated animals) revealed significant differences 
regarding Fkbp5, Abcb1a and Gilz in IR animals. Additionally, Abcb1b was significantly 
different in Veh vs Flx-treated animals of the LR line. The results of the qPCR analysis 
are summarised in Table 6. 
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HR IR LR 
between line 
comparison 
post-hoc MWU-test 
(KWH-test) HR vs IR HR vs LR IR vs LR 
candidate treatment mean SEM mean SEM mean SEM H p U p U p U p 
Nr3c1 
Veh 0.72 0.13 1.00 0.20 0.75 0.12 1.5 0.464 
     
  
Flx 1.00 0.16 0.80 0.04 1.13 0.19 1.8 0.389             
Pomc 
Veh 1.98 0.51 1.00 0.19 0.79 0.15 4.4 0.108             
Flx 2.63 0.44 1,31 0.23 0.87 0.13 15.0 0.001*** 9 0.018* 0 0.003** 18 0.047* 
Fkbp5 
Veh 0.89 0.06 1.00 0.10 1.23 0.11 4.5 0.102 
      
Flx 1.13 0.14 1.68 ** 0.16 1.41 0.12 4.9 0.084T 
      
Abcb1a 
Veh 1.78 0.22 1.00 0.13 1.44 0.20 8.0 0.018* 7 0.027* 19 0.172 15 0.148 
Flx 1.99 0.48 1.89 * 0.24 1.62 0.19 0.4 0.784 
      
Abcb1b 
Veh 0.91 0.18 1.00 0.18 0.57 0.06 4.8 0.090T 
      
Flx 1.32 0.22 0.71 0.09 0.91 * 0.12 7.1 0.028* 11 0.048* 17 0.136 26 0.200 
Crhr1 
Veh 1.03 0.12 1.00 0.12 0.65 0.13 3.6 0.160 
     
  
Flx 1.01 0.15 0.73 0.09 0.81 0.12 2.0 0.363             
Gilz 
Veh 1.06 0.10 1.00 0.05 1.09 0.08 0.7 0.692 
     
  
Flx 1.29 0.16 1.41 * 0.12 1.08 0.11 3.4 0.174             
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3.2.1.5 Protein expression in the hippocampus 
Protein expression analysis of GR and FKBP51 in Veh- and Flx-treated HR, IR and LR 
animals was performed in the contralateral hippocampal hemisphere, which was not used 
for qPCR analysis. 
A between-line comparison showed no significant differences in the expression of GR 
between HR, IR and LR animals of both the Veh and Flx group (KWH-test: Veh, 
N=8/8/8, H=1.3, df=2, p>0.1; Flx, N=8/9/9, H=2.0, df=2, p>0.1). In addition, there were 
no significant differences comparing Veh and Flx-treated animals within the breeding 
lines (MWU-test: Veh vs Flx; HR: N=8/8, U=28, p>0.1; IR: N=8/9, U=25, p>0.1, LR: 
N=8/9, U=22, p>0.1, see Figure 28). Similarly, no significant differences in the 
expression of FKBP51 between HR, IR and LR mice of the Veh group could be detected 
(KWH-test: Veh, N=8/8/8, H=0.2, df=2, p>0.1, see Figure 28). However, Flx treatment 
increased FKBP51 in animals of the LR line compared to HR and IR mice (KWH-test: 
Flx, N=8/9/9, H=10.1, df=2, p<0.01; post-hoc MWU-test: HR vs IR, U=24, p>0.1; HR vs 
LR, U=7, p<0.05; IR vs LR, U=13, p<0.05). A within-line comparison, i.e. Veh vs Flx 
treatment, revealed no significant differences in HR and IR animals. However, a trend 
could be observed in the LR line (MWU-test: Veh vs Flx; HR: N=8/8, U=27, p>0.1; IR: 
N=8/9, U=34, p>0.1, LR: N=8/9, U=16, p<0.1). 
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Figure 28: (A) Representative Western blot pictures of the glucocorticoid receptor (GR), FK506 binding protein 
51 (FKBP51) and glyceraldehyde-3-phosphate-dehydrogenase (GAPDH). (B) GR expression (left) and FKBP51 
expression (right) in the hippocampus of high (HR), intermediate (IR) and low (LR) reactivity mice of Gen XVII 
relative to GAPDH, normalised to the IR Veh group. Statistical differences between the three lines (KWH-test) 
are given in the text, within-line comparisons (MWU-test) are indicated on top of the panel (p≤0.1 T, p>0.1 n.s.). 
3.2.2 Experiment 2: Effects of chronic fluoxetine treatment on the spatial reference 
memory, hypothalamic-pituitary-adrenal axis function and neuronal 
activation in response to stress in HR, IR and LR mice 
3.2.2.1 Assessment of spatial reference memory 
After 28 days of chronic fluoxetine treatment, the animals were subjected to a Y-maze 
test in order to assess their hippocampus-dependent, spatial reference memory abilities. In 
the retrieval phase, i.e. after a 60-min period in their homecages between acquisition and 
retrieval phase, animals of all three lines independent of treatment did not show 
significant differences in the percentage of time exploring exploration the novel arm 
versus the familiar arms of the apparatus, indicating that neither HR, nor IR, nor LR mice 
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differentiated between the newly opened arm and the previously explored ones (see Table 
7). 
Table 7: High (HR), intermediate (IR) and low (LR) reactivity mice of Gen XIX during the retrieval phase of the 
Y-maze test; per cent time spent in the novel and familiar arms. 
 novel arm familiar arms Wilcoxon-test  
line N treatment mean SEM mean SEM Z p  
HR 
12 Veh 28.58 3.01 35.71 1.50 -1.4 0.136 n.s. 
11 Flx 40.34 3.82 29.83 1.91 -1.6 0.110 n.s. 
IR 
13 Veh 34.01 3.05 33.00 1.53 -0.2 0.807 n.s. 
12 Flx 31.63 2.70 34.19 1.35 -0.9 0.347 n.s. 
LR 
12 Veh 38.11 4.14 30.94 2.07 -1.0 0.308 n.s. 
7 Flx 34.66 3.90 32.67 1.95 -0.0 1.000 n.s. 
 
Interestingly, Flx-treated HR mice revealed a significantly higher discrimination ratio 
regarding the exploration time in the novel arm compared to Veh-treated HR animals 
(MWU-test: Veh vs Flx; HR: N=12/11, U=29.5, p<0.05, see Figure 29). This indicates 
that the accuracy to visit and explore the novel arm was increased in Flx-treated HR mice. 
However, Flx did not affect the memory performance of IR and LR animals (MWU-test: 
Veh vs Flx; IR: N=13/12, U=68, p>0.1; LR: N=12/7, U=35, p>0.1). Furthermore, a 
between-line comparison did not show significant differences independent of treatment 
regarding the spatial memory performance in HR, IR and LR animals (KWH-test: 
HR/IR/LR; Veh, N=12/13/12, H=3.0, df=2, p>0.1; Flx, N=11/12/7, H=4.3, df=2, p>0.1). 
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Figure 29: Discrimination ratio (% time spent in novel arm/familiar arms) of high (HR), intermediate (IR) and 
low (LR) reactivity mice of Gen XIX during the retrieval phase of the Y maze test. For statistical differences 
between the three lines (KWH-test) see text. Statistical differences between the Veh and Flx group are given on 
top of the panel (MWU-test: p≤0.05*, p>0.1 n.s.). 
 
3.2.2.2 Assessment of stress-induced hypothalamic-pituitary-adrenal axis function and 
neuronal activation in the central nervous system 
On day 35 of chronic Flx treatment, after allowing the animals to recover from the Y-
maze testing for seven days, the experimental animals were subjected to a SRT in order to 
assess their HPA axis response to an acute stressor. The SRT also served as a 
standardised stressor to induce C-fos mRNA expression in the brain as a marker for 
neuronal activation. Animals of the two control groups (control I and II, for details see 
methods 2.5.2.2) were euthanised under basal conditions and plasma CORT 
concentrations as well as basal C-fos expression were assessed. 
3.2.2.3 Assessment of stress-induced hypothalamic-pituitary-adrenal axis activation 
As expected, the plasma CORT concentrations of Veh and Flx-treated HR, IR and LR 
animals of control I (mean ± SEM [ng/ml], Veh, HR: 14.0 ± 4.6, IR: 9.2 ± 3.1, LR: 12.6 ± 
5.8; Flx, HR: 9.8 ± 2.6, IR: 13.9 ± 5.5, LR: 10.6) were similar to the CORT values of the 
experimental group, which were obtained immediately before the restraint (see below). 
The plasma CORT levels of the naïve control II animals were slightly lower (mean ± 
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SEM [ng/ml], HR: 3.9 ± 0.8, IR: 6.2 ± 2.4, LR: 5.9 ± 2.4) than the values of the 
experimental animals and control I. This suggests that the chronic daily injection 
procedure induced a moderate rise in basal CORT levels, which were, however, still in 
the range of unstressed CORT values (mean maximum of approx. 14 ng/ml). 
In the experimental animals that were subjected to the SRT, plasma CORT concentrations 
did not differ significantly between the three lines of the Veh and Flx-treated group 
immediately before the SRT (KWH-test: Veh, N=9/10/9, H=3.8, df=2, p>0.1; Flx, 
N=9/8/7, H=5.0, p<0.1), with a range between 3 ng/ml and 14 ng/ml (mean ± SEM, Veh, 
HR: 9.9 ± 2.8, IR: 11.0 ± 2.5, LR: 5.2 ± 0.8; Flx, HR: 11.5 ± 3.4, IR: 13.7 ± 4.9, LR: 3.8 
± 0.8). Furthermore, there were no significant differences between Veh and Flx-treated 
animals in any of the three breeding lines (MWU-test: Veh vs Flx; HR: N=9/9, U=37, 
p>0.1; IR: N=10/8, U=38, p>0.1; LR: N=9/7, U=22.5, p>0.1). After 15 min of restraint, 
plasma CORT levels in HR, IR and LR animals were elevated independently of 
treatment, with HR animals displaying markedly increased CORT concentrations 
compared to IR animals, while LR mice had the lowest stress-induced plasma CORT 
levels (HR>IR>LR; Veh, KWH-test: N=9/10/9, H=22.4, df=2, p≤0.001; post-hoc MWU-
test: HR vs IR, U=6, p≤0.001; HR vs LR, U=0, p<0.01; IR vs LR, U=0, p<0.01; Flx, 
KWH-test: N=9/8/7, H=20.4, df=2, p≤0.001; post-hoc MWU-test: HR vs IR, U=0, 
p<0.01; HR vs LR, U=0, p≤0.001; IR vs LR, U=0, p<0.01). However, Flx-treated LR 
animals revealed a tendency towards lower stress-induced plasma CORT levels compared 
to Veh-treated LR mice. Interestingly, 60 min after the onset of the stressor, Flx-treated 
LR animals showed significantly reduced plasma CORT concentrations compared to 
Veh-treated LR mice (MWU-test: Veh vs Flx; N=9/7, U=12, p<0.05). This indicates that 
Flx treatment increased the negative feedback inhibition of the adrenal CORT secretion in 
animals of the LR line. However, Flx treatment did not affect the plasma CORT 
concentrations 60 min after the onset of the SRT in HR and IR animals (MWU-test: Veh 
vs Flx; HR: N=9/9, U=36, p>0.1; IR: N=10/8, U=32, p>0.1). Moreover, 60 min after the 
onset of the stressor, plasma CORT concentrations were significantly reduced compared 
to the CORT levels immediately after the SRT only in HR animals (W-test: Veh/Flx, 
N=9/9, Z=-2.66, all p<0.01, see Figure 30), while there was no decrease in the respective 
samples for IR and LR animals of the Veh and Flx-treated group (W-test: Veh/Flx, IR: 
N=10/8, Z=-1.27/-0.56, all p>0.1; LR: N=9/7, Z=-1.00/0.00, all p>0.1).  
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Figure 30: Plasma corticosterone concentrations of high (HR), intermediate (IR) and low (LR) reactivity mice of 
Gen XIX. Blood samples were collected immediately before (initial) and right after (reaction) the 15-min 
restraint period as well as 45min after the termination of the restraint (45min post SRT). Statistical differences 
between the three lines (KWH-test) and within treatment groups (W-test) are given in the text, pairwise group 
comparisons (MWU-tests) are indicated on top of the panel (p≤0.05*, p>0.1 n.s.). 
 
3.2.2.4 Assessment of stress-induced neuronal activation in the brain 
As expected, there was only low C-fos expression (as a marker for neuronal activation) in 
control I and control II animals (reflected by the very low grey values of the in-situ signal 
hardly deviating from the background) compared to HR, IR and LR animals subjected to 
the SRT (see Figure 31). 
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Figure 31: Representative pictures of C-fos expression in the brain of the experimental mice. Left: naïve animal 
(control II). Middle: animal that received chronic injections but was not subjected to the SRT (control I). Right: 
animal that was subjected to the SRT (stressed animal). 
Additionally, no differences could be observed between animals of the control I and 
control II group regarding the C-fos expression in the investigated brain areas. 
However, Flx-treated HR, IR and LR animals of control I showed significant differences 
in C-fos expression in the BLA, CA3 of the dorsal hippocampus and CA1, CA3 and DG 
of the ventral hippocampus (see Table 5 in the appendix). In this respect, however, it 
should be emphasised that these statistical differences were potentially brought about by 
the small sample size of control I (Veh: NHR/IR/LR=4/4/4, Flx: NHR/IR/LR=4/4/2) as well as 
by the limited sensitivity (close to the detection limit) of the method. Thus, reliable 
statistical conclusions cannot be drawn from this data. 
Table 8 shows the C-fos mRNA expression obtained from HR, IR and LR which were 
subjected to the 15-min SRT. As expected, the 15-min restraint stress considerably 
increased C-fos mRNA expression 60 min after the onset of the stressor in all analysed 
brain areas with the exception of the dentate gyrus of the dorsal and ventral hippocampus, 
where the increase in C-fos was less prominent and already the animals of both control 
groups showed a considerable C-fos expression. In most of the analysed brain regions, 
Flx treatment had no major effect on the neuronal activation, except for the CA2 of the 
dorsal hippocampus and CA3 of the ventral hippocampus in LR, as well as the CA3 of 
the dorsal hippocampus in HR animals. Here, significant differences between Veh and 
Flx-treated animals were detected. 
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 HR IR LR 
between line 
comparison 
post-hoc MWU-test 
 
(KWH-test) HR vs IR HR vs LR IR vs LR 
brain region subregion N=HR/IR/LR treatment mean SEM mean SEM mean SEM H p U p U p U p 
PFC 
 
9/10/9 VEH 47.33 2.37 45.46 1.47 51.38 2.29 3.2 0.200 
      
8/8/6 Flx 47.54 1.81 44.43 2.48 50.98 3.30 1.0 0.599 
      
PVN  
9/10/9 VEH 46.47 4.14 38.92 2.89 30.32 2.13 9.0 0.011* 32 0.288 8 0.012* 20 0.082T 
 
8/8/6 Flx 47.00 2.58 36.56 3.51 28.49 4.43 8.6 0.013* 13 0.092T 5 0.042* 10 0.071T 
BLA  
9/10/9 VEH 35.41 3.23 29.90 1.53 28.43 1.86 2.4 0.288 
      
 
8/8/6 Flx 30.95 2.13 30.95 2.56 22.33 2.14 7.8 0.020* 31 0.916 5 0.028* 5 0.042* 
dHC 
CA1 
9/10/9 VEH 29.09 2.81 28.34 1.62 33.10 2.76 1.8 0.397 
      
8/8/6 Flx 28.95 2.06 27.44 3.13 28.32 2.42 1.0 0.581 
      
CA2 
9/10/9 VEH 23.25 3.04 29.89 2.01 29.23 2.39 3.1 0.208 
      
8/8/6 Flx 22.30 1.99 25.38 1.79 22.76* 0.58 1.5 0.450 
      
CA3 
9/10/9 VEH 21.20 1.70 27.03 1.80 28.14 2.48 6.4 0.040* 18 0.081T 16 0.062T 45 1.000 
8/8/6 Flx 25.32* 1.25 27.17 2.74 24.28 1.36 1.2 0.545 
      
DG 
9/10/9 VEH 25.63 1.68 22.46 0.92 27.15 1.86 3.8 0.148 
      
8/8/6 Flx 23.98 0.78 20.86 1.96 25.37 2.18 2.0 0.353 
      
vHC 
CA1 
9/10/8 VEH 20.15 2.22 23.86 1.96 26.99 2.42 2.9 0.225 
      
8/8/6 Flx 19.59 1.45 21.03 1.48 22.13 2.01 1.0 0.587 
      
CA3 
9/10/8 VEH 12.14 1.13 12.24 0.84 16.05 1.36 4.7 0.093 
      
8/8/6 Flx 12.64 1.38 12.69 1.18 11.84* 1.69 0.6 0.715 
      
DG 
9/10/8 VEH 11.45 1.17 12.40 0.93 16.15 1.30 6.1 0.046* 35 0.414 14.5 0.076T 16 0.099T 
8/8/6 Flx 13.18 1.17 11.48 0.88 12.91 1.19 1.6 0.429 
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More strikingly, independent of treatment, HR animals showed a significantly higher C-
fos expression in the PVN compared to LR animals. Additionally, a trend was observed 
between both, Veh and Flx-treated IR and LR animals (see Table 8 and Figure 32). This 
is of interest, since the PVN is highly involved in the control of HPA axis function, 
integrating neuronal inputs from a multitude of brain regions and consequently initiating 
HPA axis activity which, eventually, results in CORT secretion from the adrenal cortex. 
These results show that the distinctly different CORT increase between HR, IR and LR 
animals in response to stressors is not only a peripheral phenomenon (e.g. ACTH release 
from the pituitary or differential adrenal sensitivity) but also has a CORT-independent 
neuronal correlate in the central nervous system. 
In summary, C-fos expression analysis in HR, IR and LR animals showed that (i) acute 
restraint stress prominently increased C-fos expression in all investigated brain regions, 
(ii) strikingly, in the PVN of HR animals, this increase was significantly higher compared 
to LR animals and (iii) Flx treatment had no major effect on neuronal activation in the 
investigated brain regions. 
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Figure 32: (A) Representative pictures of C-fos mRNA expression in the paraventricular nucleus of the 
hypothalamus (PVN) detected by in-situ hybridisation (B) C-fos mRNA expression in the PVN of high (HR), 
intermediate (IR) and low (LR) reactivity mice of Gen XIX. Statistical differences between the three lines 
(KWH-test) are given in the text, within-line comparisons (MWU-test) are indicated on top of the panel (p>0.1 
n.s.). 
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4 Discussion 
The body of work presented here aimed to characterise the molecular-genetic 
underpinnings of the distinctly different neuroendocrine and associated behavioural 
phenotypes of the HR, IR and LR line of the SR mouse model in more detail. Therefore, 
not only the distal branches of the HPA axis such as the adrenals, the pituitary as well as 
corticosteroid-binding globulin were investigated in the three lines, but we furthermore 
aimed to find molecular correlates of HPA axis dysfunction in the central nervous system 
of the animals. The HPA axis is a complex and highly dynamic system with regulatory 
elements on many different levels, peripheral as well as in the CNS. Thus, we wanted to 
elucidate whether in HR, IR and LR animals, albeit these mice are selectively bred for 
differences in CORT secretion in response to stressors, preceeding levels in the chain of 
HPA axis regulatory elements would be affected.  
Indeed, through our studies, we gained insight into the mechanisms of HPA axis 
dysfunction beyond the selection criterion of stress-induced CORT secretion, thus 
revealing differences between HR, IR and LR mice on all levels of HPA axis function, 
i.e. the hypothalamus, the pituitary as well as the adrenals.  
4.1 Peripheral regulation of the hypothalamic-pituitary-adrenal axis 
Metyrapone inhibits corticosterone secretion in response to stress 
At the adrenal level, we pharmacologically inhibited CORT synthesis and secretion using 
metyrapone (Met) in order to evaluate whether the differences in stress reactivity between 
the three lines were associated with the divergent coping strategies in behavioural tests. 
After Met treatment, there was a significant decline in plasma CORT concentrations in 
animals of all three lines compared to Veh-treated animals in response to the FST (see 
Figure 13). This was expected, since at this dose Met, which suppresses de novo 
steroidogenesis by inhibiting cytochrome P450 11β-hydroxylase (CYP450c11), produces 
a greater than 50% reduction in plasma CORT within the first hour in rats (Jenkins et al., 
1958; Roberts et al., 1984; Piazza et al., 1994). Interestingly, the significant differences in 
stress-induced plasma CORT concentrations between the three lines persisted in Met-
treated animals. This indicates that (i) the enzymatic activity of CYP450c11 was not 
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completely suppressed by Met at a dose of 50 µg/g BW or (ii) other mechanisms than de 
novo synthesis were involved in the secretion of CORT from the adrenals in HR, IR and 
LR animals. In a pilot study, validating the CORT-suppressive effect of Met, we injected 
animals of all three lines with two doses of Met, either 50 µg/g BW or 100 µg/g BW and 
subjected them to a FST. We observed that neither the lower dose, nor the high dose of 
Met completely suppressed the CORT secretion of HR, IR and LR animals. Moreover, 
the differences between the three lines (HR>IR>LR) in plasma CORT levels still 
persisted. Therefore, we suggest that the differences in plasma CORT concentration 
between Met-treated animals of the three lines are brought about by the stress-induced 
secretion of CORT vesicles stored in the adrenal cortex. This is supported by studies 
demonstrating the involvement of coated vesicles in the secretion of CORT by the zona 
fasciculata of the rat adrenal cortex (Bassett et al., 1980; Mohn et al., 2005).  
 
Inhibition of corticosterone secretion alters the emotional behaviour of stress 
reactive mice 
In the FST, HR, IR and LR animals showed significant differences in their stress-coping 
behaviour with HR mice displaying an hyper-active coping style, while LR animals 
showed signs of behavioural despair reflected by high immobility (see Figure 14). This 
was expected since previous studies showed that already in generation III of the SR 
model, animals of the three lines showed robust differences in their stress-coping 
behaviour which persisted in the following generations (Touma et al., 2008; Knapman et 
al., 2010a). Interestingly, Met treatment induced a further increase in active stress-coping 
behaviour in HR and IR mice, i.e. increased struggling. It remains to be clarified whether 
these effects were brought about by the inhibition of CORT synthesis and secretion per 
se. In a study performed in our group with a similar experimental setup, we could show 
that exogenously administered CORT did not affect the behavioural phenotype of HR, IR 
and LR animals in the FST (data not shown). Therefore, we hypothesised that the 
differences in the stress-coping behaviour between HR, IR and LR animals were brought 
about by other mechanisms shaping the behavioural endophenotypes of the animals of the 
three lines in the FST. The neuropeptide CRH plays a considerable role in the modulation 
of emotional behaviour. It has been shown that rats, which received i.c.v. injections of 
CRH, presented increased locomotion (Sutton et al., 1982) as well as an increased active 
coping behaviour in the FST (Dunn et al., 1990). Accordingly, mice overexpressing CRH 
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in the central nervous system displayed a more active stress-coping behaviour in the FST 
(Lu et al., 2008; Dedic et al., 2011). This increase in activity/hyperarousal was associated 
with a CRH-induced increase in activation of monoaminergic neurotransmission in brain 
structures such as the ventral tegmental area (Summers et al., 2003), the dorsal raphe 
nucleus (Linthorst et al., 2002) and the locus coeruleus (Valentino et al., 1983; Curtis et 
al., 1997). Interestingly, co-expression of glucocorticoid receptors was detected in many 
of these areas (Maras et al., 2012). Additionally, it was shown that glucocorticoids have 
suppressive effects on CRH signalling, decreasing the impact of the CRH system in these 
areas, for instance locus coeruleus (LC) activity (Lechner et al., 1999). Since the LC is 
prominently involved in the modulation of behavioural states such as anxiety and arousal 
(Berridge et al., 2003), we suggest that the pharmacological inhibition of endogenous 
CORT synthesis and secretion by Met induced an amplifying effect on the CRH-induced 
activity of the LC noradrenergic system, thus, further increasing the active stress-coping 
behaviour in HR and IR mice. On the other hand, we propose that LR animals were less 
affected by Met treatment regarding their stress coping style in the FST, since these 
animals show a less active brain CRH system, e.g. reflected by a decreased stress-induced 
excitation of the PVN (see discussion below) which, in turn, might have had a less 
prominent influence on the central monoaminergic system. 
In line with this, in-situ hybridisation studies in HR, IR and LR mice revealed a 
significantly increased CRH mRNA expression in the CeA of HR animals, while LR mice 
had the lowest expression (Touma et al., in preparation). This is of interest, since it was 
shown that repeated or chronic exposure to elevated levels of CORT (reflecting the 
condition in HR mice) induced an upregulation of CRH mRNA in the CeA (Makino et 
al., 1994a,b), a brain region critically involved in modulating the behavioural response to 
stress (Regev et al., 2011; Regev et al., 2012). Furthermore, CRH-antagonism in the CeA 
decreased anxiety-related behaviour (Liebsch et al., 1995) and attenuated foot-shock-
induced freezing behaviour (Swiergiel et al., 1993), supporting the prominent role of the 
CeA CRH system in behavioural emotionality. Furthermore, Lechner and colleagues 
showed that CRH immunoreactive neurons in the CeA colocalised with GR, suggesting 
the GC-sensitivity of this brain region (Lechner et al., 1999). Therefore, we suggest that 
(i) the hyper-active stress-coping behaviour of HR mice in the FST is associated with 
elevated levels of CRH mRNA in the CeA which is in contrast to LR mice showing more 
passive coping strategies and decreased levels of CRH mRNA in the CeA and (ii) that 
due to the GC-sensitivity of CRH neurons in the CeA, pharmacological inhibition of 
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endogenous CORT synthesis and secretion by Met potentially disinhibited the activity of 
CRH neurons, thus, further increasing the active stress-coping behaviour in HR and IR 
mice. Following this line of reasoning, the question remains why the exposure to the 10 
min open field test did not induce differential effects regarding locomotion or exploration 
between the three lines (see Table 3). However, it was shown that the intensity of a 
stressor markedly affects the adrenal response in terms of CORT secretion (Djordjevic et 
al., 2003) and that, in contrast to mild stressors such as exposure to a novel environment, 
a severe and life threatening stressor such as the FST induces a much higher secretion of 
CORT from the adrenals (Briski, 1996; Qian et al., 2011). Therefore, we speculate that 
during the 10 min open field test (resembling a relatively mild novel environment 
stressor), the level of secreted CORT was not high enough to affect GC-sensitive brain 
structures involved in behavioural emotionality. 
Adrenal gene expression in HR, IR and LR mice 
It is known that the dominant mechanism of CORT secretion in response to stressors is de 
novo biosynthesis of CORT upon ACTH stimulation (Garren et al., 1965; Boyd et al., 
1973), although CORT biosynthesis is not solely induced by ACTH (see discussion 
below). Thus, we were interested in whether the observed differences in CORT secretion 
in response to stressors between HR, IR and LR mice were brought about by mechanisms 
beyond the ACTH-induced adrenal stimulation. It has been shown that, in addition to the 
neuroendocrine signalling cascade of the HPA system, the sympathetic adrenomedullary 
system (SAM) is prominently involved in the stress response. Neuronal efferents, 
descending from the hypothalamic PVN (Harris, 1950; Yoshimatsu et al., 1987) innervate 
the adrenal cortex as well as the adrenal medulla (Bornstein et al., 1999; Engeland et al., 
2005) and that stimulation of splanchnic nerve fibres result in CORT release from the 
adrenals (Bornstein et al., 2008). Moreover, a mutual interaction of the adrenal medulla 
and the adrenal cortex has been suggested, since catecholamines released from 
chromaffin cells of the adrenal medulla stimulate steroidogenesis (Bornstein et al., 1999), 
while phenylethanolamine-N-methyltransferase (PNMT) expression in the adrenal 
medulla is dependent on high concentrations of glucocorticoids (Wurtman et al., 1965), 
for instance after stress. Kvetnansky and colleagues revealed a virtual absence of stress-
induced adrenomedullary PNMT expression in CRH knockout mice with low adrenal 
glucocorticoid concentrations (Kvetnansky et al., 2006) while in rats immobilisation 
stress increased PNMT (Axelrod et al., 1984) and tyrosine hydroxylase (TH) (Axelrod et 
Discussion 
91 
 
al., 1984; McMahon et al., 1992) expression in the adrenal medulla. This supports the 
glucocorticoid-dependency of adrenal PNMT and TH expression. Interestingly, PNMT as 
well as TH mRNA expression were not different between HR, IR and LR animals (see 
Figure 15), albeit significant differences in stress-induced plasma CORT concentrations. 
However, it is of note that the animals of the SR mouse model are selected based on their 
HPA axis reactivity in response to stress, while they do not show prominent differences in 
plasma CORT concentrations under basal conditions (for examples see Touma et al., 
2008 or Figure 19). Considering the CORT-sensitivity of PNMT and TH mRNA 
expression, this might explain the similar mRNA expression levels of these two enzymes. 
Furthermore, the gene expression analysis was performed in adrenals of mice which were 
sacrificed immediately after the termination of the stressor, therefore probably leaving 
insufficient time for the induction of transcriptional processes of adrenal PNMT as well 
as TH mRNA. 
StAR, which is critically involved in cholesterol trafficking (the precursor of all steroid 
hormones) from the cytoplasm to the inner mitochondrial membrane, catalyses the rate-
limiting step in a long enzymatic cascade of steroidogenesis (Jefcoate et al., 1992; Kim et 
al., 1997; Stocco, 2002). Moreover, the StAR system enables steroidogenic cells of the 
zona fasciculata and zona glomerulosa of the adrenal cortex to initiate and terminate 
steroidogenesis within a few minutes, permitting the rapid regulation of serum steroid 
hormone concentrations, e.g. in response to stress (Bose et al., 2002). Interestingly, 
differences in StAR mRNA expression were observed between the three lines, with HR 
animals showing a significantly increased expression of StAR compared to IR animals 
(see Figure 15 D). It has been shown that increased StAR expression and activity 
paralleled increases in plasma pregnonolone, progesterone and corticosterone levels 
(Khisti et al., 2003). Therefore, the overexpression of StAR in HR mice is in line with the 
high CORT secretion from the adrenals in response to stressors in these animals. The 
question remains, however, why animals of the LR line also showed high levels of StAR 
mRNA expression, albeit their low stress-induced adrenal CORT release. The following 
possibilities are conceivable. First, a plethora of enzymatic steps is involved in the 
conversion of cholesterol which eventually leads to CORT synthesis (Miller et al., 2011). 
Therefore, we cannot exclude that dysfunctional enzymatic activities downstream of the 
rate-limiting step of cholesterol trafficking to the inner mitochondrial membrane are 
involved in bringing about the decreased plasma CORT concentrations in response to 
stress in LR mice. Second, it has been shown that steroidogenesis is dependent on ACTH 
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and its mediator cAMP by regulating the mitochondrial precursor pool of cholesterol 
(Mahaffee et al., 1974) and that cholesterol is depleted from adrenal lipid droplets in 
response to stress inducing steroidogenesis (Trzeciak et al., 1973). Therefore, a 
diminished availability of adrenal cholesterol in LR animals could induce compensatory 
mechanisms, i.e. increasing StAR expression, to assure a functional steroidogenesis 
despite low concentrations of adrenal cholesterol, although this hypothesis has to be 
tested in further experiments in mice of the SR mouse model assessing adrenal 
cholesterol content. Since it has been shown that steroidogenesis is critically dependent 
on ACTH signalling (Garren et al., 1965) and that ACTH binding to its receptor, the 
MC2R, stimulates cholesterol transfer by increasing the susceptibility of mitochondrial 
outer membranes to cholesterol (Jefcoate et al., 1992), we investigated the expression of 
the ACTH receptor in HR, IR and LR mice and its function. Interestingly, we did not 
observe differences in MC2R mRNA expression levels in HR, IR and LR mice, 
indicating that the distinct differences in CORT secretion were not brought about by the 
abundance of the ACTH receptor. 
Assessment of the adrenal sensitivity in HR, IR and LR mice 
In the second experiment addressing peripheral mechanisms of HPA axis function, we 
showed that after pharmacological hypophysectomy by a high dose of Dex, which 
resulted in a prominently reduced baseline CORT secretion, HR, IR and LR animals 
revealed distinct differences in their adrenal CORT secretion in response to exogenously 
administered doses of ACTH (see Figure 17). HR mice showed a pronounced CORT 
secretion, whereas LR animals did virtually not respond to the same dose of ACTH, 
indicating differences in adrenal sensitivity towards ACTH between the three lines. 
Moreover, it is likely that these differences were brought about by changes in adrenal 
MC2R sensitivity towards its ligand ACTH, since the expression of the MC2R was not 
different between the three lines (see Figure 15 C). 
Studies by Ulrich-Lai and colleagues showed that chronic variable stress (CVS) in rats 
induced adrenal enlargement with hyperplasia in the outer zona fasciculata as well as 
hypertrophy in the inner zona fasciculata and medulla (Ulrich-Lai et al., 2006). 
Furthermore, adrenal enlargement has been observed after several types of stressors in 
rats (Gamallo et al., 1986; Ulrich-Lai et al., 2002) and mice (Reber et al., 2007; Uschold-
Schmidt et al., 2012) as well as after physical exercise (Moraska et al., 2000; Droste et 
al., 2003). This is in line with our findings since HR mice present a significantly higher 
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adrenal weight compared to LR animals (see Figure 18) according to their differences in 
HPA axis reactivity. Interestingly, CVS induced an enhanced plasma corticosterone 
response to exogenous ACTH in dexamethasone-blocked rats, specifically by augmenting 
the adrenal maximal response without affecting sensitivity to ACTH. It is argued, that in 
vivo tests of adrenal responses commonly used one to two doses of ACTH, thereby 
precluding definitive differentiation between maximal adrenocortical responses vs. 
sensitivity to submaximal doses of ACTH (Ulrich-Lai et al., 2006). However, since in our 
mouse model, the capacity of the adrenal, i.e. adrenal CORT secretion in response to a 
very high dose of ACTH (1 µg/g BW) was not significantly different between the three 
lines (Touma et al., 2008), we demonstrated that LR animals, irrespective of their 
decreased adrenal size, are able to adequately respond to ACTH stimulation, resulting in 
plasma CORT concentrations similar to HR and IR animals. This further supports the 
current finding that differences in adrenal sensitivity towards ACTH, at least partly, 
account for the distinct differences in stress reactivity between the three lines, although 
future studies should address whether the differences in adrenal size between HR, IR and 
LR animals are related to morphological changes, i.e. adrenal hypertrophy or hyperplasia 
in HRs and atrophy in LRs, respectively, in the different zones of the adrenal cortex and 
medulla. 
The expression and release of corticosteroid-binding globulin in HR, IR and LR 
mice 
Once released into the blood stream, CORT binds mainly to two types of carrier proteins, 
CBG and albumin (Slaunwhite et al., 1959; Burton et al., 1972) which are exclusively 
synthesised and stored in the liver (Rothschild et al., 1972b, a; Weiser et al., 1979). 
However, evidence for an intracellular location of CBG in the CNS and the pituitary is 
emerging (de Kloet et al., 1984; Möpert et al., 2006), thus exceeding its role as a mere 
steroid transporter (Henley et al., 2011). In the blood, approximately 80-90% of the 
secreted CORT is bound to CBG and 10-15% to albumin, while the remaining 5% is thus 
unbound and biologically active (Lewis et al., 2005; Henley et al., 2011), according to the 
free hormone hypothesis by Mendel (Mendel, 1989). Furthermore, a stress-induced, time-
dependent release of CBG from the liver has recently been shown in rats (Qian et al., 
2011), while following certain types of stressors or chronic stress, CBG expression was 
downregulated, increasing free glucocorticoid levels (Neufeld et al., 1994; Fleshner et al., 
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1995; Spencer et al., 1996), attributing CBG a highly dynamic role in the physiological 
stress response. 
In HR, IR and LR mice, we could show significant differences in plasma CBG levels 
already under unstressed conditions, with HR mice showing increased amounts of CBG, 
while LR animals presented the lowest plasma CBG protein abundance (see Figure 21). 
Furthermore, there were no major differences in plasma CORT concentrations between 
the three lines, which were equally low in the naïve control animals as well as 
immediately before the stressor (t=0, see Figure 19) in animals of all three lines. This is in 
accordance with studies by Richard and colleagues who revealed that partial or total 
deficiency of plasma CBG in hetero- and homozygous CBG KO mice, respectively, did 
not affect HPA axis function in resting conditions compared to wild-type controls 
(Richard et al., 2010). Thus, the significant differences in plasma CBG between HR, IR 
and LR animals might not necessarily affect plasma CORT concentrations under resting 
conditions. The question remains, why the low amounts of CORT which are secreted 
from the adrenals under non-stressed conditions are not fully bound to CBG despite its 
high affinity. This is of interest, since it was shown that total and also free (i.e. not CBG 
bound) CORT follows a distinct circadian as well as an ultradian cycle, interacting with 
MRs and GRs to regulate the basic HPA axis tone (Lightman et al., 2008), indicating that 
even under non-stressed conditions, free CORT is available to steroid receptors. Evidence 
comes from studies by Gayrard and colleagues who reported, that in resting conditions 
68% of circulating CBG is not occupied by CORT in many species (Gayrard et al., 1996), 
thus providing a pool of biologically active free CORT to exert its physiological functions 
at target tissues even under resting conditions. 
In response to 15 min of restraint stress, we observed significant differences between the 
three lines regarding their stress-induced total plasma CORT levels (HR>IR>LR, see 
Figure 19) which was similarly reflected by the increase in free plasma CORT 
concentrations (HR>IR>LR; Moisan et al., in preparation). However, plasma CBG levels 
remained unaffected by restraint stress, showing no further increase 30 min after the onset 
of the stressor (see Figure 21). These results are indicative of the following physiological 
properties of CBG. First, at least in animals of the SR mouse model, plasma CBG 
concentrations are unaffected by stress, albeit significant differences in plasma CBG 
abundance between the three lines exist. This is supported by our data providing no 
evidence for a depletion of liver-stored CBG 30 min after the onset of the 15 min restraint 
stressor (see Figure 20). Furthermore, we did not observe differences between HR, IR and 
Discussion 
95 
 
LR animals in liver-stored CBG, although CBG mRNA levels in the liver were 
significantly different between the three lines, with LR mice having the lowest expression 
(Moisan et al., in preparation). Given that CBG mRNA is consistently translated into 
CBG protein at the hepatocytic proteome and only a minor moiety is stored in the liver, 
we suggest that CBG directly tranlocates through liver sinusoidal endothelial cell 
fenestrae into the capillary lumen (Braet et al., 2002), resulting in the observed 
differences in plasma CBG between the three lines. Second, CBG is quickly saturated in 
animals of all three lines by CORT secreted from the adrenals in response to stress. 
Hence, the stress-induced surge of CORT overshoots the binding capacity of CBG in HR, 
IR and LR animals resulting in significantly increased but different free plasma CORT 
concentrations (HR>IR>LR, data not shown), thus paralleling the line-specific 
differences in total plasma CORT concentrations after stress. Accordingly, these 
differences in free CORT concentrations were also present in CORT target tissues such as 
the hippocampus (Heinzmann et al., 2010), as measured by microdialysis, although the 
rise of free CORT in the CNS was delayed by about 30 min. This is in line with other 
studies showing a delayed increase in free CORT levels in the brain and other GC target 
tissues in rats (Droste et al., 2008; Droste et al., 2009; Qian et al., 2011) and mice 
(Thoeringer et al., 2007a; Tronche et al., 2010). Qian and colleagues showed that this 
delay was associated with a concomitant increase in plasma CBG in response to stress. 
Thus, the authors concluded that the increase in circulating CBG levels after stress 
restrains the rise in free CORT concentrations for approximately 20 min in the face of 
mounting total hormone levels in the circulation, suggesting a highly dynamic role of 
CBG in CORT binding and transport (Qian et al., 2011). However, in our experiment, 
applying a similar experimental setup as the study by Qian and colleagues, we already 
observed elevated free plasma CORT concentrations after the end of the 15-min restraint 
stress without changes in plasma CBG concentrations. Therefore, it remains to be 
clarified whether the regulatory interactions of CBG and CORT are different in mice and 
rats or whether the timing of these physiological processes follows different patterns in 
these two rodent species. In addition, the binding of CORT to CBG could be stressor-
dependent since in our experiment, the mice were subjected to a more psychological, 15-
min restraint stressor, whereas the rats in the study by Qian and colleagues experienced a 
clearly stronger physical and psychological stressor, being exposed to 15 min of forced 
swimming. However, preliminary data from our group indicate, that the stress-induced 
differences in free plasma CORT levels between HR, IR and LR animals persist 
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(HR>IR>LR) even after a 6-min forced swim period (Moisan et al., in preparation). 
Furthermore, it needs to be clarified in additional studies whether the same physiological 
mechanisms in mice and rats underlie the delayed transition of plasma CORT into GC 
target tissues such as the brain. 
It should be noted that the neuroendocrine and behavioural endophenotypes of HR, IR 
and LR animals of the SR mouse model significantly parallel those of hetero- and 
homozygous CBG knockout mice. In studies by Richard et al. it was shown that mice, 
which were fully or partly deficient of CBG, presented a reduced secretion of CORT from 
the adrenals in response to restraint stress (Richard et al., 2010). Additionally, these mice 
displayed an increased passive stress-coping strategy in the FST. This parallels the 
conditions observed in LR mice, which show a decreased stress response as well as 
higher immobility in the FST compared to HR and IR animals, concomitant with 
decreased plasma CBG concentrations. This suggests that the distinct differences in 
plasma CBG levels between HR, IR and LR animals could play a pivotal role in the 
neuroendocrine and behavioural endophenotypes of these mice, although CBG release 
from the liver is not affected by stress. Furthermore, it was reported that CBG-deficient 
mice showed a very fast (within 5 min) and 4-fold higher CORT clearance compared to 
wild-type controls, which was paralleled by the upregulation of several drug-metabolising 
enzymes in the liver (Petersen et al., 2006). Thus, it can be speculated whether the 
reduced stress-induced CORT concentrations in LR mice were partly brought about by an 
increased CORT clearance in the liver of these animals, beside the observed reduction in 
adrenal sensitivity (see discussion above). Future studies should address this possibility, 
e.g. by determining the amount and the time course of excreted radiolabelled CORT 
metabolites in the urine and in the feces of HR, IR and LR mice, which previously have 
been injected with 3H-CORT (cf. Touma et al., 2003). Moreover, functional alterations in 
liver enzymes due to alterations in GC signalling are frequently associated with obesity 
(Livingstone et al., 2000; Seckl et al., 2004; Bornstein et al., 2006). This is of interest, 
since LR animals present an increased body-weight associated with larger fat storages 
compared to HR and IR animals in the absence of increased food intake (Touma et al., 
2008). 
Moreover, it is of note that CBG acts as a protein thermocouple (Burton et al., 1972). 
Studies by Cameron and colleagues showed that the affinity of glucocorticoids for CBG 
drops approximately 16-fold as the temperature increases from 35 °C to 42 °C, while the 
binding of GCs to albumin remained unaffected by temperature changes (Cameron et al., 
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2010). According to this study, a rise in body temperature from 36.5 °C to 38 °C, as seen 
in HR, IR and LR animals subjected to the stress-induced hyperthermia test (Touma et 
al., 2008), would increase the dissociation constant of CBG towards GCs from 25 nM to 
40 nM (Cameron et al., 2010). This accounts for an almost 50 % reduction in binding 
affinity of CBG at a temperature increase of 1.5 °C. Since a 15-min restraint period would 
induce similar changes in body temperature in animals of the SR mouse model, this 
would result in a decreased binding affinity of CBG towards CORT. 
Therefore, it can be speculated, by which mechanism the temperature-sensitive decrease 
in CBG binding affinity towards CORT is counterbalanced. Although CORT-binding to 
albumin in temperature-insensitive (Cameron et al., 2010), it is unlikely that this second 
major CORT binding protein ‘adopts’ the function of CBG. Preliminary data from our 
group show that albumin is not differentially expressed in the liver and in the plasma of 
HR, IR and LR animals. Moreover, the release of this protein is apparently not modulated 
by stress (data not shown). 
Taken together, we conclude that CBG is important for the transport of GCs, such as 
CORT and it largely contributes to the bioavailability of free CORT at target tissues. We 
further suggest that, according to the presented results that the significant differences in 
plasma CBG concentrations might contribute to the neuroendocrine and behavioural 
phenotypes of HR, IR and LR animals. However, our data could not confirm the highly 
dynamic role of CBG proposed by other studies (Qian et al., 2011). Further studies are 
necessary to provide a more comprehensive picture on the role of corticosteroid-binding 
globulin in HR, IR and LR mice, particularly considering the intracellular localisation of 
CBG in the CNS and in the pituitary (de Kloet et al., 1984; Möpert et al., 2006). 
Adrenocorticotropic hormone synthesis and secretion 
In the pituitary of HR, IR and LR animals, significant differences in ACTH abundance 
were observed between the three lines (see Figure 23), with HR mice showing a 
significantly higher amount of ACTH compared to animals of the IR and LR line. This is 
in accordance with an increased POMC mRNA expression in the pituitary of the animals 
(see Table 6), indicating alterations in HPA axis regulatory mechanisms at levels 
preceding the adrenocortical (dys)function of HR and LR animals. Interestingly, we did 
not observe a decrease in pituitary ACTH abundance 30 min after the onset of a 15 min of 
restraint stressor (see Figure 23). This indicates that (i) in response to this moderate 
psychological stressor, only a minor part of the available pool was secreted from the 
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pituitary into the blood stream to trigger the release of CORT from the adrenal cortex 
and/or (ii) the chosen method for detecting pituitary ACTH, i.e. Western blot, was too 
insensitive to uncover differences between stressed animals and their unstressed 
littermates. However, there was a significant increase in plasma ACTH levels in response 
to stress in all three lines. Unexpectedly, the stress-induced rise in plasma ACTH levels 
did not parallel the increase in plasma CORT concentrations (see Figure 22 and Figure 
19). In response to the 15-min of restraint stress, plasma CORT levels significantly 
increased in animals of all three lines (HR>IR>LR) with a further increase 30 min after 
the onset of the stressor. Only in IR animals, plasma ACTH was significantly increased 
after 15 min of restraint stress with a further significant rise 30 min after the onset of the 
stressor (as expected), whereas there were no differences in HR and LR animals at t=15 
compared to the unstressed control group. Moreover, a significant increase in stress-
induced plasma ACTH concentrations in HR and LR animals was not reached until 30 
min after the onset of the stressor. Interestingly, the significant surge in plasma ACTH 
concentrations at t=30 was not different between the three lines, albeit the observed line-
specific differences in plasma CORT concentrations (see Figure 19). However, 
dissociations between plasma ACTH and CORT levels have been frequently reported 
(Bornstein et al., 2008) and the existence of a temporal lag between stimulus-induced 
changes in ACTH and CORT levels are well documented (Engeland et al., 1977). Both, 
ACTH and CORT are secreted in a pulsatile or episodic fashion under basal (Lightman et 
al., 2008) and stress conditions (Windle et al., 1998), which might well occur in non-
overlapping pulses (Bornstein et al., 2008). Moreover, as discussed previously, neuronal 
efferents, descending from the hypothalamic PVN (Harris, 1950; Yoshimatsu et al., 1987) 
innervate the adrenal cortex as well as the adrenal medulla through splanchnic nerve 
fibres (Bornstein et al., 1999; Engeland et al., 2005), which, in turn, stimulate CORT 
release from the adrenals (Engeland, 1998; Bornstein et al., 2008). Thus, it can be 
speculated that starting from the PVN of the hypothalamus, two independent but 
synergistically acting mechanisms, the SAM system and the endocrine pituitary-adrenal 
signalling cascade, are involved in bringing about the significant, line-specific differences 
in stress-induced adrenal CORT secretion between HR, IR and LR animals. This 
hypothesis is supported by data presented in this study. First, after 15 min of restraint 
stress there was a significant increase in plasma CORT concentrations of HR and LR 
animals in absence of rising plasma ACTH levels. However, we could show, that in 
response to 15 min restraint stress, C-fos mRNA expression, a CORT-independent marker 
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for neuronal activation (Melia et al., 1994; Helmreich et al., 1996; Weiser et al., 2011), 
was markedly enhanced in the PVN of HR, IR and LR animals (see Figure 32). 
Strikingly, HR mice showed a significantly increased C-fos activity compared to IR 
animals, while animals of the LR line presented the lowest neuronal activation. Given that 
excitatory nerve fibers descending from the PVN directly stimulate the adrenals 
(Katafuchi et al., 1988; Coote et al., 1998), an ACTH-independent stimulation of the 
adrenal cortex through these nerve fibres must be considered, which would act faster than 
the endocrine signalling pathway mediated by ACTH. Thus, rising plasma CORT 
concentrations in response to stress in absence of increasing plasma ACTH levels are 
plausible. Second, 30 min after the onset of the stressor, plasma ACTH levels were 
significantly increased between HR, IR and LR animals without showing differences 
between the three lines. However, at this time point of sampling, plasma CORT levels 
showed the distinct line-specific differences in HR, IR and LR mice. Interestingly, this 
very well reflects the animals’ response in the adrenal sensitivity test to a standardised 
dose of exogenous ACTH (see discussion above). In this test, HR animals presented a 
significantly increased CORT secretion 30 min after the administration of ACTH 
compared to LR animals which virtually did not respond to the same dose (cf. Figure 17). 
Thus, HR, IR and LR animals show significant differences in their ACTH-induced CORT 
release, irrespective of an exogenously or endogenously transmitted ACTH stimulation. 
Taken together, our data indicates that in addition to alterations in functional mechanism 
on the adrenal level, preceding levels of HPA axis function such as the pituitary and/or 
the PVN are involved in bringing about the neuroendocrine phenotype of the HR and LR 
mouse line. We could show an upregulation of POMC mRNA and ACTH protein in 
pituitary corticotrophs of HR mice, presumably due an increased activation of the PVN. 
In contrast, LR animals presented a decreased POMC mRNA expression compared to IRs 
while the ACTH protein content was similar in both lines. Furthermore, we observed that 
the available pool of pituitary ACTH was not decreased after restraint stress in all three 
lines. However, ACTH was released from the pituitary in a time-dependent manner, not 
strictly paralleling stress-induced plasma CORT levels. Taking into account the 
significant differences in adrenal sensitivity between the three lines, we suggest that the 
endocrine pituitary-adrenal signalling cascade as well as the SAM system is considerably 
involved in bringing about the distinct differences in stress reactivity between HR, IR and 
LR animals. 
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4.2 Central regulation of the hypothalamic-pituitary-adrenal axis 
In our final experiments, we aimed to investigate whether in addition to the differences 
between HR, IR and LR animals in the peripheral functions of the HPA axis (as discussed 
above), molecular correlates in the CNS of these mice could be found, which would 
support the assumption of a central origin of these line-specific differences in stress 
reactivity. Moreover, we addressed the question, whether pharmacological treatment with 
fluoxetine (Flx), one of the most frequently applied antidepressants, would impact the 
behavioural and neuroendocrine phenotype of HR, IR and LR animals. 
The impact of fluoxetine on stress-coping behaviour 
Our results show that Veh-treated as well as Flx-treated animals presented the robust, 
line-specific differences regarding their coping-strategies in the FST, which were already 
observed in earlier generations of the SR mouse model (Touma et al., 2008; Knapman et 
al., 2010a). Interestingly, after Flx treatment, animals of the SR mouse model showed an 
increase in passive stress-coping behaviour. In particular, an increased floating behaviour 
and, accordingly, less time spent struggling could be observed in HR and IR mice (see 
Figure 24). 
As discussed previously, it has been shown that mice overexpressing CRH in the central 
nervous system displayed a more active stress-coping behaviour in the FST (Lu et al., 
2008; Dedic et al., 2011), similar to the behavioural phenotype observed in HR mice. 
This increase in activity/hyperarousal was associated with a CRH-induced increase in 
activation of monoaminergic neurotransmission in brain structures such as the locus 
coeruleus. Interestingly, in this study, inhibition of NE synthesis by the tyrosine 
hydroxylase inhibitor α-methyl-para-tyrosine methyl ester (AMPT) resulted in a 
significant increase in floating behaviour of the animals in the FST, supporting the pivotal 
role of NE in active stress-coping strategies (Lu et al., 2008). 
Since the LC is innervated by serotonergic (5-HT) afferents of the dorsal raphe nucleus 
(Pickel et al., 1977; Morgane et al., 1979; Kim et al., 2004) and these 5-HT neurons have 
been shown to attenuate the activation of NE-neurons in the LC (Segal, 1979; Aston-
Jones et al., 1991), an increase in 5-HT in the dorsal raphe nucleus, induced by the Flx-
mediated inhibition of 5-HT reuptake into the pre-synapse, might suppress the activity of 
the LC-NE system in animals of the SR mouse model. Thus, the increase in passive 
stress-coping behaviour after Flx treatment in HR, IR and LR animals could be brought 
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about by augmenting levels of 5-HT in the dorsal raphe nucleus resulting in a suppression 
of the LC and hence, NE activity. So far, it can only be speculated about the molecular 
origin of the different stress-coping strategies observed between HR, IR and LR animals. 
Future studies also need to address the question to what extent the sympathetic nervous 
system is involved in bringing about the behavioural phenotype of the animals. Our 
results revealed no significant differences in adrenal PNMT and TH mRNA expression 
between the SR lines. However, future studies should investigate basal and stress-induced 
plasma NE levels. Moreover, brain areas known to be critically involved in 
catecholaminergic and serotonergic neurotransmission such as the raphe nucleus or the 
locus coeruleus need to be studied. Subsequently, the functional implications of 
adrenergic receptor antagonists should be tested, since stress is associated with alterations 
in catecholamine synthesis as well as changes in the noradrenergic receptor system, such 
as reduced β-adrenoceptor or increased α1- and α2-adrenoceptor expression (Brunello et 
al., 2002). 
Impact of fluoxetine on hypothalamic-pituitary-adrenal axis reactivity 
We were interested whether Flx impacts the key endophenotype of HR, IR and LR 
animals, i.e. the distinctly different CORT secretion in response to stressors, since it has 
been reported that antidepressants such as Flx can modify the negative feedback 
mechanisms of the HPA axis (Holsboer, 2000; Pariante et al., 2004). To this end, two 
different experimental approaches were conducted. First, after four weeks chronic Flx 
treatment, we subjected the animals to an acute stressor (10-min OF + 6-min FST) in 
order to evaluate the impact of Flx on rapid, non-genomic effects of corticosteroids on 
HPA axis activation (de Kloet et al., 2008; Evanson et al., 2010; Tasker et al., 2011). 
Second, we aimed to investigate the effects of chronic Flx treatment on delayed, 
genetically-driven negative feedback mechanisms by means of the Dex/CRH test. 
In response to the FST, HR, IR and LR animals showed the expected line-specific 
differences in stress-induced plasma CORT secretion (HR>IR>LR, see Figure 26). 
However, Flx had no significant effect on stress-induced plasma CORT levels in any of 
the three lines. Thus, our data indicates that Flx did not modulate the fast feedback 
mechanisms of the HPA axis in HR, IR and LR mice (see Figure 26). Consistently, 
chronic Flx treatment did also not affect plasma CORT concentrations in response to a 
15-min restraint stressor (see Figure 30). In recent years, evidence has emerged that fast 
feedback mechanisms, involving corticosteroid binding to the MR as well as the 
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activation of the endocannabinoid system in the PVN, are implicated in a rapid 
downregulation of HPA axis activity in response to stressors (Atkinson et al., 2008; Joels 
et al., 2008; Groeneweg et al., 2012). It has been shown that fast feedback mechanisms 
are sensitive to blocking or knocking out the MR, suggesting a role for this receptor in the 
rapid GC signalling. Moreover, this fast feedback was mediated by membrane receptors 
which involved the activation of G-protein coupled receptors (GPCR) and intracellular 
signalling cascades downstream from GPCRs, e.g. by modulating membrane potentials 
through inhibiting high-voltage gated Ca2+ channels (Tasker et al., 2006). The 
endocannabinoid system has likewise been implicated in the regulation of the HPA axis 
(Tasker et al., 2011). For instance, endocannabinoid receptor 1 (CB1) knockout mice 
showed an enhanced response to stress, indicating an endocannabinoid-mediated 
inhibitory tone on HPA axis activity (Aso et al., 2008; Steiner et al., 2008a;b). In 
addition, it has been shown that acute restraint stress induced a rapid (within 10 min) rise 
in 2-arachidonoylglycerol (2-AG) levels in the PVN, resulting in an immediate 
downregulation of HPA axis activity. This suggests a fast, non-genomic glucocorticoid 
suppression by the endocannabinoid system (Evanson et al., 2010). Until now, it can only 
be speculated, to what extent these fast feedback mechanisms might contribute to the 
neuroendocrine phenotype of the animals of the SR mouse model. Future studies should 
address this question, for instance by applying selective MR or CB1 receptor antagonists. 
So far, our data demonstrate that these fast feedback mechanisms are obviously not 
modulated by chronic Flx treatment in HR, IR and LR mice. 
Impact of fluoxetine on hypothalamic-pituitary-adrenal axis regulation in the 
combined dexamethasone/corticotropin-releasing hormone test 
In contrast to the fast feedback mechanisms, Flx treatment significantly affected the 
delayed, genetically-driven negative feedback mechanism of the HPA axis. Furthermore, 
HR, IR and LR animals showed a differential response in the Dex/CRH test already under 
untreated conditions. This is of interest since it has been shown that the re-establishment 
of a balanced HPA system is an important prerequisite for the recovery from affective 
disorders such as MD (Zobel et al., 2001). The outcome of the Dex/CRH test was also 
used to evaluate the effectiveness of antidepressant therapy in clinical settings (Holsboer-
Trachsler et al., 1991; Heuser et al., 1994; Ising et al., 2005).  
Veh-treated animals of all three lines showed significant differences in the suppression of 
their plasma CORT concentrations after Dex treatment. In particular, HR mice presented 
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a reduced CORT-suppression, while the plasma CORT levels of IR and LR mice were 
readily suppressed (see Figure 27). After the stimulation of the HPA axis with CRH, in 
turn, HR, IR and LR mice showed the line-specific, significant rise in plasma CORT 
levels (HR>IR>LR). This is consistent with clinical findings. It has been shown that 
patients suffering from MD frequently show an insufficient suppression of CORT after 
Dex treatment (Dex non-suppressors), whereas they present an overshooting CORT 
response after CRH stimulation (Bardeleben et al., 1989; Heuser et al., 1994; Ising et al., 
2005). This neuroendocrine response pattern is reflected by the hyper-reactive HPA axis 
phenotype of HR animals. In contrast, a hypo-reactive HPA axis has been associated with 
a blunted response in the Dex/CRH test (Rydmark et al., 2006), similar to the situiation 
seen in LR animals. This finding underlines the clinical relevance of the three mouse lines 
of the SR mouse model to gain more insight into the mechanisms responsible for HPA 
axis dysfunction. Moreover, the model could serve as a valuable tool to investigate the 
effect of antidepressant drugs on HPA axis function. Indeed, our experiment 
demonstrated that Flx treatment affected HPA axis function in HR, IR and LR mice. 
Strikingly, the CORT non-suppression observed in HR animals was restored after Flx 
treatment, which was reflected by markedly decreased plasma CORT levels after Dex 
administration in these mice. Similarly, Dex administration after chronic Flx treatment 
induced a decrease in plasma CORT concentrations in IR animals (see Figure 27). 
However, comparing the low median levels of the Veh- and Flx-treated group, the 
CORT-suppressive effect of Dex was less prominent though statistically significant in 
this line. An impact of Flx treatment on plasma CORT levels of LR mice could not be 
observed, presumably due to floor effects. 
The CRH stimulation induced an increase in plasma CORT concentrations in all three 
lines. Flx treatment did not affect the CRH-mediated CORT increase in HR mice. 
However, in animals of the IR line, Flx-treated animals showed a reduced CORT surge 
after CRH stimulation mirrored by the lower median levels in this group (see Figure 27). 
Finally, Flx-treated LR mice presented a significantly blunted CORT response after CRH 
compared to their Veh-treated littermates. 
Taken together, the data demonstrate that (i) Flx restored Dex-mediated CORT 
suppression in HR animals, (ii) after Flx treatment, Dex clearly suppressed CORT in all 
three lines and (iii) this Dex-induced suppression was weakest in HR mice since it could 
be overridden by CRH stimulation resulting in similar plasma CORT levels after CRH 
challenge, while in Flx-treated LR animals, CRH stimulation resulted in a blunted CORT 
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response. Thus, we conclude that chronic Flx treatment had a significant impact on the 
delayed negative feedback mechanism in animals of the SR mouse model.  
Gene expression in the hippocampus and pituitary of HR, IR and LR mice 
The synthetic GC Dex is a selective GR agonist (Rousseau et al., 1972; de Kloet et al., 
1999). Hence, it is likely that the Dex-mediated feedback suppression of the HPA axis in 
HR, IR and LR mice was brought about by activation of the GR, which was even more 
enhanced after chronic Flx treatment. Surprisingly, we could not detect differences in 
corticosteroid receptor mRNA levels in the pituitary (GR) as well as in the hippocampus 
(GR and MR) between the three lines, both under control conditions or after chronic Flx 
treatment (see Table 5 and Table 6). Moreover, GR and FKBP51 protein levels in the 
hippocampus did not differ between the three lines and were not affected by chronic Flx 
treatment (see Figure 28). This indicates that neither the differences in the Dex-mediated 
feedback suppression of the HPA axis between HR, IR and LR mice, nor its enhancement 
after Flx treatment were associated with an increase in receptor abundance in the pituitary 
or in the hippocampus. However, other mechanisms in addition to receptor expression 
have been reported to be involved in the activation of GR signalling. 
The access of GCs into the brain is tightly regulated by the multidrug resistance 1 P-
glycoprotein (MDR1 Pgp) (Schinkel, 1997; Schinkel et al., 2003). In contrast to humans, 
two isoforms of this efflux pump (Mdr1a Pgp and Mdr1b Pgp) are expressed in rodents, 
which are encoded by two different genes (Abcb1a and Abcb1b). The Mdr1a isoform is 
mainly located in the endothelial cells of microvessels forming the blood-brain barrier 
(BBB) (Regina et al., 1998), whereas the Mdr1b isoform is particularly expressed in glia 
cells and neurons (Volk et al., 2004; Löscher et al., 2005) probably regulating the access 
of GCs on a cellular level. Both isoforms function as drug efflux pumps and protect the 
brain from xenobiotics (Schinkel, 1997) but are also involved in the extrusion of synthetic 
steroids such as Dex (Meijer et al., 1998) as well as endogenous steroids such as CORT 
(Wolf et al., 1992; Uhr et al., 2002), implicating an involvement of Mdr1 Pgp on HPA 
axis function and regulation. 
In a study by Uhr and colleagues, it has been shown that the endogenous steroid CORT is 
transported by the Mdr1 Pgp since Abcb1ab double-knockout resulted in an increased 
accumulation of CORT in the brain of these animals (Uhr et al., 2002). Moreover, 
Thoeringer and colleagues reported that Mdr1 Pgp inhibition by tariquidar in mice 
resulted in decreased stress-induced plasma CORT levels, which was attributed to an 
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enhanced negative feedback suppression of HPA axis activity in these animals 
(Thoeringer et al., 2007b). In another study, Abcb1ab Pgp knockout mice presented 
decreased stress-induced plasma CORT levels compared with their wildtype littermates, 
while plasma CORT concentrations in these mice did not differ under basal conditions 
(Müller et al., 2003). Moreover, in this study the Abcb1ab knockout mice showed 
increased Dex-mediated CORT suppression compared to wildtype animals, indicating a 
prominent role of Mdr1 Pgp in HPA axis activity and negative feedback regulation. 
Interestingly, clear differences in the expression levels of Abcb1b were detected in 
animals of the SR mouse model with HR mice showing a significantly increased Abcb1b 
expression in the hippocampus, whereas LR animals presented markedly reduced Abcb1b 
mRNA levels (see Table 5). Thus, the findings of the above mentioned studies are 
consistent with the neuroendocrine phenotype of animals of the SR mouse model. HR 
animals with an increased expression of Abcb1b in the hippocampus showed a reduced 
negative feedback and, in turn an increased stress-induced CORT secretion. This might be 
due to an increased extrusion of GCs from brain cells by Mdr1b Pgp resulting in a 
restricted access of GCs to the cytosolic GR. In contrast, LR animals with a low 
expression of Mdr1b Pgp presented an enhanced negative feedback suppression due to an 
increased GC receptor binding, resulting in a reduced CORT surge in response to stress. 
Taken together, a contribution of Mdr1b Pgp to the neuroendocrine phenotype of HR, IR 
and LR mice as well as the outcome of the Dex/CRH test must be considered. However, 
the question remains by which molecular mechanism chronic Flx treatment enhanced the 
negative feedback suppression of plasma CORT levels in the animals of all three lines in 
the Dex/CRH test. A potential mechanism is provided by studies from Peer and 
colleagues who showed that Flx significantly increased the accumulation of anticancer 
drugs within multidrug resistant cells by inhibiting the drug efflux transporters in those 
cells (Peer et al., 2004). This is consistent with studies reporting that in addition to 
anticancer drugs, Flx induced a substantial increase in intracellular GC levels as well as 
GC-induced GR activation due to inhibition of membrane steroid transporters (Pariante et 
al., 2003). It has been proposed that antidepressants could inhibit the steroid transporters 
localised on the BBB and in neurons, and thus increase the access of GCs to the brain and 
the GC-mediated negative feedback on the HPA axis (Pariante et al., 2003). Hence, Flx 
might have facilitated the access of GCs such as Dex into cells of the PVN, the 
hippocampus and/or the pituitary of HR, IR and LR mice, thereby increasing GR-
mediated feedback mechanisms which, eventually, enhanced the Dex-mediated 
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suppressive effect on plasma CORT concentrations. Future studies should investigate the 
enhanced activation of the GR after Flx treatment in more detail, including mechanisms 
involved in the translocation of the ligand-activated GR from the cytosol into the nucleus 
(Spencer et al., 2000). This is of interest since our data demonstrate that in the 
hippocampus of LR animals, which showed the lowest Abcb1b gene expression, Flx 
induced the most prominent Dex-mediated CORT suppression which paralleled an 
increased expression of GR target genes known to have a glucocorticoid response element 
(GRE) in their promoter region, e.g. Abcb1a, Fkbp5 and Gilz (Wang et al., 2004; Narang 
et al., 2008) (see Table 5). 
Moreover, it has been shown that an increased GR activation after treatment with the 
SSRI sertraline induced neurogenesis in a human hippocampal progenitor cell line 
(Anacker et al., 2011). In addition, chronic Flx treatment stimulated maturation and 
synaptic plasticity of adult-born hippocampal granule cells (Duman et al., 2001; Wang et 
al., 2008), which was associated with an enhanced hippocampus-dependent negative 
feedback regulation of the HPA axis in mice (Surget et al., 2011). This suggests that a 
restored negative feedback regulation of the HPA axis might not only be mediated by 
enhanced GR signalling per se but also by a GR-mediated induction of neurogenesis in 
the hippocampus after chronic antidepressant treatment, resulting in a functional HPA 
axis regulation through a reinstated neuronal network.  
In this respect, studies by Knapman et al. revealed decreased expression of brain-derived 
neurotrophic factor (BDNF) with concomitantly decreased hippocampal N-
acetylaspartate (NAA) levels, a marker for neuronal integrity, in the hippocampus of HR 
animals (Knapman et al., 2010a; Knapman et al., 2012). Accordingly, it has also been 
shown that high levels of GCs prevent cell proliferation in the hippocampus of rats 
(Gould et al., 1992) and monkeys (Gould et al., 1998). Interestingly, Castren and 
colleagues reported that antidepressant drugs elicit neurotrophic effects particularly in the 
hippocampus (Castren, 2004). Furthermore, this antidepressant-induced increase in cell 
proliferation has been associated with an increased expression of BDNF (Nibuya et al., 
1995; Sairanen et al., 2005), which was found to be essential for neurogenesis (Lee et al., 
2009). Thus, future studies should address the question whether the restored negative 
feedback inhibition of the HPA axis in HR animals was due to a Flx-dependent increase 
in hippocampal neurogenesis, potentially associated with augmented hippocampal BDNF 
levels in these mice. 
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Effects of fluoxetine on spatial memory 
Studies by Knapman and colleagues also revealed a reduced memory performance in HR 
animals, which was linked to the increased stress reactivity of these animals (Knapman et 
al., 2010a,b). Consistently, it has been reported that increased glucocorticoid levels 
impair memory retrieval (Conrad et al., 1996; de Quervain et al., 1998; Roozendaal, 
2000). In contrast, antidepressant treatment markedly ameliorated GC-induced cognitive 
deficits in mice (Flood et al., 1987; Song et al., 2006) and rats (Oitzl et al., 1998). Thus, 
we investigated whether chronic treatment with Flx modulated the spatial memory 
performance in animals of the SR mouse model. In particular, we were interested whether 
Flx would be able to restore the observed cognitive deficits of HR mice, since these mice 
have been shown to perform worse in hippocampus-dependent memory tasks such as the 
Y-maze test, compared to IR and LR animals (Knapman et al., 2010a; Knapman et al., 
2012). Indeed, we could observe a significantly enhanced discrimination ratio in Flx-
treated HR animals compared to their Veh-treated littermates (see Figure 29). Thus, the 
accuracy to visit and explore the novel arm in the retrieval phase was apparently 
increased in Flx-treated HR animals. This is consistent with other studies reporting an 
increased cognitive performance after Flx treatment (Flood et al., 1987; Grote et al., 
2005; Song et al., 2006; Li et al., 2009), potentially via a BDNF-mediated mechanism 
resulting in increased hippocampal neurogenesis (Nibuya et al., 1995; Sairanen et al., 
2005). However, these results have to be interpreted with care. In our experiment, IR and 
LR animals spent similar amounts of time in the novel as well as in the familiar arms 
during the retrieval phase (see Table 7). This was unexpected since in previous studies by 
Knapman and colleagues, the animals of these two mouse lines consistently spent more 
time exploring the novel arm compared to the familiar arms (Knapman et al., 2010a; 
Knapman et al., 2012). Thus, we cannot exclude that the behavioural readout in the Y-
maze test was obscured. We do not have a plausible explanation for the failure of animals 
of the IR and LR line to discriminate between the novel and familiar arms during the 
retrieval phase of the testing period. Maybe the animals’ performance in the Y-maze test 
was affected by the number of experimenters handling the animals during the test. In the 
studies by Knapman and colleagues, all mice were handled and tested by only one 
experimenter, whereas in our study three scientists performed the tests due to the high 
number of experimental animals. Moreover, Knapman and colleagues tested the animals 
under naïve conditions, whereas in this study, we chronically injected all experimental 
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animals over a time period of 28 days before subjecting them to the Y-maze task. Thus, 
the injection procedure per se might have interfered with the outcome of this test. This is 
supported by our results demonstrating a slight increase in neuronal C-fos expression in 
the brain of chronically injected mice compared to naïve control mice, although this 
increase was not statistically significant. 
Stress-induced neuronal activation in the brain 
In our final experiment we aimed to find neuronal correlates in the CNS of HR, IR and 
LR animals reflecting a central origin of the differences in the neuroendocrine phenotypes 
of these animals. Furthermore, we tested whether potential differences in neuronal 
activity would be altered by chronic Flx treatment. To this end, we used C-fos in-situ 
hybridisation to determine the neuronal activation in different brain regions known to be 
involved in the regulation of HPA axis activity. The immediate early gene C-fos has been 
used as an indicator for neuronal activation in response to various forms of stress such as 
restraint or swim stress (Cullinan et al., 1995). Moreover, it has been shown that C-fos 
mRNA expression in different brain regions is not affected by the amount of circulating 
glucocorticoids (Melia et al., 1994; Helmreich et al., 1996; Weiser et al., 2011). This was 
of importance for our studies since the differences in stress reactivity between HR, IR and 
LR mice would have been a major confounding factor in the analysis of the C-fos signal. 
To induce C-fos expression in the experimental animals, we subjected them to 15 min of 
restraint stress and finally sacrificed them 45 min after the cessation of the stressor to 
determine C-fos mRNA expression. We expected a strong C-fos signal at this time point 
(60 min after the onset of the stressor), since studies by Cullinan and colleagues had 
detected the highest C-fos signals within 30 min to 60 min after the end of a 30-min 
restraint period or a 6-min FST in rats (Cullinan et al., 1995). In addition, we determined 
plasma CORT concentrations immediately before, straight after and 45 min after the 15 
min restraint stress as a neuroendocrine readout to assess stress-induced HPA axis 
activation. 
Hypothalamus-pituitary-adrenal axis reactivity in response to restraint stress 
HR, IR and LR animals showed the expected line-specific differences regarding the 
increase of plasma CORT concentrations in response to the 15 min restraint stressor. 
Moreover, Flx treatment did not affect the stress-induced rise in plasma CORT levels (see 
Figure 30). Consistently, also no differences in plasma CORT concentrations were 
Discussion 
109 
 
observed in response to 6 min of forced swimming between Flx- and Veh-treated animals 
of all three lines (see Figure 26). Thus, independently of the stressor, the fast feedback 
mechanisms of the HPA axis were obviously not modulated by chronic Flx treatment. In 
contrast, Flx-treated LR mice showed a significant decrease in plasma CORT levels 45 
min after the cessation of the restraint period compared to their Veh-treated littermates. 
This suggests that to this time point, Flx treatment enhanced the delayed, or at least the 
intermediate, feedback mechanisms (Keller-Wood et al., 1984; Watts, 2005). These 
findings are in accordance with our data investigating the impact of chronic Flx treatment 
on the functional regulation of the HPA axis in the Dex/CRH test (see Figure 27). There, 
a similarly reduced CORT surge after CRH stimulation was observed in Flx treated 
animals, particularly in the LR line, which was attributed to an enhanced Dex-mediated 
suppression of HPA axis activity. Thus, we suggest a common underlying molecular basis 
since an endogenous, anticipatory stressor (e.g. FST) as well as an exogenously applied, 
pharmacological stressor (Dex treatment) induced similar effects on the delayed HPA 
axis negative feedback. This common mechanism is presumably constituted by an 
enhanced GC-mediated activation of the GR brought about by the chronic Flx treatment. 
Acute stress induces differences in PVN excitation in HR, IR and LR mice 
Regarding the C-fos mRNA expression in response to 15 min of restraint stress, a 
significant increase was observed in all investigated brain areas of HR, IR and LR mice 
(see Table 8). Thus, the stressor strongly induced neuronal activation in limbic forebrain 
structures such as the hippocampus, the prefrontal cortex (PFC) and the basolateral 
amygdala (BLA) which are involved in stress perception (Herman et al., 2003). 
Moreover, there was a significant difference regarding the neuronal activation in the PVN 
of the animals, with HR mice showing the strongest activation, while in LR animals the 
C-fos signal was less pronounced (see Figure 32). These differences, however, were not 
affected by Flx, since Flx-treated as well as Veh-treated animals presented a similar 
neuronal activation of the PVN (see Table 8 and Figure 32).  
In mammals, the stress response comprises the activation of the HPA axis which is driven 
by a neuronal signal originating from the PVN, eventually resulting in a release of stress 
hormones such as CORT from the adrenal cortex. Thus, our results demonstrate that the 
differences in stress reactivity between HR, IR and LR animals were not only a peripheral 
phenomenon brought about by a differential ACTH release from the pituitary or an 
altered adrenal sensitivity towards ACTH, but also have a neuronal correlate in the CNS 
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of the animals. However, the PVN is suggested to be an ‘executing’ brain area and the 
perception of stressors is mediated by other brain regions (Herman et al., 2005). PVN 
neurons are activated by neuronal inputs from a number of sources (see Figure 33). 
 
 
Figure 33: Simplified diagrammic representation of direct limbic stress-integrative pathways 
to the paraventricular nucleus of the hypothalamus (PVN) and the peri-PVN region from the 
prefrontal cortex (PFC), basolateral amygdala (BLA) and hippocampus (HC) as well as from 
brainstem regions such as the nucleus of the solitary tract (NTS). Indirect projections of these 
brain regions via transsynaptic intermediaries such as the bed nucleus of the stria terminalis 
(BNST) are also presented. Excitatory projections are indicated by (+) and filled lines ending 
in arrows, inhibitory projections are indicated by (-) and dotted lines ending in squares. ac, 
anterior cingulate cortex; pl, prelimbic cortex; il, infralimbic cortex; 3V, third ventricle. 
Figure modified from (Herman et al., 2005). 
 
Brain stem areas signalling systemic challenge (e.g. humoral homeostatic imbalance) 
such as the nucleus of the solitary tract (NTS) or the circumventricular organs provide 
direct excitation to the PVN, whereas anticipatory HPA axis responses are mediated by 
multisynaptic limbic forebrain circuits (Ulrich-Lai et al., 2009; Myers et al., 2012). This 
suggests that the activation of the PVN did not result from an intrinsic stress-induced 
stimulus but was rather evoked by superior brain structures known to project neuronal 
efferents to the PVN such as the hippocampus (Sapolsky et al., 1984; Herman et al., 
1989; Jacobson et al., 1991), the BLA (Jones et al., 2011; Myers et al., 2012) and the 
PFC (Spencer et al., 2005; Radley et al., 2006). Hence, we determined the neuronal 
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activation in these brain areas in order to investigate their implications in the excitation of 
the PVN. 
The applied 15-min restraint stressor, however, did not induce a significantly different 
neuronal activation between the three lines in most of the investigated limbic brain 
regions or subregions (see Table 8). Only in the CA3 subregion of the dorsal 
hippocampus (dHC) and in the dentate gyrus of the ventral hippocampus (vHC) of Veh-
treated animals, a significant difference could be observed between the three lines. HR 
animals presented a lower stress-induced activation of these two hippocampal subregions 
compared to LR mice. This is of interest since it has been shown in a number of studies 
that the hippocampus exerts inhibitory actions on the HPA axis (Jacobson et al., 1991; 
Herman et al., 1997). Hippocampal stimulation has been shown to decrease GC secretion 
in rats and humans suggesting that activation of this region is sufficient to inhibit HPA 
response (Rubin et al., 1966; Dunn et al., 1984). Thus, a stronger activation of the 
hippocampus (as seen in LR mice) would increase the inhibitory tone on PVN neurons 
which would, in turn, result in more dominant inhibition of CORT release. In contrast, a 
dampened inhibition of the PVN would cause an increased release of ACTH 
secretagogues (CRH and AVP) and eventually lead to an enhanced CORT secretion (as 
observed in HR mice). Furthermore, although not statistically significant, a comparison 
between the mean values of the C-fos expression in different subregions of the vHC and 
dHC of HR and LR mice revealed a tendency towards a more active hippocampus in LR 
animals, supporting the more prominent inhibitory role of this brain region on PVN 
activity in LR mice. It should be noted, that the dentate gyrus (DG) of both, the dHC and 
the vHC of HR, IR and LR mice, already showed a prominent neuronal activity under 
unstressed conditions. Moreover, restraint stress induced only a marginal increase in C-
fos expression in this brain area (see Table 8 in the results section and Table 5 in the 
appendix). Consistently, a prominent neuronal activity in the hippocampus under 
unstressed conditions has also been reported in other studies (Cullinan et al., 1995; 
Herdegen et al., 1995). However, considering the multitude of brain areas integrating 
information into the hippocampus, its role in the processing of environmental stimuli and 
its profound regulatory functions regarding the basal and stress-induced HPA axis tone, a 
prominent neuronal activity in the hippocampus already under basal conditions is not 
surprising. 
Similar to the hippocampus, the PFC also projects to the PVN, modulating the activation 
of the HPA axis, albeit in a more complex fashion (Herman et al., 2005; Spencer et al., 
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2005; Radley et al., 2006; Myers et al., 2012). For instance, the infralimbic cortex 
projects to the bed nucleus of the stria terminalis (BNST) and amygdala which are 
implicated in stress excitation, whereas the prelimbic cortex does not target these regions 
but projects to the peri-PVN region, an area which is implicated in stress inhibition 
(Sesack et al., 1989; Hurley et al., 1991; Herman et al., 2005). Thus, the role of the PFC 
in HPA axis activation remains less clearly defined. Furthermore, the implication of the 
PFC in HPA axis activation seems to be stressor specific (Herman et al., 2005). However, 
a between-line comparison of the C-fos signal in the PFC of HR, IR and LR animals did 
not yield significant differences in both treatment groups (Flx and Veh). Therefore, we 
suggest that the PFC and its subregions were marginally contributing to the differences in 
PVN excitation between the three mouse lines. 
In contrast to the hippocampus and the PFC, the BLA is believed to activate the HPA axis 
(Herman et al., 2005). The stimulatory role of the BLA on HPA axis activity has been 
investigated in studies showing that lesions of the BLA dampened the HPA axis response 
to stressors (Bhatnagar et al., 2004), whereas intra-BLA CRH injections increased adrenal 
GC secretion (Daniels et al., 2004). This indicates that the BLA might provide 
feedforward regulation of the HPA axis. In the animals of the SR mouse model, Flx-
treated HR mice revealed a significantly increased C-fos mRNA expression in this brain 
region compared to LR animals of the same group. This suggests a more pronounced 
excitatory input of the BLA to the PVN in Flx-treated HR mice. A tendency in the same 
direction could be observed in Veh-treated animals, although statistical significance was 
not reached in this group (HR>IR>LR, p=0.288). 
Taken together, our data clearly demonstrate that the distinct neuroendocrine phenotypes 
of the different breeding lines of the SR mouse model do not exclusively arise from a 
peripheral source but are driven by a neuronal signal originating from the PVN. 
Furthermore, we could show that the perception and interpretation of stressful stimuli 
might have induced a differential integration of hippocampal, amygdalar and prefrontal 
cortical information in the PVN, resulting in the observed differences in PVN excitation 
between HR, IR and LR animals. However, we could not detect an impact of chronic Flx 
treatment on the neuronal activation of the investigated limbic forebrain structures as well 
as on the PVN. It should be emphasised here, that the neuronal circuitry of stress in the 
brain includes many more regions than the areas that were investigated in this study, 
which could be influenced by antidepressant treatment, including important subcortical 
relay stations modulating the input from limbic structures to the PVN, e.g. the BNST 
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(Cullinan et al., 1993; Crane et al., 2003; Spencer et al., 2005; Choi et al., 2007). In 
addition, there is a considerable overlap of innervation fields from inhibitory 
(hippocampus, partly PFC) and excitatory (BLA) structures which imply that limbic 
information might be summated at subcortical sites (Herman et al., 2005). Hence, it might 
be possible that the differences in neuronal activity of the PVN were brought about by 
excitatory or inhibitory inputs from several limbic brain areas, which only showed 
marginal differences between HR, IR and LR animals in the respective brain region per 
se but together had a cumulative effect on the neuronal activation of the PVN. How these 
subcortical intermediaries, as well as the subregions and nuclei of a given limbic brain 
region, might be involved in the perception and interpretation of stressful stimuli and 
HPA axis activation in animals of the SR mouse model, should be addressed in future 
studies.
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5 Conclusion and perspectives 
Using a selective inbreeding approach, three mouse lines were generated with distinct 
differences in their HPA axis reactivity in response to a standardised, psychological 
stressor, the high (HR), the intermediate (IR) and the low (LR) reactivity line. We could 
show in our study that the HR and LR animals of the SR mouse model reveal alterations 
on all levels of the HPA axis - peripheral, central as well as regarding the regulation – 
similar to the pathophysiological conditions observed in MD patients. This is an 
intriguing finding since no selection pressure was exerted on other, upstream control 
centres of the HPA axis, but was limited to the selection of extremes in stress-induced 
CORT secretion from the adrenals. Moreover, we could demonstrate that antidepressant 
treatment restored regulatory functions of the HPA system, thereby highlighting the 
predictive validity of the SR mouse model in addition to its previously assessed face and 
construct validity. 
Thus, the SR model is of special interest for the psychiatric research since it has been 
shown that a dysregulation of the HPA axis is a prominent risk factor for the development 
of psychiatric diseases (de Kloet et al., 2005). Moreover, several studies also presented 
evidence that feedback resistance and mild hypercortisolism are already present in 
healthy subjects at genetic risk for depression, indicating that an imbalance in the HPA 
axis activity and negative feedback drive are preceeding the clinical manifestations of the 
disorder (Holsboer et al., 1995; Modell et al., 1998). Thus, molecular-genetic studies on 
the SR mouse model could yield promising insights into the mechanisms by which 
pathophysiological alterations of the HPA axis are linked to the increased risk of 
developing psychiatric diseases. Furthermore, the SR mouse model holds several 
advantages for psychiatric research due to the vulnerable genetic predisposition towards a 
HPA axis dysfunction of the three breeding lines. Compared to other mouse models, it is 
closely related to the natural aetiology of developing pathophysiologies which are 
associated with affective disorders such as MD. In contrast to genetically engineered or 
knockout models, animals of the SR mouse model are derived from CD-1 outbred 
founder population with a heterogenic background. Thus, by selective inbreeding, genetic 
factors which are associated with the respective phenotype are taken into account which, 
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in turn, considers the heritability of genetic risk factors in the aetiology of psychiatric 
diseases. 
As already outlined in the respective paragraphs of the discussion, there is ample of 
opportunity to put the stress reactivity to use in future experiments aimed at discovering 
the molecular underpinnings of affective disorders such as MD. 
In our study, we found significant differences in the adrenal sensitivity between the three 
mouse lines in absence of differences in ACTH receptor expression. In contrast, StAR 
was differentially regulated in HR, IR and LR animals. Thus, the adrenal presents an 
interesting target for further studies, including the investigation of adrenal and plasma 
cholesterol, the substrate for steroid biosynthesis. Moreover, a detailed characterisation of 
the enzymes involved in steroid biosynthesis would be mandatory, since adrenal 
dysfunctions, for example observed in patients suffering from an adrenal hyperfunction 
(Cushing’s syndrome), are closely associated with psychiatric diseases (Gold et al., 1986; 
Starkman et al., 1986). 
Moreover, we found significant differences in the stress-induced neuronal excitation of 
the PVN between the three lines. It has been shown that not only the neuroendocrine 
stress response is originating from this brain nucleus but the adrenal CORT secretion is 
likewise governed by direct innervation of PVN neurons (Engeland et al., 2005), 
suggesting a synergistical activation of the adrenal by these two stress systems. Thus, the 
SR mouse model could provide a good model for investigating the role of the sympathetic 
nervous system in the stress response, particularly regarding the secretion of noradrenalin 
and adrenalin from the adrenals. 
Furthermore, the SR mouse model could serve as a valuable tool to investigate the role of 
the Mdr1 Pgp in the activation and negative feedback regulation of the HPA axis since it 
has been shown that this transporter is able to restrict the access of glucocorticoids to the 
brain (Uhr et al., 2002). In our study, significant differences in the expression of Mdr1b 
in the hippocampus between HR, IR and LR mice were found. Interestingly, preliminary 
data from our group also revealed differences in the sequence of the Mdr1b gene between 
the three lines. Therefore, it is unlikely that the differential expression of Mdr1b is a 
compensatory effect, but that this transporter might be causally involved in the 
differential HPA axis reactivity between the three mouse lines. In this respect, it should 
be noted that polymorphisms in the Mdr1 Pgp gene predicted antidepressant treatment 
response in depression (Uhr et al., 2008), emphasising the important role of Mdr1 Pgp in 
psychopharmacology. Thus, pharmacokinetic studies on the SR mouse model could 
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contribute to the understanding of the mechanisms by which antidepressants penetrate the 
brain and hence improve the effectiveness of CNS drugs. 
In addition, it has been shown in several studies that psychiatric disorders such as bipolar 
disorder, major depression and schizophrenia are closely associated with impairments in 
cell energy metabolism, e.g. mitochondrial dysfunction, resulting in insufficient energy 
resources for the maintenance of functional cellular processes and physiological 
homeostasis (Shao et al., 2008; Rezin et al., 2009). Interestingly, hippocampal proteomic 
studies in HR, IR and LR mice identified several proteins, which were differentially 
expressed in HR and LR animals and were found to be involved in energy metabolism 
pathways (Knapman et al., 2012). Furthermore, microarray- and Serial Analysis of Gene 
Expression (SAGE)-based expressional profiling approaches in hippocampal tissue of HR 
and LR mice revealed clusters of differentially regulated genes contributing to 
mitochondrial morphology and function (Widner-Andrä, 2011). This data strongly 
suggests an involvement of the mitochondria in the different endophenotypes of HR, IR 
and LR animals. Hence, a recently initiated study aims to investigate the mitochondrial 
proteome of the hippocampus of HR, IR and LR mice, allowing pathway analysis in order 
to identify candidate proteins involved in an altered mitochondrial energy metabolism in 
these mice. Thus, the SR mouse model could provide essential insights into the 
mechanisms linking mitochondrial dysfunction and a dysregulated HPA axis, thereby 
improving our understanding of the biological mechanisms of affective disorders. 
Taken together, the results presented in this work as well as the findings of previous 
studies using HR, IR and LR mice, provide compelling evidence for the usefulness of the 
SR mouse model as valuable tool for elucidating the molecular and genetic underpinnings 
of affective disorders and therefore present an essential and indispensable tool for the 
future of psychiatric research. 
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6 Appendix 
 Table 1: List of used buffers for western blot analysis with their respective composition. Suppliers: (a) Carl 
Roth GmbH, Karlsruhe, Germany; (b) Merck KGaA, Darmstadt, Germany; (c) Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany; (d) Roche Diagnostics Deutschland GmbH, Mannheim, Germany. 
Name Abbreviation Composition Supplier 
Homogenisation buffer H-buffer 50mM Tris (pH=7.5) a 
150mM NaCl b 
3.33mM EDTA a 
Protease inhibitor mix 
(1 tablet on 10ml buffer) 
d 
Extraction buffer E-buffer 50mM Tris (pH=7.5) a 
150mM NaCl b 
2% NP-40 (Igepal) c 
2% Sodium Deoxycholate a 
4% SDS c 
Radioimmunoprecipitation 
buffer 
RIPA buffer 50mM Tris (pH=8.0) a 
150mM NaCl b 
0.1% SDS c 
1.0% NP-40 (Igepal) c 
0.5% Sodium Deoxycholate a 
Protease inhibitor mix 
(1 tablet on 10ml buffer) 
d 
Protein loading buffer PLB 5% SDS c 
40% Glycerin c 
160mM Tris (pH=6.8) a 
5% β-mercaptoethanol c 
Bromphenol blue b 
Electrophoresis buffer  2.5mM Tris a 
19.2mM Glycine c 
0.5% SDS c 
Wetblot buffer  2.5mM Tris a 
190mM Glycine c 
20% Methanol a 
Tris-buffered saline and 
Tween 20 
TBST 10mM Tris a 
150µM NaCl b 
0.1% Tween 20 c 
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 Table 2: Composition of the enhanced chemiluminescence solution. Suppliers: (a) Carl Roth GmbH, Karlsruhe, 
Germany; (b) Merck KGaA, Darmstadt, Germany; (c) Sigma-Aldrich Chemie GmbH, Steinheim, Germany; (d) 
Roche Diagnostics Deutschland GmbH, Mannheim, Germany. 
Name Composition Amount Mixing ratio Supplier 
ECL solution A 100mM Tris (pH=6.8) 200ml 10ml a 
Luminol 50mg  a 
ECL solution B DMSO 10ml 1ml c 
p-coumaric acid 11mg  c 
30% H2O2    3µl a 
 
 
 
 Table 3: Relative gene expression in the hippocampus of high (HR), intermediate (IR) and low (LR) reactivity 
mice of Gen XVII. Statistical parameters of the within-line comparisons, corresponding to Table 5 of the results 
section. Exact p values are given, asterisks represent the significance level (p≤0.05*, p≤0.01**). 
 Veh Flx 
Within-line comparison 
(MWU-test) 
candidate line mean SEM mean SEM U p  
Fkbp5 LR 0.76 0.04 0.95 0.05 8 0.007 ** 
Abcb1a LR 0.80 0.05 1.09 0.10 10.5 0.014 * 
Gilz LR 0.95 0.08 1.27 0.08 9 0.009 ** 
 
 
 
 Table 4: Relative gene expression in the pituitary of high (HR), intermediate (IR) and low (LR) reactivity mice 
of Gen XVII. Statistical parameters of the within-line comparisons, corresponding to Table 6 of the results 
section. Exact p values are given, asterisks represent the significance level (p≤0.05*, p≤0.01**). 
 Veh Flx 
Within-line comparison 
(MWU-test) 
candidate line mean SEM mean SEM U p  
Fkbp5 IR 1.00 0.10 1.68 0.16 8 0.007 ** 
Abcb1a IR 1.00 0.13 1.89 0.24 10 0.012 * 
Abcb1b LR 0.57 0.06 0.91 0.12 15 0.043 * 
Gilz IR 1.00 0.05 1.41 0.12 11 0.016 * 
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HR IR LR 
between line 
comparison 
post-hoc MWU-test 
 
(KWH-test) HR vs IR HR vs LR IR vs LR 
brain region subregion N=HR/IR/LR treatment mean SEM mean SEM mean SEM H p U p U p U p 
PFC   
4/4/4 Veh 9.74 3.13 13.09 3.49 9.45 2.34 0.5 0.779             
4/4/2 Flx 4.69 1.74 19.54 8.49 14.35 3.88 5.6 0.059T             
PVN  
4/4/4 Veh 11.47 1.03 9.62 1.26 10.49 1.60 1.6 0.437 
      
 
4/4/2 Flx 9.92 1.40 14.11 3.70 14.64 3.94 2.2 0.327 
      
BLA 
  4/4/4 Veh 4.10 0.89 7.42 2.29 5.18 2.49 0.7 0.694             
  4/4/2 Flx 2.83 0.42 13.03 4.44 8.90 3.28 6.6 0.036* 0 0.063 0 0.128 3 0.643 
dHC 
CA1 
4/4/4 Veh 12.92 3.64 16.54 4.40 14.64 4.38 0.2 0.874 
      
4/4/2 Flx 10.70 1.77 13.76 3.62 11.59 0.03 0.7 0.683 
      
CA2 
4/4/4 Veh 9.84 2.25 13.73 3.47 12.96 3.04 0.5 0.779             
4/4/2 Flx 9.68 1.40 10.38 2.79 12.08 1.01 0.327 0.849             
CA3 
4/4/4 Veh 13.56 3.09 15.84 3.20 15.05 2.94 0.4 0.794 
      
4/4/2 Flx 9.91 0.40 17.54 2.66 14.46 0.84 6.8 0.032* 0 0.063 0 0.128 2 0.355 
DG 
4/4/4 Veh 18.54 2.04 19.26 1.35 22.81 2.52 1.8 0.397             
4/4/2 Flx 20.22 1.34 19.65 1.60 18.27 0.49 1.5 0.453             
vHC 
CA1 
4/4/4 Veh 9.51 0.84 8.71 1.28 10.72 1.67 0.4 0.794 
      
4/4/2 Flx 4.65* 0.87 11.97 1.59 10.03 0.79 6.8 0.032* 0 0.063 0 0.128 2 0.355 
CA3 
4/4/4 Veh 8.34 0.70 7.26 0.73 8.25 0.90 1.4 0.491             
4/4/2 Flx 5.36* 0.50 10.85* 1.13 8.14 2.39 6.0 0.048* 0 0.063 1 0.330 2 0.355 
DG 
4/4/4 Veh 10.56 1.29 8.08 0.86 11.90 1.39 5.1 0.077T 
      
4/4/2 Flx 7.39 0.48 12.05* 1.37 12.23 3.12 6.6 0.036* 0 0.063 0 0.128 3 0.643 
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 Table 6: C-fos mRNA expression (optical density) in the brain of high (HR), intermediate (IR) and low (LR) 
reactivity mice of Gen XIX of control I (animals that received chronic injections but were not subjected to the 
SRT). Statistical parameters of the within-line comparisons, corresponding to Table 5 in the appendix. Exact p 
values are given, asterisks represent the significance level (p≤0.05*). 
 
Veh Flx 
Within-line comparison 
(MWU-test) 
brain 
region 
subregion line mean SEM mean SEM U p  
vHC CA1 HR 9.51 0.84 4.65 0.87 0 0.021 * 
vHC CA3 HR 8.34 0.70 5.36 0.50 0 0.021 * 
vHC CA3 IR 7.26 0.73 10.85 1.13 1 0.043 * 
vHC DG IR 8.08 0.86 12.05 1.37 1 0.043 * 
 
 
 
 
 Table 7: C-fos mRNA expression (optical density) in the brain of high (HR), intermediate (IR) and low (LR) 
reactivity mice of Gen XIX which were subjected to the SRT. Statistical parameters of the within-line 
comparisons, corresponding to Table 8 of the results section. Exact p values are given, asterisks represent the 
significance level (p≤0.05*). 
 
Veh Flx 
Within-line comparison 
(MWU-test) 
brain 
region 
subregion line mean SEM mean SEM U p  
dHC CA2 LR 29.23 2.39 22.76 0.58 8.5 0.029 * 
dHC CA3 HR 21.20 1.70 25.32 1.25 15 0.043 * 
vHC CA3 LR 16.05 1.36 11.84 1.69 8 0.039 * 
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7 Lists 
7.1 List of abbreviations 
2-AG 2-arachidonoylglycerol 
5-HT serotonine 
A ampere 
Abcb1a ATP-binding cassette, sub-family B, member 1A  
Abcb1b ATP-binding cassette, sub-family B, member 1B 
ACTH adrenocorticotropic hormone 
AMPT α-methyl-para-tyrosine methyl ester 
AVP arginine vasopressine 
BBB blood brain barrier 
BCA bicinchoninic assay 
BDNF brain-derived neurotrophic factor 
BLA basolateral amygdala 
BNST bed nucleus of the stria terminalis 
bp base pairs 
BW body weight 
CA cornu ammonis 
cAMP cyclic adenosine monophosphate 
CB 1 endocannabinoid receptor 1 
CBG corticosteroid binding globuline 
cDNA copy deoxyribonucleic acid 
CeA central amygdala 
Cfl1 cofilin-1 
CNS central nervous system 
CORT corticosterone 
CP crossing point 
CRH corticotropin-releasing hormone 
Crhr1 corticotropin-releasing hormone receptor 1 
CVS chronic variable stress 
Dex dexamethasone 
df degrees of freedom 
DG dentate gyrus 
dHC dorsal hippocampus 
DNA deoxyribonucleic acid 
DSM IV Diagnostic and Statistical Manual of Affective Disorders, 4th Edition 
e.g. for example 
E-buffer extraction buffer 
ECL enhanced chemoluminescence 
EDTA ethylenediaminetetraacetic acid 
ELISA enzyme-linked immunosorbent assay 
F Friedman 
FGD familial glucocorticoid deficiency 
Fkbp4 FK506 binding protein 4 
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Fkbp5/FKBP51 FK506 binding protein 5 
Flx fluoxetine 
FST forced swim test 
g rcf, relative centrifugal force 
GAPDH glyceraldehyde-3-phosphate-dehydrogenase 
GC glucocorticoid 
Gilz glucocorticoid induced leucine zipper  
GPCR G-protein coupled receptor 
GR glucocorticoid receptor 
GRE glucocorticoid response element 
H-buffer homogenisation buffer 
HPA hypothalamic-pituitary-adrenal 
HPRT hypoxanthine-guanine phosphoribosyltransferase  
HR high reactivity 
i.e. that is 
i.p. intraperitoneal 
IR intermediate reactivity 
ISH in-situ hybridisation 
kDa kilodalton 
KO knockout 
KWH Kruskal-Wallis H 
LC locus coeruleus 
LR low reactivity 
MAOI monoamine oxidase inhibitor 
MC2R melanocortin 2 receptor 
MD major depression 
Mdr1 Pgp multidrug resistance 1 P-glycoprotein 
Met metyrapone 
MR mineralocorticoid receptor 
MRAP melanocortin 2 receptor accessory protein 
mRNA messenger ribonucleic acid 
MWU Mann-Whitney U 
n.s. not significant 
NAA N-acetylaspartate 
NE norepinephrine 
Nr3c1 nuclear receptor subfamily 3, group C, member 1 
Nr3c2 nuclear receptor subfamily 3, group C, member 2 
NTS nucleus of the solitary tract 
OF open field test 
PFC prefrontal cortex 
PKA protein kinase A 
PLB protein loading buffer 
PNMT phenylethanolamine-N-methyltransferase 
Pomc proopiomelanocortin 
PTSD post traumatic stress disorder 
PVC polyvinyl chloride 
PVN paraventricular nucleus of the hypothalamus 
qPCR quantitative real-time polymerase chain reaction 
RIA radioimmunoassay 
RIPA radioimmunoprecipitation assay 
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RNA ribonucleic acid 
SAGE serial analysis of gene expression 
SAM sympathetic adrenomedullary 
SCN suprachiasmatic nucleus 
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SEM standard error of the mean 
SNRI serotonine norepinephrine reuptake inhibitor 
SR stress reactivity 
SRT stress reactivity test 
SSRI selective serotonine reuptake inhibitor 
StAR steroid acute regulatory protein 
TBP TATA-binding protein 
TBST tris buffered saline with tween 
TCA tricyclic antidepressant 
TF transferrin 
TH tyrosine hydroxylase 
Tm melting temperature 
TRI trizol 
Tris trisaminomethane 
V volt 
Veh vehicle 
vHC ventral hippocampus 
W Wilcoxon 
WHO World Health Organisation 
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7.2 List of figures 
Figure 1: Schematic diagram illustrating the different levels of hypothalamic-
pituitary-adrenal (HPA) axis control. In response to circadian stimuli or 
stress, the paraventricular nucleus of the hypothalamus (PVN) 
synergistically releases corticotropin-releasing hormone (CRH) and 
arginine-vasopressin (AVP) into the portal system of the median 
eminence. Upon adrenal stimulation by adrenocorticotropic hormone 
(ACTH) released from the anterior pituitary, glucocorticoids such as 
corticosterone (CORT) are secreted from the adrenal cortex into the 
systemic circulation. Subsequently, negative feedback mechanisms at the 
pituitary and the PVN restrict the release of ACTH and CRH/AVP, 
respectively. SCN, suprachiasmatic nucleus; CNS, central nervous 
system. Figure adopted from (Lightman et al., 2010). ..................................... 9 
Figure 2: Corticosterone (CORT) increase in the stress reactivity test (SRT) of (A) 
male and (B) female mice of the CD-1 founder population (parental 
generation, PG) and the descendent generations (Gen I-XII) of high 
(HR), intermediate (IR) and low (LR) reactivity breeding line. Already in 
Gen I, significant differences in the stress-induced CORT increase 
between the three mouse lines could be observed (KWH-test, all 
p≤0.001***). This divergence was further increased in the subsequent 
generations (Figure adopted from (Touma et al., 2008; Touma, 2011). ......... 15 
Figure 3: Mouse being restraint during the ‘stress reactivity’ test (SRT).......................... 20 
Figure 4: Experimental setup of the Open Field (OF) test................................................. 23 
Figure 5: Experimental setup of the Forced Swim Test (FST). ......................................... 24 
Figure 6: Experimental setup of the Y-maze test............................................................... 25 
Figure 7: Schematic overview of the anatomical location of the brain regions 
investigated for C-fos expression by in–situ hybridisation. Upper left: 
prefrontal cortex (PFC). Upper right: basolateral amygdala (BLA) and 
paraventricular nucleus of the hypothalamus (PVN). Lower left: dorsal 
hippocampus including the cornu ammonis 1-3 subfields (CA1, CA2, 
CA3) and the dentate gyrus (DG). Lower right: ventral hippocampus. 
Figures adopted from (Franklin et al., 2001). ................................................. 32 
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Figure 8: Schematic overview of the experimental schedule with time and intervals 
of the collected blood samples, metyrapone injection and behavioural 
tests. OF, open field test; FST, forced swim test; i.p., intraperitoneal; t, 
time; d, day. ..................................................................................................... 35 
Figure 9: Schematic overview of the experimental schedule with time and intervals 
of the collected blood samples and dexamethasone or adrenocorticotropic 
hormone (ACTH) injections. i.p., intraperitoneal; t, time. .............................. 37 
Figure 10: Schematic overview of the experimental schedule with time and intervals 
of the collected blood samples. Stressed animals were subjected to 15 
min of restraint stress and returned back to their homecages for 15 min 
before they were sacrificed. The unstressed control group was killed 
under basal conditions. t, time. ....................................................................... 40 
Figure 11: Schematic overview of the experimental schedule showing the day of 
behavioural testing (day 28) and the Dex/CRH test (day 35). The detailed 
experimental schedules on the respective days are given in the timelines 
on top or below. OF, open field test; FST, forced swim test; Dex, 
dexamethasone; CRH, corticotropin-releasing hormone; i.p., 
intraperitoneal; t, time; d, day; BW, body weight. .......................................... 43 
Figure 12: Schematic overview of the experimental schedule of the experimental 
group, control I and control II, respectively. The day of Y-maze testing 
(day 28) and the SRT (day 35) are given. The detailed experimental 
schedule of the SRT is outlined in the timeline on top. i.p., 
intraperitoneal; t, time; d, day; BW, body weight. .......................................... 45 
Figure 13: Plasma corticosterone increase in response to the forced swim test in high 
(HR), intermediate (IR) and low (LR) reactivity mice of Gen XVI. For 
statistical differences between the three lines see text. Statistical 
differences between the Veh and Met group are given on top of the panel 
(MWU-test: p≤0.001***). ............................................................................... 48 
Figure 14: Stress-coping behaviour of high (HR), intermediate (IR) and low (LR) 
reactivity mice of Gen XVI during the 6-min forced swim test (FST) 
period. (A) time spent floating (B) time spent struggling. For statistical 
differences between the three lines (KWH-test) see text. Statistical 
differences between the Veh and Met group are given on top of the panel 
(MWU-test: p>0.1 n.s., p≤0.05*). ................................................................... 51 
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Figure 15: Gene expression in the adrenals of high (HR), intermediate (IR) and low 
(LR) reactivity mice of Gen XVI (Veh group) relative to two 
housekeeping genes (Hprt and Tbp), normalised to the IR group. (A) 
tyrosine hydroxylase (Th) mRNA expression. (B) phenylethanolamine-
N-methyltransferase (Pnmt) mRNA expression. (C) melanocortin 2 
receptor (Mc2r) mRNA expression. (D) steroid acute regulatory protein 
(StAR) mRNA expression. Statistical differences between the three lines 
are given on top of each panel (KWH-test), pairwise group comparisons 
(post-hoc MWU-test) are indicated below (p≤0.05*, p<0.1 T, p>0.1 n.s.). ... 53 
Figure 16: Plasma adrenocorticotropic hormone (ACTH) concentration after 
dexamethasone (Dex) suppression in high (HR), intermediate (IR) and 
low (LR) reactivity mice of Gen XX. Statistical differences between the 
three lines are given on top of the panel (MWU-test: p>0.1 n.s.). .................. 54 
Figure 17: Plasma corticosterone (CORT) concentrations in high (HR), intermediate 
(IR) and low (LR) reactivity mice of Gen XX. (A) left: plasma CORT 
concentrations 6h after dexamethasone injection, right: plasma CORT 
concentrations 6 h after dexamethasone injection followed by a saline 
injection. (B) plasma CORT concentrations after stimulation with 
0.1ng/g BW ACTH (left) and 1ng/g BW ACTH (right). Statistical 
differences between the three lines are given on top of the panel (KWH-
test), pairwise group comparisons (post-hoc MWU-test) are indicated 
below (p≤0.01**, p≤0.05*, p>0.1 n.s.). .......................................................... 55 
Figure 18: Relative adrenal weight (with respect to body weight) of high (HR), 
intermediate (IR) and low (LR) reactivity mice of Gen XX. (A) both 
adrenals pooled. (B) adrenals weighed separately. Statistical differences 
between the three lines are given on top of the panel (KWH-test), 
pairwise group comparisons (MWU-tests) are indicated below 
(p≤0.01**, p≤0.05*, p≤0.1 T, p>0.1 n.s.). ...................................................... 56 
Figure 19: Plasma corticosterone (CORT) concentrations in high (HR), intermediate 
(IR) and low (LR) reactivity mice of Gen XX. Control animals were 
killed under basal conditions. Plasma CORT concentrations of HR, IR 
and LR animals which were subjected to a 15-min restraint period were 
determined right before (t=0) and immediately after (t=15) the stress as 
well as 30 min (t=30) after the onset of the stressor. Statistical differences 
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between the three lines are given on top of the panel (F-test), pairwise 
group comparisons (W-tests) are indicated below (p≤0.01**, p≤0.05*, 
p≤0.1 T, p>0.1 n.s.). ........................................................................................ 58 
Figure 20: (A) Representative Western blot pictures of corticosteroid binding 
globulin (CBG) and glyceraldehyde-3-phosphate-dehydrogenase 
(GAPDH). (B) CBG expression in the liver of high (HR), intermediate 
(IR) and low (LR) reactivity mice of Gen XX relative to GAPDH, 
normalised to the IR control group. Statistical differences between the 
three lines (KWH-test) are given in the text, within-line comparisons 
(MWU-test) are indicated on top of the panel (p≤0.05*, p>0.1 n.s.). ............. 59 
Figure 21: (A) Representative Western blot pictures of corticosteroid binding 
globulin (CBG) and transferrin. (B) CBG expression in the plasma of 
high (HR), intermediate (IR) and low (LR) reactivity mice of Gen XX 
relative to transferrin, normalised to the IR control group. Statistical 
differences between the three lines (KWH-test) are given in the text, 
within-line comparisons (MWU-test) are indicated on top of the panel 
(p>0.1 n.s.). ..................................................................................................... 61 
Figure 22: Plasma adrenocorticotropic hormone (ACTH) concentrations in high 
(HR), intermediate (IR) and low (LR) reactivity mice of Gen XX. 
Control animals were killed under basal conditions. Plasma CORT 
concentrations of HR, IR and LR animals which were subjected to a 15-
min restraint period were determined immediately after (t=15) the stress 
as well as 30 min (t=30) after the onset of the stressor. Statistical 
differences between independent samples (MWU-test: control vs t=15, 
control vs t=30) and dependent samples (W-test: t=15 vs t=30) are given 
on top of the panel (p≤0.001***, p≤0.01**, p≤0.05*, p>0.1 n.s.). ................. 63 
Figure 23: (A) Representative Western blot pictures of adrenocorticotropic hormone 
(ACTH) and glyceraldehyde-3-phosphate-dehydrogenase (GAPDH). (B) 
ACTH expression in the pituitary of high (HR), intermediate (IR) and 
low (LR) reactivity mice of Gen XX relative to GAPDH, normalised to 
the IR control group. Statistical differences between the three lines 
(KWH-test) are given in the text, within-line comparisons (MWU-test) 
are indicated on top of the panel (p>0.1 n.s.). ................................................. 65 
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Figure 24 Stress-coping behaviour of high (HR), intermediate (IR) and low (LR) 
reactivity mice of Gen XVII during the 6-min forced swim test (FST) 
period. A: time spent floating. B: time spent struggling. For statistical 
differences between the three lines (KWH-test) see text. Statistical 
differences between the Veh and Flx group are given on top of the panel 
(MWU-test: p≤0.05*, p≤0.1 T, p>0.1 n.s.). .................................................... 67 
Figure 25: Latency to the first floating episode of high (HR), intermediate (IR) and 
low (LR) reactivity mice of Gen XVII during the 6-min forced swim test 
(FST) period. For statistical differences between the three lines (KWH-
test) see text. Statistical differences between the Veh and Flx group are 
given on top of the panel (MWU-test: p≤0.01**, p≤0.05*, p≤0.1 T). ............ 68 
Figure 26: Plasma corticosterone (CORT) concentrations in high (HR), intermediate 
(IR) and low (LR) reactivity mice of Gen XVII three days before 
(reference) and immediately after the behavioural testing (after FST). 
Statistical differences between the three lines (KWH-test) are given in 
the text, pairwise group comparisons (MWU-tests) are indicated on top 
of the panel (p>0.1 n.s.). ................................................................................. 70 
Figure 27: Plasma corticosterone (CORT) concentrations of high (HR), intermediate 
(IR) and low (LR) reactivity mice of Gen XVII in the Dex/CRH test. 
Blood samples were collected three days before the test (reference), six 
hours after Dex application (after Dex) and 30 min after CRH stimulation 
(after CRH). Statistical differences between the three lines (KWH-test) 
are given in the text, pairwise group comparisons (MWU-tests) are 
indicated on top of the panel (p≤0.001***, p≤0.01**, p≤0.05*, p>0.1 
n.s.). ................................................................................................................. 72 
Figure 28: (A) Representative Western blot pictures of the glucocorticoid receptor 
(GR), FK506 binding protein 51 (FKBP51) and glyceraldehyde-3-
phosphate-dehydrogenase (GAPDH). (B) GR expression (left) and 
FKBP51 expression (right) in the hippocampus of high (HR), 
intermediate (IR) and low (LR) reactivity mice of Gen XVII relative to 
GAPDH, normalised to the IR Veh group. Statistical differences between 
the three lines (KWH-test) are given in the text, within-line comparisons 
(MWU-test) are indicated on top of the panel (p≤0.1 T, p>0.1 n.s.). ............. 78 
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Figure 29: Discrimination ratio (% time spent in novel arm/familiar arms) of high 
(HR), intermediate (IR) and low (LR) reactivity mice of Gen XIX during 
the retrieval phase of the Y maze test. For statistical differences between 
the three lines (KWH-test) see text. Statistical differences between the 
Veh and Flx group are given on top of the panel (MWU-test: p≤0.05*, 
p>0.1 n.s.)........................................................................................................ 80 
Figure 30: Plasma corticosterone concentrations of high (HR), intermediate (IR) and 
low (LR) reactivity mice of Gen XIX. Blood samples were collected 
immediately before (initial) and right after (reaction) the 15-min restraint 
period as well as 45min after the termination of the restraint (45min post 
SRT). Statistical differences between the three lines (KWH-test) and 
within treatment groups (W-test) are given in the text, pairwise group 
comparisons (MWU-tests) are indicated on top of the panel (p≤0.05*, 
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Figure 31: Representative pictures of C-fos expression in the brain of the 
experimental mice. Left: naïve animal (control II). Middle: animal that 
received chronic injections but was not subjected to the SRT (control I). 
Right: animal that was subjected to the SRT (stressed animal). ..................... 83 
Figure 32: (A) Representative pictures of C-fos mRNA expression in the 
paraventricular nucleus of the hypothalamus (PVN) detected by in-situ 
hybridisation (B) C-fos mRNA expression in the PVN of high (HR), 
intermediate (IR) and low (LR) reactivity mice of Gen XIX. Statistical 
differences between the three lines (KWH-test) are given in the text, 
within-line comparisons (MWU-test) are indicated on top of the panel 
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Figure 33: Simplified diagrammic representation of direct limbic stress-integrative 
pathways to the paraventricular nucleus of the hypothalamus (PVN) and 
the peri-PVN region from the prefrontal cortex (PFC), basolateral 
amygdala (BLA) and hippocampus (HC) as well as from brainstem 
regions such as the nucleus of the solitary tract (NTS). Indirect 
projections of these brain regions via transsynaptic intermediaries such as 
the bed nucleus of the stria terminalis (BNST) are also presented. 
Excitatory projections are indicated by (+) and filled lines ending in 
arrows, inhibitory projections are indicated by (-) and dotted lines ending 
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in squares. ac, anterior cingulate cortex; pl, prelimbic cortex; il, 
infralimbic cortex; 3V, third ventricle. Figure modified from (Herman et 
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